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ABSTRACT 
    Current orthotopic xenograft models of colorectal cancer (CRC) require survival 
surgery and do not robustly form tumors in liver, the most common site of metastasis in 
patients. In the work described in the thesis chapter 2, we used chemokine-targeting to 
develop cell line and primary patient-derived xenograft models that recapitulate the vast 
majority of common human somatic CRC mutations as primary gastrointestinal (GI) 
tumors in mice without requiring surgery. Importantly, we utilize early-stage mouse 
blastocyst microinjection techniques to extend this approach and model primary human 
CRCs in immunoproficient mouse hosts. Next, we show that primary GI tumors can 
inducibly and robustly metastasize to liver. Finally, we demonstrate that human CRC 
liver metastases in vivo have higher levels of DKK4 and NOTCH signaling and are more 
chemoresistant than paired sub-cutaneous xenografts. Overall, we anticipate that this 
experimental system can help improve our mechanistic understanding of human 
primary CRC progression to liver metastasis and provide a more physiological model 
than sub-cutaneous xenografts for pre-clinical drug screening. 
     Refined cancer models are urgent to bridge the gap between cell-line or animal 
based research and clinical research. In thesis chapter 3, we described an organotypic 
colon cancer model which was generated from human native matrix and have 
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pathophysiologically recapitulated the natural features of progression from APC-
dependent in situ neoplasia to sub-mucosal invasive adenoma in colorectal cancer 
(CRC)-associated genetic pathways. To identify invasion-driver genes, we performed a 
forward genetic screen using Sleeping Beauty (SB) transposon- based mutagenesis in 
the ex vivo CRC model. This screen identified 39 candidate genes, all of which are 
listed in TCGA CRC dataset. 17 of them, including TCF7L2, TWIST2, MSH2, DCC and 
EPHB1,2, most likely drive invasion of CRC through cooperation with mutant APC. 
Among the remaining genes that have not previously been implicated in CRC, seven 
out of ten were functionally validated to significantly promote the growth, migration or 
invasion of colon cells. This piece of work demonstrated the utility of ex vivo human-
originated models with transposon-based mutagenesis and provided a new system for 
studying the biology of cancer. 
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BACKGROUND 
 
Colorectal cancer (CRC) is a major public health source of morbidity and mortality. 
Approximately 5% of the population in western world will develop colorectal 
malignancies during their lifetime and 25% of CRC patients eventually die from 
metastatic disease [1, 4]. Thus, it is urgent for research to enhance our ability to 
diagnosis, prevent and treat this disease. To improve patient outcome largely depends 
on precisely interdicting the mechanisms of metastasis and developing therapy 
targeting the mechanisms. 
Genetics of Colorectal Cancer 
Each disease stage during CRC progression develops distinct pathological features 27. 
Firstly, inappropriate proliferation cause colon stem or progenitor cells to transform into 
colon cancer stem cells, which start with adenoma formation and evolve into carcinoma 
in situ. Then, pre-invasive CRCs, by accumulating more genetic mutations, acquire the 
ability to invade through the submucosa and muscularis, and metastasize out of the 
colon microenvironment niche and in the distant organs.  
In the CRC molecular etiology, each clinical stage highly correlates with sequential 
accumulations of mutations in major genes [1, 10]. CRC generally can be divided into 
two classes based on the genetic background displaying chromosomal instability (CIN) 
or microsatellite instability (MSI), in which CIN phenotype occurs in 80-90% CRC cases. 
CRCs displaying CIN frequently harbor loss-of-function mutations in adenomatous 
polyposis coli (APC) which is believed to be the initial event to transform normal colon 
epithelium into pedunculated adenomatous polyps through up-regulating WNT signaling. 
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Then additional somatic mutations occur to drive malignant transformation of 
pedunculated adenomatous polyps to invasive and metastatic adenocarcinomas [5, 10, 
27]. The “Vogelstein model” [11, 28] described oncogene KRAS/BRAF mutations 
promote the early stage adenoma to late stage adenoma, and further mutations in DCC, 
TP53, and abrogation of the TGF-β pathway, including mutations in SMAD4 and 
TGFBR2, are thought to occur later in CRC progression, transforming the adenoma to a 
carcinoma. Although colorectal cancer (CRC) progression appears to be characterized 
by high-frequency mutations, such as KRAS, SMAD, TP53, many low-frequency 
mutations are also believed to contribute to the disease development. The advance in 
secondary generation sequencing has accelerated the identification of genetic 
alterations in human cancers in whole-genome scale and comprehensive molecular 
studies such as TCGA (The Cancer Genome Atlas) [ 1] have provided a broad range of 
insights with an unprecedented level of molecular resolution into the precise molecular 
alterations that drive human CRC pathogenesis and progression. 
Chemokine Network with CRC 
Chemokines, family members of cytokines, are 8- to 12-KD polypeptides that when 
binding to specific G protein – coupled chemokine receptors, activate signaling 
cascades guiding cell migration toward chemokine ligand gradients. Chemokine-
regulating cell movements play critical roles in immunity, embryonic development, 
angiogenesis, wound healing and involved in the physiological events of central nervous 
system, and skeletal muscle. Chemokine signaling pathways are essential to the 
functions of immune system, mediating various types of immune cells trafficking 
between the secondary lymph sites and the regions of inflammation [17, 19, 21, 22].  
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The connection between inflammation and cancer has been well-established and 
more and more recent studies indicate that chemokines play key roles in both driving 
and preventing cancer progression [3, 6, 14, 15, 16 ]. Many human cancers have a 
complex chemokine network that regulates the extent and phenotype of the infiltrating 
leukocytes, as well as have an effect on tumor growth, survival, migration, and 
angiogenesis. Cancer cells can produce chemokines to regulate immune cell behaviors, 
and alter inflammation microenvironment which in turn effects cancer progression. 
Cancer cells also can express chemokine receptors and thus directly guide themselves 
into targeted organs and develop metastases. Interestingly, studies indicate that 
adaptive immune cells have the potential to limit tumor progression. Galon and 
colleagues demonstrated that the presence of CD8+ T cells infiltrate is associated with 
the absence of early metastatic processes in patients with melanoma, ovarian cancer 
and CRC [20]. In contrast, the persistence of active innate immune responses, such as 
the chronic inflammation at tumor sites, has been implicated with poor clinical outcome 
[2, 7].    
Chemokine ligand CCL25 and receptor CCR9 are unique and critical to intestinal 
immune system. Intestinal epithelial cells secrete CCL25 to attract CCR9 expressing 
lymphocytes into gut for immune function [19]. Evidence shows [3, 15, 16, 23] that gut 
produced CCL25 regulate CCR9+ melanoma or ovarian cancer cells to spread 
metastases in intestines. However, how the CCR9-CCL25 axis interacts with colon 
cancer under native intestinal conditions has been poorly understood. My first project [8] 
described in chapter 1 of the dissertation for the first time reveal a new function for 
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CCR9-CCL25 axis to inhibit CRC invasion and metastasis and describe a novel in vivo 
experimental system to study CRC mechanisms.  
Animal models of CRC 
Animal models capitulating features of specific human CRC are invaluable tools 
necessary to study carcinogenesis, the specific molecular mechanisms of colon cancer, 
to test potential preventive and therapeutic strategies, and to translate the research 
hypotheses derived from cell models into the results under physiologically – relevant 
conditions. However, one of the major limitations in current experimental system for 
studying CRC is the absence of refined animal models to bridge the gaps in 
translational research.   
A genetically engineered mouse model (GEMM, transgenetic mice) is one of the most 
used in vivo models for cancer study. However, it has some weakness: First, only some 
of major genes relevant to human CRC have been to date modified to make GEMM with 
floxed alleles, enabling specifically targeting the colon epithelial cells. The lack of mice 
with variant floxed gene alleles limits the generation of GEMM with either intestine-
specific or inducible genetic modifications. Second, almost all of whole-body gene-
modified or chemical-induced models develop tumors outside the colon or with colon 
cancer as a minor phenotype. Thus, due to its over-simple genetic background, GEMM 
hardly captures all the features of the genetic mutations and epigenetic regulations in 
human CRC diseases. For example, mouse screens for cooperating mutations are not 
always concordant with TCGA results to identify the most common mutations, genomic 
rearrangements and epigenetic in the corresponding human cancer. 
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Subcutaneous xenograft models, the current workhorse for drug screening, lack the 
native gut microenvironment and the property of distant metastasis, thus lead to many 
false positive drugs that can cure mice but fail in patients [4]. Surgical implantation of 
CRC cells under the kidney capsule, or orthotopic implantation through intra-cecum or 
rectal injection overcomes this limitation. However, injection needle tracts create 
potential artifacts for cell egress, disturb the extracellular matrix and artificially generate 
a local inflammatory microenvironment, which confound the research results. 
Additionally, we currently do not have robust, consistent models of CRC liver metastasis 
from primary intestinal sites. Advance methods are required to model more accurately 
CRC metastasis and improve therapeutics.  
In my second project described in the chapter 2, we used chemokine-targeting to 
develop cell line and primary patient-derived xenograft models that recapitulate the vast 
majority of common human somatic CRC mutations as primary gastrointestinal (GI) 
tumors in mice without requiring surgery. Importantly, we utilize early-stage mouse 
blastocyst microinjection techniques to extend this approach and model primary human 
CRCs in immunoproficient mouse hosts. We anticipate that this experimental system 
can help improve our mechanistic understanding of human primary CRC progression to 
liver metastasis and provide a more physiological model than sub-cutaneous xenografts 
for pre-clinical drug screening. 
Transposon-Mediated Mutagenesis System 
Transposons are discrete DNA elements including transposon and transposase, 
which have the unique ability to change their genomic position through “cut and paste” 
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mechanism [12, 13]. The Tc1/ mariner transposons are the most wide-spread 
transposons found in nature and have little insertion site preference, except that they 
always integrate into a TA dinucleotide. Ivics and colleagues genetically engineered a 
synthetic transposase, SB10, which can precisely mobilize the Tc1/ mariner elements in 
all the major types of vertebrate cells. This transposon system was named Sleeping 
Beauty (SB). SB Transposon-based insertional mutagenesis (TIM) provides an 
alternative high-throughput platform for cancer gene discovery [24, 25]. To our 
knowledge, the SB-TIM system has been considered non-biased, efficient, and thus the 
best mutagenesis system to date to simulate somatic mutations in cancer models.  
Copeland & Jenkins Lab, one of our collaborators [9], developed a new mutagenic 
transposon T2/Onc2, which could up-regulate the expression of oncogenes or inactivate 
tumor suppressor genes. T2/Onc2 has been used to model many types of mouse 
cancers through introducing into the mouse germ line by microinjection, and the 
transgenic lines carrying enough high copy numbers of the transposon genes were 
selected to develop mouse tumors in multiple organs. Several research groups reported 
that SB inducing somatic-cell insertional mutagenesis in mice was successfully used for 
the identification of novel cancer genes and signaling pathways through forward 
genetics screen. The T2/Onc mobilization driven by the gastrointestinal tract-specific 
Villin promoter (Vil-Cre) can generate intestine-specific mutagenesis in APC min mouse 
models and this tissue-specific TIM system has been used for the identification of novel 
driver genes causing CRC progression through cooperation of APC mutations.  
Decellularization – Recellularization in Tissue Engineering  
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    Extracellular matrix (ECM) consists of the proteins and other biomolecules produced 
by cells, with cells made up the whole tissues. Each tissue has tissue-specific 
dynamically reciprocal communication in that cells response to the signals of ECM to 
regulate cellular behaviors and the cells in turn alter the composition of ECM and thus 
the entire tissue-specific microenvironment and so on. Similar to normal tissues, ECM 
and tissue microenvironment also play critically important roles in cancer initiation, 
promotion and progression. Studying cancer cells in 3D tissue context can produce 
more comprehensive and physiologically relevant results with concordance of 
translation to the clinical research.  
    The advance in tissue engineering and regenerative medicine shed more light on the 
technology of isolating the whole tissue matrix through efficient removal of cellular 
components. Through acid, enzyme or detergent-based methods, several groups have 
successfully in generating acellular organs of heart, lung, liver and kidney, with some 
further attempts to orthotopic transplantation of the organ constructs by recellularization. 
The decellularized matrix preserves the main proteins and biomolecules in ECM and 
retains complex tissue-specific geometry and structure including relative intact 
vasculature, thus provides an ideal culture platform for cancer cells to grow, form 
shapes and maintain cell-cell, cell-ECM interactions. Recently, Mishera and colleagues 
have developed ex vivo lung cancer models by growing several human lung cancer cell 
lines (A549, H1299 and H460) in the acellular rat lung matrix and the lung cancer cells 
grown in the matrix had features similar to the original human lung cancer. 
    In the chapter 3, we described, to our knowledge, the first ex vivo colon cancer model 
engineered from the native human colon tissue matrix using the decellularization-
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recellularization techniques. Furthermore, we applied the CRC models combined with 
TIM in studying cancer genetics.  
    Currently large-scale and high-throughput genetic sequencing have facilitated the 
identification of genetic alterations in human cancers. However, because tumor 
heterogeneously evolves and numerous passenger mutations confound the footprints of 
driver alterations, most cancer studies using reverse genetics yield numerous and 
complex genetic candidates, making it difficult to identify the driver genes [5]. Another 
major obstacle to distinguish drivers from passengers rises from technical limitations of 
existing experimental systems. Conventional cell culture models as research platforms 
lack the capacity to maintain multiple-cellular interactions and tissue-specific 
microenvironment, which are required for tumor progression. Animal models are short of 
appropriate resolution and sensitivity to track the dynamics of cancer malignant 
transition. Animal study can also show considerable differences from humans with 
regard to requirements for oncogenic transformation. To bypass the above difficulties, 
we engineered ex vivo human CRC models with transposon-based mutagenesis that 
allowed us to perform rapid forward genetics study in human-originated colon tissues for 
exploring novel CRC-driver genes and improve the understanding of CRC biology. This 
work is described in chapter 3 in the dissertation.  
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CHAPTER 1 
The Chemokine 25/Chemokine Receptor 9 Axis Suppresses Colon 
Cancer Invasion and Metastasis 
(Contribution: Steven Lipkin, Huanhuan Chen and Xiling Shen designed the project; 
Huanhuan Chen, Robert Edwards and Serena Tucci performed experiments; Steven 
Lipkin, Huanhuan Chen, Xiling Shen wrote the manuscript; Winfried Edelmann and 
Zeynep H. Gümüş helped with project discussion.) 
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INTRODUCTION 
Colorectal cancer is a leading cause of cancer death worldwide. CRC progresses 
through multiple distinct stages in its evolution. Morphologically, inappropriate 
proliferation and anti-apoptosis cause formation of adenomas, which evolve into pre-
invasive carcinoma in situ. Then, pre-invasive CRCs acquire the ability to invade 
through the submucosa and muscularis, metastasize, and survive outside the colon 
microenvironment niche [1-3]. Mechanistically, mutations activating WNT signaling in 
transformed colon cancer cells are an early event [4-6]. Subsequently, mutations in 
KRAS, TGFBR1, BRAF, TP53, DNA mismatch repair genes, FBXW7, NOTCH, PI3 
Kinase and other signaling pathways accumulate to promote CRC tumor progression to 
invasive and metastatic disease [7-11]. As 5-year survival for early stage CRC is ~90% 
vs. ~15% for metastatic CRC, understanding in great detail the mechanisms that 
regulate the transition from indolent (adenomas and carcinoma in situ) to locally 
invasive early clinical stage(stage I-II) and metastatic later stage(stage III/IV) CRC is 
critical to improving patient outcomes[12]. 
Chemokines are a family of secreted ligands that play important roles in regulating 
lymphocyte intra- and intercellular signaling, anti-apoptosis and trafficking between 
different organs, such as bone marrow and intestinal mucosa[13]. The G-protein 
coupled chemokine receptor CCR9 and its ligand CCL25 comprise a signaling axis that 
is particularly important for the small intestine and colon. Small intestine and colon 
epithelial cells produce CCL25 [14-17]. This attracts circulating CCR9+ T cells to 
intravasate into the gut towards the CCL25 source.CCL25 binding promotes CCR9 Gβγ 
interaction with PI-3 kinase, which initiates a downstream cascade activating AKT 
 26 
 
kinase. AKT phosphorylates several targets, including GSK3B, promoting T cell 
proliferation, anti-apoptosis and mucosal immunity [14, 15, 18-20]. In addition to 
producing CCL25, small intestine and colon epithelial cells also express CCR9. Small 
intestinal epithelial cell CCR9 increases local immune response, while colonic epithelial 
cell CCR9 reduces inflammation, possibly by acting as a CCL25 “sink”[15]. Furthermore, 
melanoma, ovarian, breast and prostate adenocarcinomas express CCR9 [21-25]. This 
is proposed to play a role in tumor cell anti-apoptosis and proliferation. Overall, these 
findings show that CCL25/CCR9 plays a variety of important roles in different cell types, 
including several cancers.  
Here, we reveal a novel role for CCR9 to inhibit colorectal cancer invasion and 
metastasis. Compared to normal colon mucosa, CCR9 is upregulated in adenomas and 
pre-invasive colorectal cancers. In contrast, CCR9 expression is subsequently 
downregulated in invasive and metastatic CRCs. Because the commonly used 
colorectal cancer cell lines we tested were CCR9-, we searched for new cell culture 
models and found that both primary colorectal cancer cell cultures and CCIC lines made 
from early stage tumors are CCR9+. In vivo, systemically injected CCR9+ early stage 
CCIC spontaneously form orthotopic colon and small intestinal xenografts, which has 
never been observed with any previous CRC cell line, while commonly used colorectal 
cancer cell lines (as has been described in the literature) and CCR9- CCIC form only 
extra-intestinal tumors.  Blocking the CCR9-CCL25 axis inhibits CCIC intestine/colon 
tumor formation while increasing extra-intestinal tumor multiplicity. Finally, we show that 
NOTCH signaling, which stimulates CRC invasion and metastasis, promotes CCR9 
proteosomal degradation, inhibits CCL25 dependent AKT signaling and increases extra-
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intestinal colorectal cancer tumors. Overall, these data provide insights into the 
mechanism by which CCR9/CCL25 promotes colon-localized, early stage colorectal 
cancer growth while inhibiting invasion and metastasis, its suppression by NOTCH 
signaling in late stage colorectal cancer, and provide a novel in vivo model system to 
study CRC tumor progression in the native colon microenvironment.   
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RESULTS 
CCR9 is upregulated in pre-invasive CRC and downregulated in invasive and 
metastatic CRC 
    To understand the expression pattern of CCR9 in colorectal cancer, we 
immunostained representative sections from patient tumors.  Cases varied in clinical 
stage from adenoma to carcinoma in situ (Tis) to transmural involvement (T4).  CCR9 
staining intensity was scored for normal crypt epithelium and neoplastic tissue from 
each involved layer of the colon wall (Figure 1). Consistent with previous studies, CCR9 
is expressed in normal colonocytes essentially throughout the entire crypt. To quantify 
CCR9 staining intensity, we used a histopathology scoring system ranging from 0-3. 
Normal colon epithelium had a mean staining intensity of 1.60±0.04, n=55.  CCR9 
staining in adenomatous foci was significantly increased (2.26±0.06, n=46) vs. normal 
tissue.  In contrast, staining intensity progressively decreased in carcinoma in 
situ(2.03±0.08, n=19), and in carcinomas invasive into the submucosa (1.47±0.06, n=44) 
and muscle wall (1.13±0.08, n=42; all p < 0.001) (Figure 1 A-I). Additionally, we 
quantified CCR9 expression in primary CRC culture by FACS. Consistently, high 
percentages (~90%) of early stage (I/II) primary CRC cells areCCR9+, while much lower 
percentages of late stage (III/IV) invasive or metastatic CRCs (~10%) are CCR9+ 
(Figure 1 J). Overall, CCR9 levels are highest in non-invasive tumors (adenomas and 
in situ carcinomas) and progressively downregulated in submucosal invasive, muscle 
invasive and metastatic colorectal cancer tumors, consistent with a potential role for 
CCR9 to suppress invasion and metastasis. 
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   To understand CCR9’s role in colorectal cancer, we tested several commonly used 
colorectal cancer cell lines (HCT116, RKO, SW480 and LoVo) and found very low or 
undetectable CCR9 protein levels (Figure 1 K,L). In contrast, we found that several 
colon cancer initiating cell lines (CCIC) derived from early-stage/colon-localized 
(American Joint Committee on Cancer stage I/II) CRC patients [26, 27] generally have 
robust CCR9 protein expression. In contrast, CCIC lines derived from later stage (III/IV) 
patients whose tumors had spread beyond the colorectum have much lower CCR9 
expression. This suggested that CCIC lines derived from early stage/colon-localized 
colorectal cancer patients might be a useful system for mechanistic studies of CCR9. 
Additionally, while only correlative, these data are consistent with immunohistochemistry 
that CCR9 protein levels are more closely associated with earlier stage CRC tumors 
that have less invasive and metastatic potential vs. later stage tumors with poorer 
prognosis. 
 
Stage I/II CCIC form orthotopic xenograft CRC tumors in the colon and small 
intestine CCL25 produced by small intestine and colon epithelial cells attracts 
circulating CCR9+ T lymphocytes [28]. To understand the in vivo role of CCR9 in 
colorectal cancer, we injected CCIC lines systemically into the tail vein of  
immunodeficient mice (NOG mice).  73.3% of mice injected with early stage CCIC 
became moribund and developed average of 3.7 tumors in intestine/colon at mean 8.55 
weeks post-inoculation (Table 1). Of mice that developed gastrointestinal (GI) tumors, 
69% had tumors in both small intestine and colon, 19% only in colon and 12% only in 
small intestine (Figure 2 H). No upper GI or rectal tumors were seen. Many of these 
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tumors caused intestinal obstructions and pneumatosis coli (gas in the intestine from 
bacterial stasis and dysmotility secondary to obstruction) (Figure 2 A,B), pathologies 
often seen in patients with obstructing primary colorectal cancer adenocarcinomas. 
Evaluation of other organs showed that 35.6% of mice developed an average of 126 
extra-intestinal tumor foci, mostly lung, and all were in mice that also carried 
intestine/colon tumors. In contrast, mice injected with CCIC derived from later stage 
tumors or commonly used colorectal cancer cell lines SW480 or LoVo formed tumors 
only outside the small intestine and colon (Figure 2 H,I). Similar to CCIC dermal 
xenografts and the vast majority of human primary and metastatic colorectal cancer 
tumors, CCIC colon/intestine and extra-GI tumors have adenocarcinoma morphology 
containing distorted crypt-like structures (Figure 2 D-F).  
Mice injected with either early or late stage CCIC also became moribund at significantly 
earlier times post-inoculation vs. commonly used CRC cell lines (P<0.001) 
(Supplemental Figure 1). The colon/intestine tumors we observed could have arisen 
directly from early stage CCIC, or indirectly by stimulating endogenous mouse intestinal 
tumorigenesis. We systemically injected and tracked early stage CCIC carrying the PGK 
promoter driving constitutive expression of an eGFP reporter. First, we tested whether 
these tumors contained human DNA. PCR using two different human centromeric 
repeat sequences from genomic DNA isolated from intestine/colon tumors showed that 
they contain human DNA (Figure 3 A). Next, we examined the lower GI tract from mice 
carrying early stage CCIC colon/intestine tumors for eGFP fluorescence. This revealed 
that GI tumors consist of eGFP+ cells (Figure 3 B, C, D), indicating that the colon/ 
intestine tumors were formed by early stage CCIC in mouse hosts. As anticipated, the 
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intestine and colon sites where tumors formed expressed Ccl25 while sites of ex-GI 
tumors, such as lung, did not have detectable levels (Figure 3 F, G). Interestingly, early 
stage GI CCIC tumors were CCR9+ whereas ex-GI tumors were CCR9- (Figure 3E). 
  
Stage I/II primary CRC cultures and CCIC show CCL25 dependent chemotaxis 
To understand the role of the CCR9/CCL25 axis in primary colorectal cancer cells, we 
cultured tumor cells directly from patient tumors. Cells were sorted for expression of the 
colorectal cancer marker carcinoembryonic antigen (CEA) and plated in Boyden  
chambers. Consistently, more primary early stage colorectal cancer cultured cells 
migrated toward the chamber compartment containing recombinant CCL25 than mock 
control (p<0.001) (Figure 4 A, B) while SW480 did not. Migrated primary early stage 
colorectal cancer cells were double immunopositive (yellow) for CEA (red) and CCR9 
(green) (Figure 4 C). Similarly, consistent with our in vivo xenograft studies, more early 
stage CCIC migrated in vitro towards a chamber containing CCL25 vs. a mock control 
while this activity overall was much lower for experiments with late stage CCIC (Figure 
4 D-F). Altogether, these data show that both CCR9+ early stage colorectal cancer cells 
and CCIC functionally chemotax towards CCL25. 
 
Inhibiting the CCR9/CCL25 axis reduces CCIC colon/intestine tumor formation 
To test the role of CCR9 in CCIC orthotopic colon/intestine xenograft formation, we 
performed cell sorting for CCR9 and systemically injected CCR9+ or CCR9- early stage 
CCIC (Supplemental Figure 5A). Mice injected with CCR9+ CCIC had a high 
incidence of colon/ intestine tumors (both sites produce CCL25), whereas CCR9- CCIC 
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had low incidence (P<0.001) (Table 2). The mean number of colon/intestine tumors in 
mice injected with CCR9+ CCIC was also significantly higher than mice injected with 
CCR9- CCIC. At the same time, the incidence and mean number of tumors outside the 
colon/intestine were significantly higher in mice injected with CCR9- vs. CCR9+ CCIC 
(Table 2).  
To confirm the role of CCR9/CCL25, we used anti-CCL25 antibodies to inhibit 
bioavailable intestinal CCL25. Pre-treating mice with anti-CCL25 antibodies before and 
concurrent with early stage CCIC injection reduced colon/intestine tumor multiplicity 
(Supplemental Figure 5A). Anti-CCL25 antibody treatment also trended towards 
reduced colon/ intestine tumor incidence and increased ex-GI incidence and multiplicity, 
although these differences were not statistically significant (Table 2).  Additionally, we 
used CCR9 short hairpin RNA (shRNA) knockdown in CCIC. Mice injected with CCR9 
shRNA knockdown CCIC had lower incidence, mean number of colon/intestine tumors 
and higher mean extra-intestinal tumors vs. mice injected with CCIC expressing a 
control shRNA (Table 2 and Supplemental Figure 2B). The overall survival of mice 
injected with anti-Ccl25 antibodies or CCR9 shRNA knockdown CCIC was also 
significantly longer vs. control (Table 2 and Supplemental Figure 2C).  
 
The CCR9/CCL25 axis regulates CCIC metastasis out of the GI tract 
To understand whether CCR9/CCL25 regulates CCIC metastasis out of the GI tract, we 
performed three sets of experiments involving antagonism of CCL25/CCR9 signaling 
after GI tumor initiation. First, we injected mice with CCR9+ CCIC, waited 3 weeks for 
colon/intestinal tumors to form and then treated mice with anti-Ccl25 antibodies. This 
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significantly increased both the incidence and multiplicity of CCIC ex-GI tumors (Table 3, 
Supplemental Figure 3D, Supplemental Figure 4 and Supplemental Figure 5B). 
Second, we injected CCR9+ CCIC with doxycycline inducible expression of anti-CCR9 
or control shRNA. Approximately 3 weeks after injection, we administered doxycycline 
to induce CCR9 knockdown. This also significantly increased ex-GI CCIC tumor 
incidence and multiplicity (Table 3,Supplemental Figure 3, Supplemental Figure 4, 
and Supplemental Figure 5B). Third, we created HCT116 (which are CCR9-) sub-lines 
that stably express CCR9 (HCT116 CCR9+) and used IVIS imaging to monitor the sites of 
tumor formation after tail vein injection. While HCT116 cells form ex-GI tumors, HCT116 
CCR9+cells in contrast form GI tumors in addition to ex-GI tumors. Interestingly, stable 
expression of CCR9 also reduces the overall burden of ex-GI tumors, as quantified by 
IVIS photon counting (Supplemental Figure 6).  Altogether, these studies are 
consistent with CCL25/CCR9 antagonism causing CCIC in the intestine and colon to 
migrate outside the GI microenvironment and form additional ex-GI tumors.   
CD26 and SNAL1 are associated with colorectal cancer migration and metastasis[29-
31]. To understand whether they could play a role in CCIC migration outside the GI tract, 
we used shRNA to knock down expression of CD26 or SNAL1 by ~70% (Supplemental 
Figure 2A). However, neither of these gene knockdowns affected colon/intestine or ex-
GI CCIC tumor formation, or survival of mice systemically injected with CCIC 
(Supplemental Figure 2 B, C.).   
 
CCR9/CCL25 stimulates AKT signaling and cell proliferation in stage I/II CRC 
primary culture and CCIC 
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Our hematogenous xenograft studies show that CCR9+ early stage CCIC formed 
colon/intestinal tumors while CCR9- cells formed ex-GI tumors. To understand the 
signaling mechanisms regulated by CCL25/CCR9, we performed gene expression 
profiling of FACS sorted CCR9+ and CCR9- early stage CCIC (both treated with CCL25) 
with the Wafergen Human Oncology Panel Chip.  Mapping all known interactions 
between differentially expressed genes to the Ingenuity Pathway Analysis mammalian 
interaction database revealed a network of CCR9/CCL25 upregulated oncogenic 
transcriptional regulators associated with cell proliferation, including FOS, FOSL1, JUN, 
EGR1 and ETS1 (p=9.86e-12), directly downstream of AKT and NOTCH signaling 
pathways (Figure 5 A).To test whether CCL25/CCR9 regulates AKT signaling in CRC, 
we treated early stage primary colorectal cancer or CCIC cells with CCL25 and assayed 
for phospho-Ser473 AKT, a biomarker of activated AKT signaling. CCL25 treatment 
increased the number of phospho-Ser473+ and Thr 308 CCIC (Figure 5 B-D), 
consistent with activation of AKT signaling.   
NOTCH signaling downregulates CCL25/CCR9 AKT signaling and chemotaxis 
NOTCH signaling plays an important role in both normal intestine and CCIC.NOTCH 
signaling is activated by JAGGED 1 (JAG1) and Delta-like ligand binding to NOTCH 
receptors. This activates multiple proteolytic cleavage events [32, 33], after which the 
NOTCH receptor intracellular domain (NICD) is released and translocates to the 
nucleus. NICD interacts with the DNA-binding protein RBPJκ, which recruits co-
activators and stimulates expression of NOTCH target genes including HES family 
genes[32]. Recently, an important new role for NOTCH signaling in promoting CRC 
invasion and metastasis was demonstrated [11, 34]. Because CCR9/CCL25 is 
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associated with early stage, colon-localized CRCs, we compared NOTCH signaling 
levels in FACS sorted CCR9+ and CCR9– early stage CCIC treated with CCL25. NICD 
and HES1, biomarkers of active NOTCH signaling, were significantly higher in CCR9- 
vs. CCR9+ CCIC (Supplemental Figure 8 A). Confirming these data, we FACS sorted 
CCIC expressing eGFP under the control of a NOTCH responsive promoter containing 
multiple RBPJ binding sites (GFP-NOTCH) (Supplemental Figure 7A). GFP-NOTCH 
High early stage CCIC had lower levels of CCR9 and phospho-AKT (and higher levels 
of NICD and HES1) than GFP-NOTCH Low cells (Supplemental Figure 8B). Next, we 
treated stage I/II CCIC with a high concentration of JAG1. JAG1 treatment increased 
CCIC NICD, HES1 and the number of GFP-NOTCH+ cells (Supplemental Figure 7 C 
and Supplemental Figure 8B). JAG1 also downregulated CCR9 protein levels (Figure 
8C), consistent with a role for NOTCH as an upstream regulator of CCR9/CCL25 in 
colorectal cancer. To understand the mechanism of CCR9 downregulation by NOTCH 
signaling, we analyzed CCR9 mRNA and (co-treated with the proteosomal inhibitor PS-
341), protein levels.CCR9 mRNA levels in two CCIC lines did not change in response to 
NOTCH activation, as measured by qPCR. In contrast, when cells were co-treated with 
the proteosomal inhibitor PS-341, CCR9 protein levels increased (Figure 6 A, B). 
Overall, these data are consistent with a mechanism whereby NOTCHlowers CCR9 
protein levels by increasing its proteosomal degradation. Functionally, we found that 
JAG1 inhibited CCL25 induced AKT phosphorylation and that co-incubation of CCIC 
with JAG1 inhibited CCIC chemotaxis towards CCL25 (Figure 6 C,D). Similarly, in a 
migration assay, addition of CCL25 to the upper chamber inhibited migration to 5% 
serum in the lower chamber, and co-incubation with JAG1 antagonized  migration 
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stimulated by CCL25 (Supplemental Figure 8D, E). We did observe that addition of 
CCL25 downregulated NOTCH2 receptor levels. However, CCL25 did not 
downregulateNOTCH signaling as assayed by NICD and HES1 protein levels (data not 
shown). Therefore, these data are consistent with NOTCH acting upstream of 
CCR9/CCL25 to inhibit AKT and migration, but that this interaction is not reciprocal.  
 
NOTCH signaling promotes CCIC tumor formation outside the colon and intestine 
Our in vitro studies are consistent with the NOTCH pathway acting upstream of 
CCR9/CCL25 to inhibit its function. To understand the in vivo role of NOTCH on the 
CCR9/CCL25 axis in CCIC, we used CCIC expressing a GFP-NOTCH reporter. We 
FACS sorted these CCIC into GFP-NOTCH High and Low cell populations, and injected 
cells systemically into the tail vein of immunodeficient mice. Consistent with the role of 
NOTCHto promote colorectal cancer invasion and metastasis[11], GFP-NOTCH High 
CCIC formed significantly more tumors outside the colon/intestine than GFP-NOTCH 
low CCIC (Figure 6 E and Supplemental Figure 7 C.). Conversely, GFP-NOTCH High 
CCIC formed significantly fewer intestine/colon tumors than GFP-NOTCH Low CCIC. 
Overall, these data are consistent with an in vivo role for NOTCH signaling to inhibit 
CCR9/CCL25 signaling in CCIC and promote invasion, metastasis and tumor formation 
at sites outside the GI tract.  
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DISCUSSION 
Chemokines regulate anti-apoptosis, migration, recruitment of tumor associated cells, 
metastasis and trafficking for many cancers [13]. The CCR9/CCL25 axis specifically 
regulates gut mucosal immunity. CCL25 is produced by small intestine and colon 
epithelia, which recruit to the gut circulating CCR9+ T and dendritic cells, increases AKT 
signaling and prevents T lymphocyte apoptosis[14-17].  Here, we demonstrate an 
unexpected role for GI epithelium produced CCL25 to suppress CRC invasion and 
metastasis. The great majority of colonocytes express both CCR9 and CCL25 [15]. 
Compared to normal human colon, CCR9 is upregulated in adenomas and early stage 
CRC, but downregulated in invasive and metastatic CRC (Figure 1). Early stage 
colorectal cancers have better prognosis and less metastatic potential than late stage 
tumors. Both early stage primary tumor cells and CCIC demonstrate CCL25-dependent 
upregulation of AKT signaling, chemotaxis and proliferation (Figure 4). In colorectal 
cancer patients, AKT signaling (particularly in tumors carrying PIK3CA mutations) is 
associated with a good prognosis and is inversely correlated with later stages[35]. 
Conversely, NOTCH signaling is associated with CRC invasion and metastasis[11, 34] 
(Figure 6). Overall, our data are consistent with a model (Supplemental Figure 9)   
whereby pre-invasive (adenoma, carcinoma in situ) colorectal cancer cells upregulate 
CCR9 levels. Paracrine CCL25 produced by surrounding colon epithelium stimulates 
proliferation and anti-apoptosis signaling that contributes to increased tumor size, and 
likely superficial tumor spread along mucosal margins. This is accomplished 
mechanistically through upregulating AKT signaling and a downstream network of 
oncogenic transcription factors that promote proliferation. As tumors progress, some 
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cells upregulate NOTCH signaling. During this transition, upregulation of NOTCH 
signaling drives proliferation, taking over for CCL25/CCR9 signaling. This causes an 
“invasive switch” that stimulates CCR9 proteosomal degradation, inhibits CCR9/ CCL25 
signaling, promotes NOTCH driven invasion and ultimately metastasis[34]. Consistent 
with this model, NOTCH signaling is higher in CCR9- vs. CCR9+ CCIC. Consequently, 
late stage invasive and metastatic colorectal cancer tumors do not express CCR9, as 
there is no proliferative advantage if CCL25 is absent from the microenvironment of 
metastatic sites. Overall, our data provide insights into the regulation of colorectal 
cancer tumor progression by the CCL25/CCR9 mechanism and the evolution of pre-
invasive to invasive and metastatic CRC cells. Our data also suggests that CCR9 may 
be a useful prognostic marker to distinguish indolent from invasive and metastatic 
colorectal cancer.   
Which NOTCH ligands are most important for stimulating CCR9 downregulation? 
Because there are multiple roles for NOTCH signaling in colorectal cancer, including 
roles in tumorigenesis, progression, chemoresistance and angiogenesis, and because 
there are five canonical NOTCH ligands, additional non-canonical NOTCH ligands (e.g. 
DLKs) that influence signaling levels, and post-translational modification of these 
ligands by glycosyltransferases (e.g. POFUT1) that affect their ability to bind to different 
NOTCH receptors[11, 32, 36-47], the answer is complex . The multiple roles of NOTCH 
signaling in normal colon homeostasis, different CRC mechanisms and the large 
diversity of possible ligands makes the association of individual ligands with NOTCH 
driven colorectal cancer progression by in situ hybridization or immunohistochemistry 
difficult both to study and interpret. However, it is important to note that previous studies 
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have shown that the NOTCH ligand DLL4 is upregulated in vascular endothelial cells 
located within colorectal cancers, but not in endothelium adjacent to normal mucosa 
[44]. Furthermore, some colorectal cancer cells themselves express NOTCH ligands 
such as JAG1 or DLK1 and are able to stimulate paracrine signaling [48, 49], in addition 
to expression of JAG1, JAG2, DLL1 and DLL4 ligands by normal colon epithelial cells. 
Therefore, while the overall situation is complex because of the multiple roles of 
NOTCH signaling in colorectal cancer, it is most likely that DLL4, JAG1, and possibly 
DLK-1, play the most important roles in CCR9 downregulation.   
The chemokine receptor CXCR4 plays an important role in the homing and retention of 
hematopoietic stem cells within the bone marrow microenvironment [50]. Targeted 
disruption of CXCR4 signaling results in rapid mobilization of hematopoietic stem cells 
into the peripheral circulation [51-55]. The finding that downregulation of CCL25/CCR9 
signaling can increase colorectal cancer migration out of the intestine/colon is therefore 
analogous to thesituation with CXCL12/CXCR4 and hematopoietic stem cells. 
Furthermore, because CXCL12 (also called SDF1α) is implicated in metastasis of 
multiple tumor types (with more than 700 citations in Medline on this topic) including 
colorectal cancer, we tested ex-GI CCIC tumors and found that they can express 
CXCR4 at high levels (Supplemental Figure 10). Overall, these findings are consistent 
with a potential colorectal cancer chemokine driven “metastatic switch,” during tumor 
progression. In future studies it will be important to evaluate this potential metastasis 
mechanism. Experimental approaches could include carefully designed experiments 
tracking colon cancer cell CCR9 vs. CXCR4 cell surface membrane protein levels in 
CCIC and other mouse models of stochastic colon cancer metastasis[56], for example 
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by FACS,  to see if expression of these specific chemokine receptors are mutually 
exclusive, and whether CXCR4 correlates with NOTCH signaling upregulation [11]. 
Alternatively, new techniques using dual wavelength luciferase reporter genes driven 
respectively by the CCR9 or CXCR4 promoters could be monitored in vivo in surgical 
models of colon cancer metastasis [57]. Another approach would be to use dual 
immunofluorescence for CCR9 and CXCR4 to screen tissue microarray biospecimens 
from both early and late stage colorectal cancers to evaluate for mutual exclusivity of 
their expression in tumor progression.  Overall, these experiments could create a strong 
rationale to repurpose existing CXCL12/ CXCR4 antagonists that are used for 
hematopoietic stem cell mobilization for clinical trials to inhibit colorectal cancer 
metastasis. 
The commonly used colorectal cancer cell lines we tested express little or no CCR9. 
When injected systemically in mice, some lines can form tumors outside the GI tract. 
However, no spontaneous orthotopic colon/intestine tumor formation has ever been 
reported previously with any colorectal cancer cell line. Precisely why these commonly 
used cell lines do not express CCR9 is unknown. We speculate that this may reflect 
their long term in vitro culture in the absence of CCL25. 
Since our novel in vivo orthotopic CRC tumor formation system models the transition 
directly from GI-localized neoplasms to metastatic carcinomas, the CCIC lines 
described here have the potential to be a useful model to identify important “driver” 
mutations, epigenetic changes and signaling pathways that regulate pre-invasive to 
invasive and metastatic CRC progression, with less confounding by the high 
background “passenger” mutation rates seen in advanced CRC tumors. 
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Functional CCR9 responsive to CCL25 is expressed by multiple tumor types, including 
prostate, ovarian, breast and pancreatic adenocarcinomas and melanomas [21-24, 58]. 
The role of CCR9 in these cancer types is unclear. One possibility is that a driving force 
is the upregulation of AKT signaling and cell proliferation. Because some chemokine 
receptors bind multiple ligands, we speculate additional CCR9 ligands may exist that 
play a role in these tumor types. Alternatively, CCR9 could cause constitutive activity 
even in the absence of ligand in these tumors (perhaps from somatic activating 
mutations) or paracrine CCL25 could be produced by infiltrating lymphocytes. Future 
experiments in these other tumors will be required to understand the precise role of 
CCR9 in these contexts outside of the intestine and colon.  
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METHODS 
Histology and Immunohistochemistry Representative sections from patient CRC 
specimens were immunostained for CCR9 using a 1:150 dilution of anti-human CCR9 
(Abcam #ab38564) with antigen retrieval and peroxidase-based detection.  Cases 
varied in clinical stage from in situ carcinomas (Tis) to transmural involvement (T4).  For 
each case, CCR9 staining intensity was assessed (range 0-3) for normal crypt 
epithelium, and neoplastic tissue from each involved layer of the colon wall using double 
blank scoring method. Intensity ± S.E.M. is shown. 
Cell Culture. AJCC clinical stage I/II (referred to here as early) and stage III/IV (late) 
CCIC lines were generated using colon cancer “stem” cell culture conditions of 
Vermeulen et al [59] with several modifications as previously described by our lab[27]. 
Briefly, CRC patient fresh primary and metastastic tumor biospecimens were 
extensively washed with PBS, minced, and incubated at 37°C with collagenase. Cells 
were then strained through 40-μm filter and cultured as “colonospheres” [59]. 
Colonospheres were cultured in ultralow-attachment flasks in DMEM/F12 containing 
nonessential amino acids penicillin (500 U/ml), streptomycin (500 mg/ml), and 
amphotericin B (1.25 mg/ml) and heparin (4 μg/mL; Sigma). Changes from [59]included 
increased concentrations of epidermal growth factor (40 ng/mL), and basic fibroblast 
growth factor (20 ng/mL) and the addition of B27 supplement (Invitrogen). Cells were 
incubated at 37°C and 5% CO2.  Cells were cloned as single cells, expanded and 
frozen in DMSO. With these conditions clonal cultured colonospheres were considered 
to be CCIC based on the following criteria: (1) 50+% FACS positive status for CD44, 
CD133 and ALDH1 (tested individually)[26], (2) 1:1,000-1:10,000 cell ability to form 
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subcutaneous xenografts in NOG mice, (3) capable of serial self-renewal in sub-
cutaneous xenografts assays, (4) ability to form subcutaneous xenograft tumors with 
adenocarcinoma histomorphology. Additionally, CCIC were also noted to express LGR5, 
NOTCH 1,2 receptors, JAG1, DLL4 and nuclear β-catenin (consistent with expression of 
WNT target genes such as CD44 andLGR5). CCR9/ALDH1 co-expressing cells are also 
observed (data not shown). 
 
Primary CRC culture Primary CRC culture used the method of collagenase /dispase 
enzyme digestion with slight modification, as previously described [60, 61]. Fresh 
samples of CRC were collected in DMEM/F12 supplemented with 10% FBS and 2% 
penicillin/streptomycin, immediately after patient operative resection. Tissue was 
dissected free of fat and blood clots and rinsed 5 times with PBS supplemented with 2% 
penicillin/streptomycin. Then tissue was minced into approximately1 mm fragments and 
digested in DMEM/F12 containing collagenase type XI (150 U/ml, Sigma, St. Louis, MO), 
dispase neutral protease (40 μg/ml, Roche Applied Science) and 1% FBS, stirring at 
37°C for 30 min. After centrifugation, cells were re-suspended in the CCIC culture 
medium containing 5% FBS, 1% penicillin/streptomycin and cultured in the ultra low-
attachment flashes for a short time (1-2 passages), then the cell culture was shifted into 
complete CCIC medium without FBS. FACS with ESA was used to purify CRC and cells 
within 5 passages were used for following experiments.  
 
CCR9 constitutive and inducible knockdown;Snail or CD26 knockdown in CCIC 
and NOTCH reporter CCIC The lentiviral vector pEco-CMV-H1-shRNA-GFP encoding 
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a shRNA hairpin sequence (CCR9: 5’-CTTGTACTGGCTCGTGTTCAT; Snail: 5’-
GAGCTGCAGGACTCTATCCA; CD26: 5’- CATTCCTACACAGCTTCATAT) was used 
for CCR9, Snail or CD26 expression knockdown and the lentiviral vectors pEco-CMV-
H1-GFP (GenTargetInc, San Diego, CA) and pEco-CMV-H1-scrambled-shRNA-GFP 
served as controls. To generate the lentiviral vectors, the above plasmids were 
transfected into HEK293T cells with the Genetargetlentivirus packaging mix 
(GenTargetInc, San Diego, CA) according to the manufacturer’s protocol. For CCR9 
tetracycline inducible knockdown, the same shRNA hairpin sequence against CCR9 
gene was inserted into pLenti-H1-shRNA-RSV (GFP-Puro) vector (GenTargetInc, San 
Diego, CA) and packaged into lentivirus particles as the same previous procedure, 
which were used together with another TetR expression lentivirus (RFP-Bsd) 
(GenTargetInc, San Diego, CA) to infect CCICs. After antibiotic selection and GFP/RFP 
dual FACS purification, the CCR9 shRNA knockdown can be induced by1ug/ml (in vitro) 
or 1mg/ml (in vivo) doxycycline. NOTCH signaling reporter CCIC was generated by 
infecting CCIC with pCignalLenti RBP-Jk Reporter (GFP) ready lentivirus 
(SABiosciences, Inc.). After infecting CCIC lines with these lentiviral vectors, stable 
knockdown clones were obtained through antibiotic selection of blasticidin (Invitrogen, 
Carlsbad, CA). The efficiency of the CCR9, SNAIL or CD26 knockdown in CCIC was 
verified by Western Blotting and efficiency of NOTCH signaling reporter was tested by  
2 μg/ml Jagged-1[62-64] (AnaSpec) treatment following by GFP-FACS sorting. 
 
CCIC xenograft tumor formation in colon/intestine and other organs 0.5-1 x 
106CCIC or common CRC cells were injected into 6-8 weeks old non-obese 
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diabetic/severe combined immunodeficient (NOD/SCID) mice (Jackson Laboratory, Bar 
Harbor, Maine) by tail vein injection. Tumor incidence was monitored 2-3x weekly. 
When mice became moribund, they were sacrificed immediately, necropsy performed 
and tumors harvested using a dissecting microscope. For ex vivo GFP imaging of tumor 
tissues, lentiviral infection by the pEco-CMV-GFP vector was used to generate CCIC 
lines that stably express GFP and maintained in puromycin selection. 106 of these 
fluorescent CCIC were systemically injected as described above. Intestinal tissues 
harvested at the time of sacrifice were analyzed for GFP expression with Cri Maestro 
Imaging Systems (Cambridge Research & Instrumentation Inc, Woburn, MA). 
For the CCR9 study, native CCICs, CCICs with CCR9, Snail (SNAL1) or CD26 
knockdown (or commonly used CRC cell lines such as HCT116, etc. as indicated), 
CCR9+ CCIC with CCR9 inducible knockdown were intravenously inoculated into the 6-
8 weeks old NOD/SCID mice by tail vein. Mice that became moribund were sacrificed 
immediately, whereas the rest were closely monitored for 16 weeks before sacrifice. To 
test whether CCL25 antibody could inhibit the CCL25-CCR9 GI homing mechanism in 
vivo, a dose of 100 ug goat anti-mouse CCL25 neutralization antibody (R&D systems, 
Cat# AF-481-NA), was IP administrated to each mouse twice (the same dose and 
schedule as used in [65]). As a negative control, a dose of 100 ug Goat IgG (R&D 
systems) was administered to each mouse in the control group. Then 1 x 106CCIC were 
injected into the mice 8 hours after or with the injection of the antibody. To test whether 
extra-GI metastasis is induced by CCR9/CCL25 signaling blockade, CCL25 
neutralization antibody with the same dose was IP administrated to each mouse every 
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three days or 1 mg/ml doxycycline in drinking water was given to mice every other days 
starting from the fourth week after CCIC inoculation until mice get moribund.  
Genomic DNA extraction and semi-quantitative PCR 
Genomic DNA from CCIC culture, lung and intestinal adenomas normal tissues, or 
mouse tail was extracted using a tissue DNA extraction kit (Qiagen, Valencia CA). 
Semi-quantitative PCR was done followed by DNA gel electrophoresis. Human 
centromeric repeat loci were used as markers to detect human cells in harvested mouse 
tissues. Primer sequence pairs used are (1) 5’-GAGTGCACATTCAGACAAGACCC-3’ 
and 5’- CCATTAGAGAGCTTTCCTCATTGC-3’or (2) 5’-
CGTGTGTTTTTGGTTACTTCTCCCC- 3’ and 5’-CTTAGCCATTGCCCATTGATGGA- 3’. 
Quantitative real-time PCR 
Total RNAs from cells were extracted by using RNeasy Kit (Qiagen, Valencia CA). 2 μg 
of total RNAs were reverse-transcribed into cDNA by using  RT first stand kit (SA 
Biosciences) and RNA levels, normalized to GAPDH as the comparative CT (cycling 
threshold)= CT (target)- CT (control), were analyzed by the iCycler (Bio-Rad).  
Primer pairs used are (1) GAPDH 5’-ACAGTCAGCCGCATCTTCTT-3’ and 5’-
AATGAAGGGGTCATTGATGG-3’; (2) HES 15’- ACGACACCGGATAAACCAAA-3’ and 
5’-CGGAGGTGCTTCACTGTCAT-3’; (3) CCR9 5’-CACAGACTTCACAAGCCCTA-3 
and 5’-GTACAAGGGTGGGAGGAAAT-3’ . 
Transwell migration assay 
Transwell Boyden chambers (BD Pharmingen Mountain View, CA) of 8-μm pore size 
were used to evaluate primary CRC cell and CCIC migration in vitro. Primary CRC cells 
or CCICs were seeded at a density of 5 x 105 per well into the upper chamber. CCIC 
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culture medium as described above with 100 ng/ml recombinant mouse CCL25 protein 
(R&D systems Inc; Minneapolis, MA) or 5% FBS was loaded into the lower chamber. 
Chambers of cells were incubated in 37oC and 5 % CO2 conditions for 8-12 hours. At 
the time of harvest, cells remaining inside the upper chambers were removed while cells 
attached to the lower surface of the membrane were fixed and stained with 
hexamethylpararosaniline chloride (Crystal violet) (Sigma, St Louis, MO) or 
immunofluorescence staining with anti-CCR9 or CEA antibodies, followed by imaging 
analyses. 
SmartChip RT-PCR Procedures and Functional Analysis 
Early stage CCIC were FACS sorted into CCR9+ and CCR9- subpopulations. 24 hours 
afterwards, cells were treated with100ng/ml human CCL25 for 30 min. RNA was 
extracted from both populations using PureLink RNA Mini kit (Invitrogen) and analyzed 
using the SmartChip Real-Time PCR System (WaferGen Biosystems, Fremont, CA). 
Briefly, cDNA was prepared using 1 ug of total RNA per sample per manufacturer’s 
recommendation. A PCR cocktail containing SYBR Green I dye and the equivalent of 
1000 ng of starting RNA for each sample was loaded onto the SmartChip Human 
Oncology V2 Panel (containing 1,296 unique real-time PCR reactions in quadruplicate 
for a total of 5,184 reactions/sample). The volume was 100 nL with an equivalent of 96 
pg of RNA loaded per reaction. Forty cycles of real-time PCR were performed on the 
SmartChip Cycler collecting both raw Ct and Tm of each gene and sample for data 
analysis.  A data quality screen on amplification, Tm curves, and Ct and Tm variability 
was performed to remove any outlier data. All-means normalization was performed on 
quadruplicate PCRs and delta-delta Ct calculations were used to determine fold change 
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in expression. Genes either with a log2 fold change by a factor of greater than 1.8 (that 
correlates to ~3.3 fold or higher), or expressed in only one sample with min raw of Ct of 
24.99 were deemed significantly differentially expressed between CCR9- and CCR9+ 
early stage CCIC cells.The complex biological processes that differentiate between 
CCR9- and CCR9+ CCIC were examined in the context of biomolecular networks. The 
interaction network shown in Figure 5 was generated with Ingenuity Pathway Analysis 
(IPA), a web-delivered application used to discover, visualize and explore relevant 
networks (www.ingenuity.com). Gene symbol identifiers and log2 fold changes of 
differentially expressed genes were uploaded to IPA, each identifier was mapped to its 
corresponding gene object in the IPA Knowledgebase and direct interactions were 
queried only between these gene objects. The direct interaction network of differentially 
expressed genes between CCR9- and CCR9+ CCIC was manually integrated with 
signaling proteins known to be involved in the CCR9/CCL25 pathway. 
 
Statistics Summary 
 
All experiments were done with four to eight samples per group, unless otherwise 
indicated, and all results were derived from at least five independent experiments. 
Values are expressed as mean ± SEM. For Student’s t test, a 2-tailed test was used.  
A p value less than 0.05 was considered significantly. Statistical calculations were 
performed with the Statistical Package for the Social Sciences version 11.5 software 
(SPSS Inc, Chicago, IL) or GraphPad. The statistical test used for each figure or table 
panel is indicated.   
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Figure 1. CCR9 is expressed in early stage CRC and early stage colon cancer initiating cells 
(CCIC). CCR9 protein in normal colon epithelium (B), pre-invasive (A&C), invasive (D&E) and liver 
metastatic (F&G) CRCs are shown by immunohistochemistry with anti-human CCR9 and developed by 
DAB (brown). Dotted line in E indicates the boundary between normal epithelium (CCR9+) and invasive 
CRC (CCR9-).(H), negative control with control IgG; Scale bars, 100μ in A,D,F; 50 μ in E,G,H; 10 μ in 
B,C (I) CCR9 expression levels by immunohistochemistry scoring. Error bars indicate SEM. * and ** 
indicate statistical difference with P < 0.001 and P<0.01, respectively, compared to normal colon.  (J) 
FACS quantification of membrane and cytoplasmic CCR9+ cells in early or late stage primary CRCs. 
Gates are set for high CCR9+ signal intensity.(K) Western blot of CCR9 protein levels in common CRC 
lines (RKO, SW480, LoVo), 3 early stage CCIC lines (Stage I/II) and 2 late stage CCIC lines (Stage III/IV), 
β-actin is loading control. Lymphoma cells are used as a positive control for CCR9.(L) FACS 
quantification of cell surface membrane CCR9+ cells in common CRC lines (HCT116 as representative), 
early stage CCIC and late stage CCIC (early stage CCIC1 and late stage CCIC1 as representative).  
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Figure 2.Early stage CCIC form orthotopic xenograft tumors in mouse intestine, colon and other 
sites. (A)Post-mortem analysis of NOD/SCID mice with tail vein-injected CCIC (4X). Arrows show CCIC 
tumors in lung (white spots; upper part of photo) and intestine (lower part of photo). Small bowel is 
distended and inflamed. (B)Close up of mouse abdomen showing (1) distended small intestine loop 
proximal to CCICtumor obstruction with adhesion to adjacent (non-obstructed and grossly normal) small 
intestine loop and (2) Pneumatosisintestinalis from bacterial stasis in right colon proximal to another CCIC 
obstruction.(C) High low power light microscopy close up of CCIC jejunal adenocarcinoma, Scale bars, 
0.5 mm. Multiple CCIC tumors with histopathology in small intestine (D), colon (E&F) and lung (G). Arrow 
denotes adenocarcinomas in D-G. Scale bars,100μ. (H)Xenograft tumor incidence by site of implantation 
mice injected with CCIC or CRC cell lines. * P< 0.01 and **P< 0.001 compared to non-CCIC. Error bars 
indicate S.E.M.  
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Figure 3.CCIC colon and intestinal tumors consist of human cells and are CCR9 positive. 
(A). PCRof human centromeric repeat sequences from DNA extracted from CCIC (positive 
control), CCIC injected mouse tail, intestine, lung tissue and no DNA control (negative control).  
(B). Maestro GFP imaging system images of intestinal tumor of PGK-eGFP expressing CCIC. 
Scale bars, 0.5 cm.(C).Light microscopy close up of eGFP+ CCIC tumor in (B).Scale bars, 0.5 
mm.(D). Anti-GFP-immunofluorescence imaging of CCIC intestinal tumor with adenocarcinoma 
morphology. Left upper window shows H+E staining of the same intestinal tumor as control. 
Arrows indicated eGFP+ cells. M, mucosa. Scale bars, 100μ.  (E). CCR9 immunofluorescence 
of CCIC intestinal and lung tumors.CCR9 protein was detected by anti-human CCR9 antibody 
(green) and nuclei were stained with DAPI (blue). Scale bars, 50 μ. (F).CCL25 
immunofluorescence in mouse intestine and lung.CCL25 expression was detected by anti-
mouse CCL25 antibody (red) and nuclei were stained with DAPI (blue). Scale bars, 100 μ. (G). 
Anti-CCl25 antibody western blot showing CCL25 expression in mouse intestine but not lung. β- 
actin is loading control. 
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Figure 4.CCL25 dependent chemotaxisin early stage primary CRC and CCIC. 
(A)Boyden chamber assay of 7 early stage primary CRCs chemotaxis to chamber containing 
CCL25. (-) CCL25 absence or (+) CCL25 presence. Error bars indicate S.E.M. *P < 0.0001 
compared to matched (-) cells by one-way ANOVA (n=4). SW480 is used as a negative control. 
(B)Crystal violet staining of early stage primary CRC cells migrating into chamber with CCL25 
(bottom) or mock (top).Scale bar, 50μ. (C).CEA (Red) and CCR9 (green) immunofluorescence 
of early stage primary CRC cells that migrated to chamber with CCL25. DAPI, blue. Scale bar, 
10μ. IgGis negative control. (D) Crystal violet staining of Transwell chambers with early stage 
CCIC1 or late stage CCIC1(as representatives) that have migrated to CCL25or PBS (mock). 
Scale bar, 50μ. (E)CCR9 immunofluorescence of early stage CCIC that migrated to CCL25 
containing chamber. CCR9 (green) and DAPI (blue).Control IgGis used as negative control. 
Scale bar, 10μ.(F) Percentage of earlyor late stage CCIC that migrated to CCL25 or mock (PBS) 
in Transwell assay.  **P<0.001.  
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Figure 5.CCR9/CCL25 Increases AKT signaling in early stage CRC primary culture cells and 
CCIC.(A)Ingenuity Pathway analysis (IPA) direct interaction network of differentially expressed genes 
between CCR9- and CCR9+ early stage CCIC with signaling proteins known to be involved in the 
CCR9/CCL25 pathway(please see Method Section (SmartChip RT-PCR Procedure and Functional 
Analysis).  Solid lines correspond to all direct interactions in IPA database. Dashed lines represent 
indirect interactions. Genes either with a log2 fold upregulation (red nodes) or downregulation (green 
nodes) are integrated in the signaling network. Blue lines correspond to direct interactions in NOTCH, 
AKT and GSK3β signaling pathways. (B). Levels of phosphorylated AKT (Ser473 &Thr 308) and GSK-3β, 
which are increased by incubation with 0.5 or 1.0 µg/ml CCL25 for 30 min in early stage CCIC by western 
blot. β-actinis loading control. (C). Levels of phospho-AKT (Ser 473) in early stage primary CRC cultured 
cells and early stage CCIC1 after 30 minutes of 0.5 ug/ml CCL25 treatment. Imaging analysis software 
Ariol SL-50 was used to evaluate immunofluorescence signals of cells (-) or (+) CCL25. * P < 0.001 
compared to control by one way ANOVA. Error bars indicate S.E.M. (D).Phospho-AKT (Ser 473) in early 
stage primary CRC cultured cells after treatment with 0.5 ug/ml CCL25 for 30 minutes as detected by 
immunofluorescence (green). Scale bar, 10μ.  
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Figure 6.NOTCHdownregulates CCR9/CCL25 axis signaling in early stage CCIC and 
increases extra-GI tumor formation. (A)CCR9 mRNA levels in CCR9+ cells of early stage 
CCIC1 & CCIC2 in response to JAG1 induced NOTCH activation using quantitative PCR, HES1 
is used as positive control.(B)CCR9 protein levels in CCR9+ early stage CCIC1 & CCIC2 co-
treated with or without proteasome inhibitor (100nM PS341, 4 hours before harvest) in response 
to JAG1 induced NOTCH activation using western blot, HES1 is used as positive 
control.(C)Pretreatment of CCIC with 5μg/ml JAG-1 peptide for 8 hours suppresses CCL25 
dependent chemotaxis in Boyden chamber assay. *P < 0.0001 vs. control by one way ANOVA; 
**P < 0.001 vs. CCL25 alone. (N=3). Error bars indicate S.E.M. (D)Pretreatment of CCR9+ 
CCIC with 2μg/ml JAG1 peptide for 8 hours suppresses CCR9 protein and CCL25 
inducesphospho-AKT (Ser473) levels, with essentially no change in total AKT levels. Western 
analysis used anti- human CCR9, phospho-AKT, total AKT (AKT 1, 2, 3), NICD and HES1 
antibodies. β-actin was used as a loading control. (E)CCIC carrying GFP-NOTCH reporter were 
sorted into NOTCH high and low subpopulations by FACS and injected into NOD/SCID tail vein. 
NOTCH high CCICform more extra-GI tumors while NOTCH low CCIC form more GI tumors. 
Error bars indicate SEM. ** and * indicate statistical difference with P < 0.001 and P<0.05, 
respectively, comparing to each other.Also see supplemental figures 6 and 7. 
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                                                             Mean                 GI Tumor           Mean GI           Ex-GI Tumor        Mean Ex-GI      
        Cells                  # Mice           Progression          Incidence           Tumors /           Incidence       Tumors/Mouse     
                                                           (weeks)                    (%)                 mouse                     (%)  
   Early Stage 
      CCIC 
       62       8.6        73.3       3.7        35.6       126.0 
   Late Stage 
      CCIC 
       11       6.5*          0*         0*        91.0*        71.1* 
  Non-CCIC 
  CRC lines 
       24      11.8*          0*         0*        20.0*        66.2* 
 
 
Table 1. CCIC and common CRCs form orthotopic xenograft tumors in mouse intestine, colon and 
other sites. colon/intestine and ex-GI tumors from mice injected with cells by tail vein. Asterisks denote 
statistically significant differences among CRC cell lines SW480 and LoVo, early and late stage CCIC as 
determined by one way ANOVA. * P< 0.01 compared to early stage CCICs. 
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                                                             Mean                 GI Tumor           Mean GI           Ex-GI Tumor        Mean Ex-GI      
        Cells                  # Mice           Progression          Incidence           Tumors /           Incidence       Tumors/Mouse     
                                                           (weeks)                    (%)                 mouse                     (%)  
   CCR9+ 
 
        8         9.4       75.0*       3.8*       25.0         8.3* 
   CCR9- 
 
        8        10.0       12.5       0.25       87.5        75.6 
Anti-CCL25
 a
 
(Pre-injection) 
        6        11.3       28.5       1.1*       100.0        95.9 
Control IgG 
 
        6         9.2       83.3       3.0        83.3        77.5 
  CCR9 KD
 b 
 
        7        13.0*       14.3*       0.3*       85.7        105.0* 
   Control 
   shRNA    
 
        7         9.6       100.0       3.7       71.4        82.5 
 
a
anti-CCL25 (pre-injection) means mice were IP injected with anti-CCL25 neutralization antibody before 
and concurrent with CCSC tail vein injection.  
b
CCIC with CCR9 shRNA knockdown were tail vein injected in mice. 
 
Table 2.CCR9/CCL25 is required for CCIC colon/intestine tumor formation. 
mice injected with early stage CCIC.Rows1-2:Mice injected with CCR9+ CCIC or CCR9- CCIC 
(*P<0.001 for Row 1-2 comparison). Rows 3-4: Anti-Ccl25 antibody reduces GI tumor incidence 
(*P<0.05 for row 3-4 comparison). Rows 5-6: CCR9 shRNA lentiviral knockdown (KD) reduces 
GI tumor incidence and multiplicity, and increases ex-GI multiplicity (*P < 0.01 for row 5-6 
comparison).  
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                                                             Mean                 GI Tumor           Mean GI           Ex-GI Tumor        Mean Ex-GI      
        Cells                  # Mice           Progression          Incidence           Tumors /           Incidence       Tumors/Mouse     
                                                           (weeks)                    (%)                 mouse                     (%)  
   Anti-CCL25
a
 
(post injection) 
       7        7.9        71.4        2.4        42.8*         2.9* 
   Control IgG 
 
       7        8.7        85.7        3.3          0          0 
   CCR9
 b
 
   Inducible KD 
       8        8.1        62.5        2.2        50.0*         3.4* 
   Control 
   shRNA    
 
       8        8.9        87.5        3.2        12.5         0.2 
 
a
anti-CCL25 (post injection) means mice were IP injected with anti-CCL25 neutralization antibody three 
weeks after CCR9+ CCIC tail vein injection. 
b
CCR9+CCIC with CCR9 inducible shRNA were tail vein injected in mice and CCR9 knockdown were 
generated in vivo by administration of doxycycline three weeks later.   
 
Table 3. BlockingCCR9/CCL25 signaling after intestinal tumor formation increases 
metastasis. Mice injected with early stage CCIC. Top, after three weeks to allow GI tumors to 
form from injected CCR9+ early stage CCIC, mice were IP injected with 100 μg/mouse goat 
anti-mouse CCL25 neutralization antibody or goat control IgG every three days until moribund. 
The mice in anti-CCL25 groups formed extra-intestinal metastatic tumors in abdominal tissues, 
pancreas, kidney and liver (*P<0.001 statistically significant different to goat control IgG 
treatment, row 2).Bottom, after 3 weeks to allow GI tumors to form from injected CCR9+ early 
stage CCIC carrying either doxycycline regulatable anti-CCR9 or control shRNA, 1mg/ml 
doxycycline in drinking water was given to the mice every other day until moribund to induce 
CCR9 knockdown in tumor cells.  The mice with inducible CCR9 knockdown formed extra-
intestinal metastatic tumors in abdominal tissues, pancreas, kidney and liver (*P < 0.001). Also 
see supplemental figures 2 and 3. 
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SUPPLEMENTAL INFORMATION 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Immunohistochemistry For mouse experiments, histology and immunohistochemistry 
were performed on paraffin-embedded or frozen sections from xenograft tumors as 
previously described [27]. Intestinal, extra-GI tumor and corresponding normal tissues 
were snap frozen in OCT (Fisher Scientific, Pittsburgh, PA) and fixed in 10 % buffered 
formalin followed by paraffin embedding. For immunofluorescence, sections were 
immunostained with antibodies, counterstained with 4,6-diamidino-2-phenylindole 
(DAPI). H+E adjacent sections were used for comparison. 
Immunocytochemistry. Cells were fixed with mixture of acetone and methanol (1:1) at 
-20°C for 20 min, then rinsed three times with PBS. Following cells were incubated in a 
blocking solution (5% BSA or normal serum (goat, rabbit or horse) and 0.1% Triton-X in 
PBS) for 1 hour. For single or co-immunofluorescence staining, primary antibodies 
diluted in blocking solution were added overnight at 4°C overnight. To ensure specificity, 
a no primary antibody control staining was performed. The slides were then washed in 
PBS and incubated with the appropriate secondary antibody for 1 hour at room 
temperature and counterstained/mounted with Vectashield containing DAPI (Vector 
Laboratories). Images were acquired on an inverted fluorescence microscope (Nikon 
Eclipse E800, Morrell Instruments). Ariol SL-50imaging software (Applied Imaging 
Instruments) was used to quantify biomarker staining. At least n=100 cells from three 
independent staining experiments were analyzed. Data are presented as means ± SEM 
and the significance was tested with the Student t test.  
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Fluorescent activated cell sorting (FACS) analysis FACS with anti-epithelial specific 
antigen (ESA, BD Pharmingen #347197) antibody was used to purify primary CRC cells 
[26, 66] or with anti-CCR9 antibody (BD Pharmingen Mountain View, CA) to sort CCR9+ 
and CCR9- CCIC, essentially as previously described [26, 66]. Cells were first 
incubated with anti-human CCR9 antibody for 30 minutes on ice and then were washed 
in 1% BSA/PBS buffer. FACS was then used to separate CCIC into CCR9 positive and 
negative sub-groups by signal intensity gating. Approximately 6-8 hours after sorting, 
CCR9+ and CCR9- subsets from 1x 106 CCIC were inoculated into two mice by tail vein 
injection and monitored as described above.  GFP-NOTCH FACS sorting was 
performed as described (44). 
Western Blotting 
Isolated mouse intestine, lung tissues, cultured CCIC, or ATCC CRC cell lines were 
homogenized in RIPA buffer and complete protease inhibitor cocktail (Roche Applied 
Science, Indianapolis, IN)] with brief sonication on ice, and centrifuged for 5 minutes at 
14,000 r.p.m to remove large debris. Protein concentration of the supernatant was 
determined by Bradford protein assay (Bio-Rad Laboratories Inc, Hercules, CA). Fifty 
micrograms of protein derived from tissue or cell lysates were separated by SDS-PAGE 
and transferred to polyvinylidenedifluoride membranes. Following blocking, membranes 
were probed with primary antibodies to determine different levels of protein expressions. 
Specific antibodies targeting CCR9 (Abcam, Cambridge, MA), CCL25 (R&D systems 
Inc; Minneapolis, MA, Cat# AF-481-NA), AKT (Cell Signaling, Inc, Cat# 9272), phospho-
AKT (ser 473, Cell Signaling, Inc, Cat# 9271), phospho-AKT (thr 308, Cell Signaling, Inc, 
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Cat# 9275),  GSK-3β (Cell Signaling, Inc, Cat# 9315), phosphor-GSK-3β (Cell Signaling, 
Inc, Cat# 9336), NICD (R&D Systems, Cat# AF3647), HES1 (Santa Cruz, Cat# sc-
13842), Snail (Cell Signaling, Cat# 3879), CD26 (Calbiochem, Cat# IM1004) were used, 
and anti-actin antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, Cat# sc-1616-R) 
was used as internal controls. Immunoreactive antibody-antigen complexes were 
visualized with the enhanced chemiluminescence reagents from GE Healthcare 
(Uppsala, Sweden). The software of Quantity One (BioRad) was used to semi-quantify 
protein levels in western. 
Generation of CCR9 constitutive expression CRC line. 
 The SureTiter TM lentivector (GenTarget Inc, San Diego, CA) in which the sub-cloned 
human CCR9 ORF sequence (gene ID: NM_006641) and a firefly luciferase gene were 
under control of CMV promoter was used to generate constitutively CCR9 expressing 
cell lines. To generate the lentiviral particles, the above plasmids were transfected into 
HEK293T cells with the Genetarget lentivirus packaging mix (GenTarget Inc, San Diego, 
CA) according to the manufacturer’s protocol. The common used CRC line HCT116 
was infected with lentivirus and positive cells selected by antibiotic. 
Luciferase imaging in whole animal or ex vivo tissues:   
Each NOG mouse was tail vein injected with 0.5x106 CCR9 constitutively expressing or 
scrambled control HCT116 cells and tumor formation was determined by luciferase-IVIS 
imaging system every 3 days  For luciferase imaging, D-luciferin of 1.5mg/10g body 
weight was intra-peritoneally injected into mice and 10 min later, luciferase imaging 
(Xenogen IVIS-200) was applied on whole-mouse body or ex vivo tissues.     
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Cell proliferation assay 
CCR9+ primary CRC and CCIC were FACS sorted and seeded in ultro-low attachment 
24-well plates for 12 hours. 100ng/ml human CCL25, 1μg/ml CCR9 neutralizing 
antibody (R&D systems Inc;), 2 μM pan-AKT inhibitor Triciribine (Sigma) or control goat 
IgG were added into culture medium and cells were continued to incubate for 36 hours. 
The cellular ATP (adenosine triphosphate) levels were measured to quantify cell 
proliferation and viability using the ViaLightPlus Kit (Lonza Rockland, Inc.) and GloMax-
20/20 Single-Tube Luminometer (Promega) per manufacture instructions.  
 
SUPPLEMENTAL INFORMATION 
All experiments were done with four to eight samples per group, unless otherwise 
indicated, and all results were derived from at least five independent experiments. 
Values are expressed as mean ± SEM. For Student’s t test, a 2-tailed test was used.  
A p value less than 0.05 was considered significantly. Statistical calculations were 
performed with the Statistical Package for the Social Sciences version 11.5 software 
(SPSS Inc, Chicago, IL) or GraphPad. The statistical test used for each figure or table 
panel is indicated. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1. Related to Figure 2. Survival of mice systemically injected with 
early stage CCICs, late stage CCICs and non-CCIC CRC lines. Kaplan-Meier survival 
analysis of mice after tail vein injection with early stage CCIC (blue), late stage CCIC (grey) or 
the non-CCIC commonly used CRC cell lines LoVo and SW480 (black). P<0.0001 difference 
between the early stage CCIC and commonly used CRC cell lines by log-rank test (Graphpad 
Prism software version 5). 
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Supplemental Figure 2. Related to Figure 5. Anti-Ccl25 antibody systemic injection or 
shRNA knockdown of CCR9, but not CD26 or SNAIL, increases survival of mice 
systemically injected with CCIC. (A) shRNA constitutive knockdown efficiencies of CCR9, 
CD26 or SNAIL in CCIC were tested by western (left) and quantified (right) by using western 
quantification software of Quantitity One (BioRad). (B) Xenograft tumor incidence in mice 
injected with CCIC expressing anti-CCR9, SNAIL1 or CD26 shRNA knockdown, organized by 
tumor site. * P< 0.01 compared to scrambled shRNA control. Error bars indicate S.E.M. (C) 
Kaplan-Meier survival analysis of mice after tail vein injection with anti-Ccl25 antibodies or CCIC 
lentivirally infected with scrambled shRNA control (Mock), shRNA against CCR9, SNAIL1 or 
CD26. Survival curve data match Table 1. P=0.0007, Log Rank test comparison of overall 
survival of mice injected with CCIC expressing either scrambled shRNA control vector or anti-
CCR9 knockdown sequences (Graphpad Prism version 5).  P=0.023 Log Rank test comparison 
of overall survival of mice injected with anti-Ccl25 or IgG control (Graphpad Prism version 5).   
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Supplemental Figure 3. related to Figure 6. CCR9/CCL25 signaling is inhibited after CCIC 
intestinal tumor initiation by anti-CCL25 antibody treatment or CCR9 inducible shRNA. 
(A). Schematic of CCR9 inducible shRNA, in which anti-CCR9 hairpin sequence was cloned in 
the 3’pH1 TetO promoter. Expression of anti-CCR9 hairpin was inhibited by TetR (Tet-repressor) 
and induced by tetrycycline derive doxycycline. (B). Efficiency of CCR9 inducible knockdown in 
CCIC. The CCR9 protein levels in CCICs with only shRNAtetO vector, tetO + tetR or tetO+tetR+ 
doxycycline were detected by anti-human CCR9 antibody (left) and semi-quantified (right)by 
Quantitity One (BioRad).(C & D) Xenograft tumor incidence in mice injected with CCR9+ CCR9, 
and anti-CCL25 antibody therapy (C) or CCR9 inducible knockdown (or control, scr) by 
doxycycline (D) three weeks after tail vein injection organized by tumor site. * P< 0.01 compared 
to mock control. Error bars indicate S.E.M. 
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Supplemental Figure 4. related to Figure 6. CCIC extra-GI metastatic tumors are 
induced by anti-CCL25 treatment or CCR9 inducible knockdown. (A)and (B)Light 
microscopy of CCIC abdominal metastasis. (C) Light microscopy of CCIC liver 
metastasis, Metastatic foci are indicated by arrows. (D). H+E of CCIC metastatic tumors 
in pancreas. Arrows denote metastatic foci. Scale bar, 100μ. 
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Supplemental Figure 5. related to Table 2 and 3. (A). Schema of the experimental 
procedures in Table 2. (B)Schema of the experimental procedures in Table 3. 
Colon/intestine tumors (blue) and ex-GI tumors (green) dots. 
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Supplemental Figure 6. Related to Figure 6. CCR9 overexpression in HCT116 
significantly increased GI tumor formation and reduced extra-GI tumor 
formation (A). Western blot of CCR9 expression in HCT116 cells transfected with 
control vector or CCR9 constitutive expression vector. β-actin is loading control. (B). 
Quantification of GI and extra-GI tumors in mice that have HCT116 cells transfected 
with either CCR9 overexpression or control vector (n=6) injected by tail vein. Xenograft 
tumors were quantified by luciferase - photon signals with Xenogen software. ** P< 
0.001; * P< 0.01 compared to the control group. Error bars indicate S.E.M. The whole-
mouse (right upper panel) or an ex vivo GI (right down panel) representative imaging is 
shown in (C). 
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Supplemental Figure 7. related to Figure 8.CCICNotch reporter cells and in vivo 
xenografts formed by Notch high and Notch low CCICs. (A) schematic of Notch 
GFP reporter vector which has tandem repeats of RBP-Jk transcription responsive 
elements (TRE) binding to Notch downstream transcriptional factor RBP-Jk, activating 
promoter (TATA) and GFP expression. (B)CCIC Native Notch signaling was detected 
by GFP and increased when treated with 3μg/ml JAG1 for 4-6 hours. Scale bar, 
20μ.(C)Xenograft tumor incidence in mice injected with FACS sorted GFP-Notch high or 
GFP-Notch low CCIC, organized by tumor site. * P< 0.01 compared to mock control. 
Error bars indicate S.E.M. 
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Supplemental Figure 8. Related to Figure 8. NOTCH downregulates CCR9/CCL25 axis 
signaling in early stage CCIC, and early stage CCIC chemotaxis to 5% FBS is inhibited by 
CCL25 and partially restored by JAG1 (A)CCR9+ CCIC have lower NICD and HES1 levels vs. 
CCR9- CCIC as shown by western blot. (B). GFP-NOTCH reporter CCIC were sorted into high 
and low NOTCH signaling sub-populations by FACS; CCR9 and phospho-AKT (ser 473) levels 
were detected higher in GFP-NOTCH- CCIC, but with no change in total AKT levels. NICD, 
HES1 and β-actin levels are shown for comparison. (C) Pre-treatment of CCR9+ CCIC with 
2μg/ml JAG1 peptide for 8 hours decreases CCR9 protein expression. NICD and HES1 levels 
are shown for comparison. (D) Schematic of CCIC incubated with different ligands in different 
chambers. Blue dots are representative of the relative number of cells in each chamber. FBS, 5% 
fetal bovine serum. (E) Graph of the percentage of early stage CCIC migrating to 5% FBS (%). 
The ligands match the schematic in (D). *P<0.001 by one way ANOVA for comparisons of mock 
control vs. CCL25 or JAG1 vs. CCL25+JAG1 data points. 
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Supplemental Figure 9. Model figure of CCR9/CCL25 in the evolution of early 
stage to advanced CRC.  Normal colon is schematized, with the crypt base on the 
bottom and crypt mouth at the top of the figure. A legend is given for each of the major 
normal colon cell types, as well as colon cancer cells and colon cancer stem cells. Early 
stage non-invasive CCIC and non-CCIC CRC cells upregulate the CCR9 receptor. 
Paracrine CCL25 from adjacent normal colon upregulates AKT signaling, proliferation, 
anti-apoptosis and likely superficial tumor spread along mucosal margins. As tumors 
progress, some cells upregulate NOTCH signaling (perhaps in response to NOTCH 
ligand expressing tumor associated cells such as vascular endothelium). Upregulation 
of NOTCH signaling causes an “invasive switch” that suppresses CCR9 and promotes 
NOTCH driven invasion and metastasis. Invasive and metastatic CRC tumors do not 
express CCR9, and CCL25 is absent from metastatic sites.   
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A                                                                             B 
 
 
Supplemental Figure 10. CXCR4 expression in early stage CCIC extra-GI tumor. 
CXCR4 protein detected by immunohistochemistry in xenograft lung tumors, shown by 
DAB (brown), (A) IgG control; (B) anti-human CXCR4 antibody; red arrows designate 
tumor foci.  
 
 
 
 
 
 
 
 73 
 
Supplemental Table 1:   Primary human colorectal cancers used for CCR9 FACS, 
chemotaxis, p-AKT and cell proliferation analyses  
ID Age Gender Stage Histopathology  Assays
a
         
1 81 M I Adenocarcinoma, 
moderately 
differentiated 
    FACS/ 
    p-AKT/ 
chemotaxis 
2 74 M I Adenocarcinoma, 
moderately 
differentiated  
    FACS/ 
    p-AKT/ 
chemotaxis 
3 70 F I Adenocarcinoma, well 
to moderately 
differentiated 
    FACS/ 
    p-AKT/ 
chemotaxis 
4 86 F II Adenocarcinoma, well 
to moderately 
differentiated 
    FACS/ 
chemotaxis 
5 58 M II Adenocarcinoma, well 
to moderately 
differentiated 
    FACS/ 
chemotaxis 
6 63 M I Adenocarcinoma, well 
to moderately 
differentiated 
    FACS/ 
chemotaxis 
7 59 F II Adenocarcinoma, 
poorly differentiated 
 
    FACS/ 
chemotaxis 
8 90 F II Adenocarcinoma, 
poorly differentiated 
 
    FACS/ 
Proliferation 
9 85 M I Adenocarcinoma, 
poorly differentiated 
 
    FACS/ 
Proliferation 
10 40 M II Adenocarcinoma, 
poorly differentiated 
 
    FACS 
 
a 
The primary CRC cells were used for the assays of FACS, chemotaxis function,  AKT phospholation 
    or cell proliferation. 
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Supplemental Table 2:   Colorectal Cancer Initiating Cell Lines used for             
multiple analyses  
ID Age Gender Stage Histopathology  Assaysa         
(early 
stage) 
CCIC1 
57 M I Adenocarcinoma, well 
to moderately 
differentiated 
FACS/ Mouse/ 
p-AKT/ 
Chemotaxis/ 
Proliferation / 
Western/ 
Q-PCR/ 
Microarray 
(early 
stage) 
CCIC2 
51 M II Adenocarcinoma, well 
differentiated 
 
FACS/ Mouse/ 
p-AKT/ 
Chemotaxis/ 
Proliferation / 
Western/ 
Q-PCR 
(early 
stage) 
CCIC3 
74 F I Adenocarcinoma, well 
to moderately 
differentiated 
FACS/  
Mouse/  
Western 
(late 
stage) 
CCIC1 
54 M III Adenocarcinoma, 
moderately 
differentiated  
FACS/  
Mouse/  
Chemotaxis/ 
Western 
(late 
stage) 
CCIC2 
61 M IV Carcinoma, poor to 
moderately 
differentiated (liver 
metastasis) 
FACS/  
Mouse/  
Western 
 
a 
The CCIC cells were used for the assays of FACS, in vivo mouse study, chemotaxis function,  AKT 
phospholation, cell proliferation, western blot, quantative PCR, or micro-array.   
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CHAPTER 2 
Chemokine-Targeted Mouse Models of Human Primary and Metastatic 
Colorectal Cancer 
(Contribution: Steven Lipkin, Huanhuan Chen and Xiling Shen designed the project; 
Huanhuan Chen, Jian Sun, Harry Hou Jr, Myra Arcilla, Daniel Joe, Nikolai Rakhilin, 
Jiahn Choi, Poornima Gadamsetty, Randy Longman and Jonlin Chen performed 
experiments; Huanhuan Chen, Steven Lipkin, Xi Kathy Zhou, Robert Edwards, Jian Sun, 
Kai Yuan Chen and Zeynep H. Gümüş analyzed the data; Steven Lipkin, Huanhuan 
Chen, Xiling Shen wrote the manuscript; Winfried Edelmann and Zeynep H. Gümüş, 
Micheal Shuler, Nozomi Nishimura helped with project discussion.) 
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of cancer death world wide.The most 
common site of CRC metastasis is the liver[67]. When CRC hepatic metastases are 
treated with chemotherapy, they almost invariably become chemoresistant. 
Consequently, five-year survival for metastatic CRC is only ~15% and, despite recent 
advances, current chemotherapy regimens almost never cure advanced disease. 
Genetically engineered mouse models (GEMM) are powerful tools for studying CRC, 
but they only represent a subset of CRC driver mutations. Human subcutaneous 
xenograft and orthotopic models in immunodeficient mouse hosts are widely used for 
mechanistic studies, drug screening, and have provided many critical insights into CRC 
pathogenesis[27, 68-72]. However, the persistence of poor outcomes among many 
CRC patients highlights the need for new approaches to complement existing models. 
For example, there is currently no robust non-survival surgery requiring model that 
recapitulates the process of human CRC cell metastasis from the GI tract to the liver, 
the site of more than 50% of CRC metastases. Another problem is that pre-clinical 
evaluation of new CRC therapies has a high false-positive success rate[69-72] and 
there is an urgent medical need for less chemosensitive pre-clinical models to reduce 
the number of futile CRC clinical trials conducted. A third problem is that human cancer 
cell studies in vivo require immunodeficient mouse hosts to avoid xeno-immunorejection, 
a barrier that has limited mechanistic studies of adaptive immunity in CRC progression, 
tumor vaccines and immunotherapies[72].    
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To expand the range of pre-clinical human CRC models, we created a resource of 
mechanistically diverse CRC cell and patient-derived xenograft (PDX)lines that 
collectively carry the majority of common recurrent somatic CRC mutations, represent 
all major molecular subtypes and robustly model primary CRCs in the native GI micro-
environment via simple tail-vein injection. By controlling the CCR9-CCL25 chemokine 
axis, these human CRC cells traffic to the GI tract and form orthotopic tumors[73]. This 
minimally invasive approach avoids potential survival surgery experimental confounders 
(e.g. needle exit wound tracts, iatrogenic local inflammation and systemic stress), and 
reduces administrative compliance burden and ethical concerns of surgery associated 
animal morbidity. 
Importantly, as proof of principle, we extended this approach to model human derived 
CRCs in immunoproficient mouse hosts. We microinjected human PDX CRC cells that 
natively express the CCR9 chemokine receptor[73] into wild-type (wt) mouse early 
blastocysts to form human-mouse chimeras. These humanized chimeric mice 
developed CRC tumors that originated from blastocyst-injected, human PDX CRC cells 
in the GI tract. This model allows the study of human primary CRCs in an 
immunoproficient GI microenvironment. 
Next, we further develop this resource and demonstrate sequential metastasis of 
primary human CRC tumors to liver, recapitulating the anatomical route occurring in 
patients. Finally, we use these hepatic metastases to show that for commonly used anti-
CRC therapies such as oxaliplatin, in vivo CRC liver metastases have elevated DKK4 
levels and upregulated Notch signaling (both of which have previously been associated 
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with CRC chemoresistance)[74, 75]and are significantly less  chemosensitive vs. paired 
sub-cutaneous xenografts generated from the same cells.  
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RESULTS 
Modeling Recurrent Human Primary CRC Mutations 
Chemokines are secreted ligands that regulate cell trafficking between different 
organs[13]. Small intestine and colon epithelia produce Chemokine 25 (CCL25), which 
binds to Chemokine Receptor 9 (CCR9) expressing cells[14-17]. Previously, we 
reported that CCR9 is up-regulated in primary tumors from early-stage CRC patients, 
but downregulated in invasive and metastatic CRC tumors. Furthermore, via only 
mouse tail-vein injection, early-stage CRC cells that endogenously express CCR9 
spontaneously form primary CRCs in the colorectum and intestine, attracted by 
CCL25[67, 73].In contrast, blocking the CCL25-CCR9 chemokine axis by short-hairpin 
RNA (shRNA) or antibodies against CCL25 promotes metastasis and formation of extra-
intestinal tumors. 
Based on these findings, we established a Chemokine-Targeted Mouse Model (CTMM) 
system that can be used to study primary human CRC mechanisms of progression and 
chemoprevention in the native GI microenvironment. Recent genome-wide 
characterization studies have highlighted the extreme molecular heterogeneity among 
human CRCs[76]. We therefore systematically generated a panel of 15 doxycycline- 
inducible CCR9+ cell and PDX lines (Supplemental Fig. 1 and Supplementary Fig. 2) 
to model a diverse spectrum of primary human CRC tumors that carry the majority of 
common recurrent somatic mutations occurring in patients (Supplementary Table 1). 
This includes not only well-established examples (e.g. KRAS and BRAF) but also 
mechanistically poorly characterized recurrently mutated genes such as ASXL1,MLL3 
and LIFR. Orthogonally, this resource includes multiple examples from all the major 
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histopathological and molecularly defined CRC sub-types, such as DNA mismatch 
repair proficient and deficient, CpG Island Methylator Phenotype (CIMP), 
adenocarcinoma and mucinous sub-types. (Supplementary Table 1). 
To facilitate quantitative experimental monitoring, each model also co-expresses 
constitutive luciferase and RFP reporters (Supplementary Fig.1a).Using tail-vein 
injection and luciferase monitoring (Fig. 1a,b and Supplementary Fig.3), within 3 
weeks, each CTMM model forms mean1.88±0.57colorectal tumors per affected mouse 
host, (whereas the CCR9- parental lines rarely, if at all, form colorectal tumors (mean 0-
0.15)) (Fig. 1c and Supplementary Table 2). 
 
In summary, we have developed a CTMM system to model primary human CRC tumor 
growth and progression in the native GI microenvironment. This system includes a 
molecularly diverse resource that spans the majority of recurrent patient CRC somatic 
mutations. CTMM models can be generated easily within weeks and avoid potential 
experimental confounding factors from survival surgery implantation (e.g. needle tract 
exit wounds, iatrogenic local inflammation and systemic stress from anesthesia), as well 
as reduce administrative compliance burden and ethical concerns of surgery associated 
animal morbidity. These qualities make CTMM a potentially useful system for evaluation 
of early-stage CRC progression mechanisms and chemoprevention drug screening. 
Human Primary Gastrointestinal CRC Tumor Formation in Immunoproficient 
Mouse Hosts  
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A current limitation of modeling human-derived cancers in mice is that immunodeficient 
hosts are required to avoid xenograft rejection. This is particularly problematic given our 
increasing appreciation of the role of the immune system in the tumor micro-
environment[77]. Therefore, it will be desirable to use immunoproficient mouse hosts to 
model CRC when studying tumor immunology, immunotherapies or other cancer cell-
microenvironment immunity cross-talk mechanisms.  
First, to test whether chemokine targeting works in immunoproficient mouse hosts, we 
generated CCR9-expressing mouse CT26 cells. Tail-vein injection into immune-
proficient Balb/c of these cells similarly generated primary CRC tumors in the colon. Co-
immunofluorescence showed that the human primary tumors are infiltrated by mouse 
CD3+ T cells and CD20+ B cells (Supplementary Fig.4).  
However, mouse cancer cells severely limit the scope and usefulness of CTMM. To 
address this limitation, we directly tested whether CTMM can model primary human 
CRC tumors in immunoproficient mouse hosts. Using essentially the same techniques 
for mouse embryonic stem cell microinjection to generate knockout mice[78, 79] we 
FACS sorted CCR9+ PDX cancer stem cells and injected 10-15 cells into wild-type 
Swiss-Webster strain mouse e3.5 blastocysts to generate human primary CRC-mouse 
chimeras (Fig. 2).  
For each CCR9+ CRC cell blastocyst microinjection session into pseudo-pregnant 
mouse foster mothers we obtained 24-40 live mouse pups. At post-natal day 21, ~10% 
have IVIS detectable luciferase activity, all of which localizes to intestine/colon (Fig. 2). 
In contrast, no IVIS detectable signal is observed in pups born from blastocysts injected 
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with CCR9- PDX cells (data not shown).  By age 3-6 months, blastocyst-injected human 
CRC cells form luciferase-detectable colon and small intestinal tumors in ~20% of 
immunoproficient mouse hosts, including locally invasive tumors that can penetrate the 
bowel wall (Fig. 2). PCR of human centromeric repeats confirmed that the dissected 
tumors consist of human and not rodent cells (Supplementary Fig.5b). 
Histopathological analysis confirmed that intestine/colon tumors are also RFP+, 
consistent with the growth of microinjected human luciferase/RFP-labeled CRC cells in 
the wt immunoproficient host GI microenvironment(Fig.2 c). In contrast, injection of 
CCR9- PDX cells did not form tumors anywhere in the body and were undetectable in 
the thoracic and visceral organs.  
At the same time, no human IVIS signal or CRC cells were detected in any other organ, 
such as lung, liver, spleen, kidney or skeletal muscle (Fig. 2b, Supplementary Fig. 5a 
and data not shown). We also performed dual-immunofluorescence with anti-RFP and 
anti-mouse CD3 (a pan T cell marker) antibodies(Fig. 2d and e). This confirmed that 
mouse hosts carrying human primary CRC tumors have T cells, as well as CD20+ B 
cells (data not shown) infiltrating the human primary CRC malignancies. Additionally, to 
further confirm that mouse hosts are systemically immunoproficient, we analyzed spleen 
and mesenteric lymph nodes (MLNs) from human primary CRC+ mice and their control 
(IVIS-negative) blastocyst-non-injected littermates. This showed that T and B cells were 
clearly present, and the relative proportions of spleen and MLN CD3+ (T cells), CD4+ (T 
helper cells),CD8+ (cytotoxic T cells), CD19+ (B cells) did not significantly differ 
between the two groups (Supplementary Fig.6).  Similarly, analysis of CD4+ T helper 
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revealed equivalent populations of CD62Lhi CD44lo (naïve cells), CD62Llo CD44hi 
(activated memory T cells), RORγt+ (Th17), and Foxp3+ (Treg).  
Overall, we have developed an orthotopic experimental system to study primary human 
colorectal cancer in the GI microenvironments of immunoproficient mouse hosts. This 
technology has the potential to significantly enhance our ability to understand and 
develop immunological therapies that target adaptive immune mechanisms in the GI 
tumor microenvironment. 
Sequential primary human CRC-liver metastasis formation 
Seven CTMM models (CCR9-PDX1, HT15, HCA7,SW48,Colo205, DLD1 and LS174T) 
spontaneously form liver tumors (mean 3.1-8.2 liver tumors/mouse by 8 weeks) but only 
in mice that have previously developed primary CRCs (Fig. 3 and Supplementary Fig. 
7). IVIS imaging revealed luciferase-detectable primary CRCs (mean 1.8 weeks post-
inoculation) preceded liver tumors (mean 5.8 weeks post-inoculation). In contrast, liver 
tumors were rarely detected in non-CTMM models, in which tail-vein injected CRC cells 
usually form tumors in the lung (Fig. 3). 
These findings are potentially consistent with a model whereby CTMM promotes cells 
from primary CRC tumors to metastasize to liver, most likely via the portal circulation. 
To test this model, we tail-vein injected mice to generate primary CRC CTMM models. 
After primary GI tumor formation was detected by IVIS imaging, we next withdrew 
doxycycline to suppress CCR9 expression. In all CTMM lines tested liver tumor 
multiplicity was significantly higher when CCR9 levels were suppressed 
(Supplementary Fig. 8a). Additionally, FACS of mouse liver cells 48 hours after tail 
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vein injection of CCR9+ CRC cells showed that RFP+ cells were essentially 
undetectable (Supplementary Fig. 8b), arguing against an alternative model in which 
CCR9 suppression stimulated expansion of previously resident human CRC cells in 
liver.   
Next, to confirm that CTMM primary CRC tumor cells could enter the portal circulation, 
we injected mice with FITC-Dextran to label vasculature and used Multi-Photon 
Microscopy (MPM) to image the primary tumor and liver metastatic tumors in vivo. This 
revealed that RFP+ human CTMM cells co-localize with and travel through host blood 
vessels, consistent with vascular intravasation (an important step prior to entry into the 
portal circulation that drains to the liver) (Supplementary Fig. 9).  
In summary, our data are consistent with a subset of molecularly well-characterized 
CTMM primary CRC tumors that are capable of sequentially modeling the progression 
of primary human CRC to liver metastases via the portal circulation that occurs in over 
50% of stage IV CRC patients. Furthermore at even later time-points, luciferase+ cells 
spreading at additional sites such as lung were also observed (Fig.3b and data not 
shown).  
Increased Chemoresistance of Human Hepatic vs. Sub-Cutaneous or Primary GI 
CRC tumors 
One challenge for cancer drug discovery is that therapies effective against 
subcutaneous xenograft tumors are often ineffective in human (especially metastatic) 
CRC patients. For proof-of-concept, we tested whether the more clinically relevant GI 
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and liver microenvironments of CTMM CRCs impact chemotherapy responsiveness vs. 
subcutaneous xenograft models. 
Oxaliplatin is an effective and widely used anti-CRC chemotherapy. We used both DNA 
mismatch repair proficient (pMMR) and deficient (dMMR) CIMM models to test whether 
the same cells have altered oxaliplatin chemosensitivity in different tumor 
microenvironments. We simultaneously injected mice subcutaneously or by tail vein to 
generate (a) subcutaneous tumors or (b) primary CRCs and sequential liver metastases. 
Quantitative IVIS imaging of constitutive luciferase reporters was used to directly 
compare tumor responses (Fig. 4a). 
As expected, oxaliplatin treatment of mice significantly inhibited the growth of sub-
cutaneous tumors for both pMMR and dMMR models after five weeks respectively, 
causing mean 53% volume reduction at week five (Fig. 4b, c and Supplementary Fig. 
10; P=0.005). Oxaliplatin similarly inhibited the growth of primary CRCs (-33.9%; 
P=0.04). This difference in tumor response was not statistically significant between the 
two different microenvironments.   
However, in the liver microenvironment, no oxaliplatin dependent growth inhibition was 
observed for CRC hepatic metastases generated from the same cells. The increase in 
oxaliplatin chemoresistance was significantly greater for liver metastases vs. either sub-
cutaneous (P<0.001) or primary GI tumors (P=0.002). 
To understand the mechanisms of CRC chemoresistance in the hepatic 
microenvironment, we performed RNA-seq gene expression profiling of liver and sub-
cutaneous tumors generated from DLD-1 cells. Consistent with this comparison, 
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Ingenuity Pathway Analysis (IPA) revealed that the Canonical Pathway of Colorectal 
Cancer Metastasis Signaling was upregulated (p=0.049). Additionally, Dickkopf 4 
(DKK4)levels were dramatically upregulated(76-fold; p=0.00001) in CRC liver 
metastases (Fig. 4d)., a finding that we subsequently confirmed using qPCR (Fig. 
4e).High DKK4 levels have previously been strongly associated with clinical CRC 
chemo-resistance[74]. Furthermore, Notch pathway signaling was also significantly 
upregulated in CRC liver metastases (p=0.012), a finding we also confirmed using 
qPCR for Notch pathway downstream target genes, including HES1, HES7, HEY1 and 
HEY2.Notch pathway signaling have also previously been associated with CRC 
chemoresistance[75]. 
In total, our CTMM model of CRC liver metastasis through the portal circulation can be 
performed within 5-8 weeks, does not require survival surgery and demonstrates 
greater oxaliplatin chemoresistance than either subcutaneous xenograft or primary GI 
orthotopic tumors, likely through a mechanism of upregulated DKK4 and Notch pathway 
signaling. 
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DISCUSSION 
Recent comprehensive molecular studies such as TCGA have provided a broad range 
of insights with an unprecedented level of molecular resolution into the precise 
molecular alterations that drive human CRC pathogenesis and progression. However, 
new pre-clinical models are needed to augment existing ones and recapitulate more 
fully the diverse nature of both cell-autonomous signaling pathways and non-cell 
autonomous interactions between tumor cells and their orthotopic primary, metastasis-
route and -destination site microenvironments.  
Towards this goal, we systematically generated a resource of human primary CRC 
CTMM models that collectively carry the major recurrent somatic alterations occurring in 
CRC patients. This can be used to study the mechanistic role of the majority of 
recurrent human CRC mutations multi-dimensionally. For example, Difluoro-
methylornithine (DFMO) is a potent anti-CRC chemoprevention agent that alters 
metabolite levels critical for DNA and histone methylation[80-83]. To study the impact of 
recurrently mutated epigenetic regulator genes such as the histone-lysine N-
methyltransferase MLL3 or the Polycomb complex chromatin binding protein ASLX1 
(Supplementary Table 1) on DFMO chemoprevention efficacy, mice carrying tumors 
from the CTMM primary CRC resource can be treated with DFMO, scored for reduced 
tumor multiplicity and in parallel efficacy assessed from the same dataset classified by 
positive vs. negative mutation status for MLL3, ASLX1 or any other epigenetic 
regulatorto assess the mechanistic role of each mutation and potential epistasisin 
DFMO chemoprevention. 
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Next, based on previous findings that fetal intestine and colon express the CCR9 ligand 
CCL25[84, 85] we extended our chemokine-targeting approach and developed an 
effective experimental system to model human cancer cell growth and invasion in 
immunoproficient mice, which has remained a challenge in the field. The precisely 
established mechanisms that permit immune tolerance of CCR9+ human cancer stem 
cells that are injected into blastocysts of wild type mice are currently poorly understood. 
But, perhaps similar to mechanisms allowing expression of human transgenes in 
genetically engineered mice, their introduction before thymus development (which also 
expresses CCL25) likely causes human cell antigens to be immunologically perceived 
as "self" by immunoproficient mouse hosts and inducing tolerance. 
The ability to model human cancers in immunoproficient mouse hosts is potentially 
significant. We anticipate that this approach can be applied to studying other aspects of 
human CRC-adaptive immunity cross-talk (ex. impact of Th17 and Treg cells on primary 
CRC formation, liver metastasis, tumor dormancy), other cancer types (ex. chimeras 
targeting CXCR4+ human Acute Lymphoblastic Leukemia cells to SDF-1α expressing 
bone marrow), and immunotherapy screening (ex. testing anti-PD1antibodies and 
cancer vaccines in immunoproficient hosts).  
With regard to modeling primary CRC tumor progression, current hepatic metastasis 
models using human CRC cells are time- and labor-intensive and technically 
challenging, which limits their usage for drug development. Direct injection of human 
CRC cells into the heart left ventricle, kidney capsule or spleen are potentially 
confounded by anatomical routes to the liver that do not recapitulate the 
microenvironment favorable for transit from the gut through the portal circulation and 
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lymphatics that occur in almost all advanced stage CRC patients[67]. The portal 
circulation is known to have distinct features that distinguish its microenvironment from 
other vasculature. For example, hepatic vein, lymphatic and tributary flow to the liver is 
unique in that it receives both oxygenated and deoxygenated blood (the latter from gut) 
and consequently has lower pO2 and hemodynamic perfusion pressure than other 
organs[86-88]. Furthermore, hypoxia can promote metastasis in multiple types of 
cancer[89-94]. Therefore, it is highly likely that not only GI microenvironment pre-
conditioning from interactions with colon myofibroblasts, dendritic cells, the gut 
microbiome and native intestinal extracellular matrix impacts CRC liver metastasis, but 
also pre-conditioning by the portal circulation microenvironment as well. 
Finally, the study of CRC cell chemoresistance is vitally important as it almost invariably 
occurs in the context of advanced disease. Previous experiments suggested that CRC 
tumors in liver are more chemoresistant than subcutaneous tumors to doxorubicin[95, 
96]. But interpretation of these experiments is complicated by the fact that doxorubicin is 
not clinically used to treat CRC patients. We therefore used a widely prescribed, 
effective anti-CRC drug, oxaliplatin, and directly tested on CTMM models whether the 
chemosensitivity of the same cells is dependent on their microenvironment. Our data 
demonstrate that in vivo CRC liver metastases are significantly less oxaliplatin 
chemosensitive vs. paired subcutaneous xenografts generated from the same cells. 
Consistent with this finding, both the WNT pathway inhibitor DKK4 and Notch pathway 
signaling have been previously associated with CRC chemoresistance[74, 75] and both 
are significantly upregulated in CTMM CRC liver metastases. 
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For the past several decades, mice carrying subcutaneous xenografts have been the 
most commonly used pre-clinical model system to screen new chemotherapy agents. 
Since this approach has a high false-positive success rate[69-72], including anti-CRC 
drugs,  and all too often fail when subsequently tested in patients, more chemoresistant 
CTMM models of CRC hepatic metastases have the potential to help reduce the 
number of futile CRC clinical trials.  
Additionally, other studies have suggested that in vitro cultured human CRC primary 
tumors are more chemosensitive to 5-FU than paired hepatic metastases from the same 
patients[97]. However, this finding was never been validated in vivo in mice. Here we 
similarly confirmed that the same CRC cells in liver are similarly more resistant than 
primary CRC tumors to oxaliplatin. 
In summary, we anticipate that the CTMM resources described here can help improve 
our mechanistic understanding of primary CRC-microenvironment interactions 
(particularly those involving adaptive immunity and immunotherapies), liver metastasis 
pre-conditioning by transit through the portal circulation, and potentially improve the 
clinical relevance of pre-clinical anti-CRC drug screening.  
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METHODS 
Tissue Culture of PDX lines. Patient derived xenograft tumors were harvested and 
generated as previously described[27, 73, 98, 99]. Briefly, fresh patient CRC samples 
were collected in Medium 199 supplemented with 200 U/ml penicillin and 200 mg/ml 
streptomycin, immediately after patient operative resection. Fat and blood clots were 
removed from tissues and they were rinsed 10 times in sterile PBS. Samples were 
minced with sterile scalpel blades into approximately 5 mm3 fragments. Tumor 
fragments were immersed into RNAlater and embedded in O.C.T. (Fisher Scientific) at - 
80ºC for histopathological or molecular analysis. Remaining tissue fragments were 
coated in Matrigel (BD Biosciences) and subcutaneously implanted into 3-4 6-week-old 
NOD/Shi-scid/IL-2Rγnull(NOG) mice (Jackson Laboratory, Bar Harbor, Maine) After PDX 
tumors reached an average volume of 400 mm3, mice were sacrificed and tumor tissue 
harvested. Part of tissue was passaged in new mice and the remainder was used to 
generated PDX cell lines using the method of collagenase /dispase enzyme digestion 
with slight modification, as previously described[73, 100]. Basically, tissue was minced 
into approximately1 mm2 fragments and digested in DMEM/F12 containing collagenase 
type XI (150 U/ml, Sigma, St. Louis, MO), dispase neutral protease (40 μg/ml, Roche 
Applied Science) and 1% FBS, stirring at 37°C for 30 min. After centrifugation, cells 
were re-suspended in the DMEM/F12 containing 1% nonessential amino acids 
(Invitrogen), penicillin (400 U/ml;Sigma), streptomycin (400 mg/ml;Sigma), amphotericin 
B (1.25 mg/ml; Sigma) and heparin (4 μg/mL; Sigma), human epidermal growth factor 
(40 ng/mL; BD scientific), human basic fibroblast growth factor (20 ng/mL; BD scientific), 
B27 supplement (Invitrogen) and 5% Fetal Bovine Serum, then transferred and cultured 
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in the ultra-low-attachment flasks (Corning) at 37°C and 5% CO2. FACS of human ESA 
(epithelial specific antigen) was used to purify cancer cells and PDX cells were 
characterized to be able to form subcutaneous xenograftswithsimilar adenocarcinoma 
histomorphology to parental PDX, when injected 0.5-1 million cells / mouse in NOG 
mice. PDX lines were frozen in DMSO. PDX freshly thawed cells,negative for 
mycoplasma, were used within 10 passages for the all experiments in this study. 
 
CCR9 inducible expression in CRC cells and PDX cells The lentiviral tetracycline-
inducible protein expression system (LifeTechnologies, T-Rex System) consists of two 
vectors: the regulatory vector, pcDNA6/TR, which encodes the Tet repressor (TetR) 
under the control of the human CMV promoter; and an inducible expression vector 
expressing human CCR9 (CDS region (181 -1290) of gene ID: NM_031200.) or mouse 
Ccr9 (CDS region (296-1405) of gene ID: NM_009913) genes[101] under the control of 
CMV promoter and two tetracycline operator 2 (TetO2) sites. To generate the lentiviral 
particles, the above plasmids were transfected into HEK293T cells with the 
Genecopoeialentivirus packaging mix (Genecopoeia) according to the manufacturer’s 
protocol. TetR expression lentiviruswas used to infect common CRC or PDX lines. After 
puromycin selection, the TetR expressing lines were then infected with the CCR9 
inducible expression lentivirus and followed with blasticidin selection and RFP FACS 
purification. The CCR9 expression can be induced by1-1.5 ug/ml (in vitro) or 1-2mg/ml 
(in vivo) doxycycline (Sigma, St Louis, MO)administered in 5% sucrose-containing 
drinking water. The efficiency of CCR9 inducible expression in these variant colorectal 
lines was verified by Western Blotting using anti-human CCR9 antibody 
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(Abcamcat.#ab38564) or anti-mouse Ccr9 antibody (Thermo Scientific. PA1-21618) and 
the software of Quantity One (BioRad) was used to semi-quantify protein levels.All non-
PDX cell lines used in this study were purchased from ATCC and were negative for 
mycoplasma.  
 
PDX xenograft tumor formation and oxaliplatin treatment  
0.5-1 x 106CRC cells with inducible CCR9 expression or control vectors were injected 
into 6-8 weeks old NOD/Shi-scid/IL-2Rγnull(NOG) mice (Jackson Laboratory, Bar Harbor, 
Maine) by tail vein injection. Tumor incidence was monitored 2-3 times weekly by whole 
body IVIS imaging. When mice became moribund, they were sacrificed immediately, 
necropsy performed and tumors harvested using a dissecting microscope. For 
oxaliplatin therapy study, 1 x 106 CCR9+ CRC cells were tail-vein injected or 
subcutaneously inoculated into the left flank of  6-week NOG mice (n=8) and IVIS 
imaging was performed to monitor tumor formation. When GI or subcutaneous tumors 
reached radiance of 5 x 106 (p/sec/cm2/sr), doxycycline was withdrawn to turn off CCR9 
expression and oxaliplatin (6mg/kg, Sigma, St Louis, MO) or normal saline as control 
was given IV once  weekly for 5 weeks. Tumor growth was quantified by luciferase - 
photon signal analysis with Xenogensoftwareuntil mice became moribund. Ex vivo IVIS 
imaging and necropsy were performed to further verify sizes and locations of tumor loci. 
Luciferase imaging in whole animal or ex vivo tissues:  For luciferase imaging, D-
luciferin (The In Vivo Imaging Community.) of 1.5mg/10g body weight was injected intra-
peritonealinto mice and 10 min later, luciferase imaging (Xenogen IVIS-200) was 
applied on whole-mouse bodies.For ex vivo imaging, mice were dissected 10 min after 
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luciferin injection. Intestine and other organs were quickly rinsed 3 times in PBS and 
place in culture dishes in which luciferase imaging was applied immediately.  
Immunohistochemistry For mouse experiments, histology and immunohistochemistry 
were performed on paraffin-embedded or frozen sections from xenograft tumors as 
previously described[27]. Intestinal, extra-GI tumor and corresponding normal tissues 
were snap frozen in O.C.T (Fisher Scientific, Pittsburgh, PA) and fixed in 10 % buffered 
formalin followed by paraffin embedding. For immunofluorescence, sections were 
immunostained with antibodies, counterstained with 4,6-diamidino-2-phenylindole 
(DAPI). H+E adjacent sections were used for comparison. 
Production of Human CRC-Mouse Chimeras: 
The methods of blastocyst microinjection and generation of chimeric mice were 
modified from standard procedures[102]. Briefly, Embryonic day (E) 3.5 or Swiss 
Webster(CFW) blastocysts (derived from natural mating. Charles River Strain code 024) 
were placed in 30 ml FHM (Millipore Cat#MR-122-D) and 10-15 CCR9+ CRC cells were 
injected per blastocyst by transfertip(ES) (Eppendorf cat. no.: 930001040) and 
vacutip(Eppendorf cat. no.: 930001015) using Eppendorf TransMan 
NKmicromanipulatorsunder invert microscope (Nikon Diaphot). The injected blastocysts 
were uterine-transferred into day 2.5 pseudopregnant CD-1 recipient females (Charles 
River Strain Code 022) at the same day (12-15 blastocysts / female). Pups were born at 
day 19-21 and fostered with lactating CD-1 mice. Live IVIS imaging was performed on 
the chimerical mice twice every week to detect the proliferation of luciferase+ cells. 
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Then ex vivo IVIS and histopathology were used to confirm the tumor formation and 
locations. 
Immune Cell Analyses in Human PDX-Mouse Chimeras 4-week old Swiss Webster 
mice from blastocysts injected with CCR9+ PDX-1 cells and the littermates from non-
injected blastocysts as control for normal immune functions were sacrificed and the 
spleens and 4 mesenteric lymph nodes (MLN) / mouse were collected in cold PBS 
under dissecting microscope. Then MLN and spleen were immediately mechanically 
disrupted and passed through a 70 um cell strainer.  Splenocytes and lymphocytes 
were collected and incubated in ACK lysis buffer (Life Technologies) to remove RBCs.  
Surface stainingwas performed with anti-CD3 (ebiosciences, clone:145-2C11), CD4 
(ebiosciences, clone:RM4-5), CD8 (ebiosciences, clone:53.67), CD44 (ebiosciences, 
clone:IM7), CD62L (ebiosciences, clone:MEL-14). Intranuclear staining with anti-
RORγt(ebiosciences, clone:B2D) and anti-Foxp3(ebiosciences, clone:fjk-16s) was 
performed according to manufacturer’s protocol (Intracellular Fixation and 
Permeabilization Kit from eBioscienes). Prior to intracellular cytokine staining, cells were 
cultured in the presence of GolgiPlug (BD Biosciences) for 4 hours or stimulated with 
phorbolmyristate acetate (PMA; 20ng/mL) and ionomycin (1μg/mL) or IL-23 (40ng/mL; 
eBioscience) in the presence of GolgiPlug (BD Biosciences) for 4 hours before staining.  
Intracellular cytokine staining was performed according to the manufacturer’s protocol 
(Cytofix/Cytoperm buffer set from BD Biosciences) using IFN-γPECy7 (ebiosciences, 
clone: XMG1.2) and IL17A FITC (ebiosciences, clone: eBio17B7).  An LSR II (BD 
Biosciences) and FlowJo software (Tree Star) were used for flow cytometry and 
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analysis. Dead cells were excluded using the Live/Dead fixable aqua dead cell stain kit 
(Invitrogen). 
Two-photon microscopyThree to six month old Balb/c male and female mice were 
kept under isoflurane anesthesia and a portion of the large intestine was externalized to 
be placed in a saline-filled, temperature-controlled chamber. The portion to image was 
covered with a glass coverslip and agarose for stability and imaged with a custom-built 
multi-photon microscope optimized for in vivo imaging. 50 mg/ml FITC-Dextran 
(FD2000S; Sigma-Aldrich, St. Louis, MO) was retro-orbitally injected in mice (0.25 ml / 
kg) and this dose allowed vasculature imaging for 1-2 hours. Simultaneous excitation 
with 900 nm and 1040 nm femtosecond laser light enables imaging of GFP (FITC-
Dextran) and RFP (human CRC cells) at the same time.  
Whole-Exome Sequencing DNA was extracted from 4 PDX lines (PDX 1-4) and 
common CRC lines (HT-15 and Caco-2) using DNeasy DNA extraction kit (Qiagen). 
Whole-Exome sequence data for the six cell lines were obtained through Agilent’s 
G9906A HaloPlexExome Target Enrichment System kits (protocol Version A, February 
2013) with Illumina HiSeq2000. Briefly, genome DNA samples were first digested by 
restriction enzymes to create a library of gDNA restriction fragments. Then the 
HaloPlexexome probe was provided as eight separate probe solutions in wells A–H of 
the HaloPlex Probe 8-well Strip. The circularized target DNA-HaloPlex probe hybrids, 
containing biotin, were captured on streptavidin beads and then DNA ligase was added 
to the capture reaction to close nicks in the circularized HaloPlex probe-target DNA 
hybrids. After a 10-minute ligation reaction period, the captured DNA libraries were 
diluted and PCR amplified with the PCR Master Mix. After the enrichment was validated, 
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the samples were pooled with different indexes, and sequenced with Illumina 
HiSeq2500.~ 60M 101bp pair-end reads for each sample were obtained from 
HiSeq2500. The mean quality score for all samples was ~ 35, and more than 90% reads 
were at least 30 base quality. All the raw reads were first processed with program 
Cutadapt[103] to remove adapter sequences from high-throughput sequencing reads. 
The processed sequence data were mapped to human genome (hg19) with program 
BWA[104]. The mapping were re-aligned and recalibrated with GATK[105]. Variants and 
mutations were detected with the module Unified Genotyper in GATK. Sequence data 
were deposited with NCBI (Accession SRP035634). 
RNA sequencing and quantitative real-time PCR 
Total RNAs from liver tumor or subcutaneous tumor cells were extracted by using 
RNeasy Kit (Qiagen, Valencia CA). For RNA-seq, library preparation and HiSeq2000 
lane analysis was performed as previously described[106].  Subsequently, 75-bp 
paired-end read sequences were mapped to human genome (hg19) with Tophat/bowtie 
(version 2.1.1). Read count for each gene transcript was obtained with Genomic 
Features (version 1.15.9). Genes with mean read count in both liver and skin samples 
less than 10 were filtered out. DESeq (version 1.12.0) was used to analyze for 
differential expression. Fisher Exact Test was used to assess statistical significance, 
with adjustment using the Benjamini& Hochberg method for multiple comparisons. 
For quantitative PCR, 2 μg of total RNAs were reverse-transcribed into cDNA by using  
RT first stand kit (SA Biosciences) and RNA levels amplified by PCR containing SYBR 
Green I dye (Invitrogen), normalized to β-actin as the comparative CT (cycling 
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threshold)= CT (target)- CT (control), were analyzed by the iCycler (Bio-Rad). Primer 
pairs used are (1) DKK4: F5’-CGTTCTGTGCTACATGTCGTGG and R5’-
GTGTGCCATCTTGCTCATCAAGC; (2) HES1: F5’-
GGAAATGACAGTGAAGCACCTCC and R5’-GAAGCGGGTCACCTCGTTCATG; (3) 
HES7: F5’-CATCAACCGCAGCCTGGAAGAG and R5’-
CACGGCGAACTCCAATATCTCC; (4)HEY1: F5’-
TGTCTGAGCTGAGAAGGCTGGTand R5’-TTCAGGTGATCCACGGTCATCTG; 
(5)HEY2: F5’-TGAGAAGACTTGTGCCAACTGCT and R5’- 
CCCTGTTGCCTGAAGCATCTTC; (6)human β-actin: F5’-
CGCGAGAAGATGACCCAGAT and R5’-ACAGCCTGGATAGCAACGTACAT; 
(7)mouse β-actin: F5’-GATCTGGCACCACACCTTCTand R5’-
GGGGTGTTGAAGGTCTCAAA. 
Fluorescent activated cell sorting (FACS) analysis FACS with anti-epithelial specific 
antigen (ESA, BD PharmingenCat #347197) antibody was used to purify PDX cells [3,4] 
Cells were first incubated with anti-human ESA antibody conjugated with Alexa Fluor 
488 for 30 minutes on ice and then were washed in 1% BSA/PBS buffer. FITC filter was 
then used to separate cells into ESA positive and negative sub-groups by signal 
intensity gating. The ESA+ cells were transferred into culture flasks for further growth 
and passages.   
To detect RFP positive cells in mouse liver, 0.5 x 106CCR9+ RFP+ Luciferase+ CRC 
cells were injected into 6-week NOG mouse (n=6) by tail vein. After 48 hours, mice were 
sacrificed and liver pieces in the same weight were treated with collagenase / dispase 
(1 mg/ml, Roche Applied Science) for 0.5-1 hour to create single-cell suspension and 
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followed with BD Pharm Lyse (BD Scientific) treatment according to company 
instruction, to destroy red blood cells. RFP cells were measured as PE positive and 
FITC negative in FACS channels. 
 
Transwell migration assay 
Transwell Boyden chambers (BD Pharmingen Mountain View, CA) of 8-μm pore size 
were used to evaluate migration in vitroofparental or CCR9 expression CRC cells and 
PDX cells. Briefly, cells were seeded at a density of 5 x 105 per well into the upper 
chamber. Culture medium as described above with 100 ng/ml recombinant mouse 
CCL25 protein (R&D systems Inc; Minneapolis, MA) was loaded into the lower chamber. 
Chambers of cells were incubated in 37oC and 5 % CO2 conditions for 12 hours. At the 
time of harvest, cells remaining inside the upper chambers were removed while cells 
attached to the lower surface of the membrane were fixed and stained with Crystal 
violet (Sigma, St Louis, MO) followed by imaging and cell number counting analyses. 
 
SUPPLEMENTAL INFORMATION 
Statistical Analyses 
Sample sizes for all figures and tables were estimated based on our previous studies[27, 
73, 100, 107]. For mouse experiments, no animals were excluded from the analyses. 
For each set of experiments, samples and animals were prepared for all experimental 
arms at the same time. For animal studies, the randomization schema had mice 
alternating in assignments to experimental groups. Both male and female mice were 
used.Values are expressed as mean ± SEM or summarized using box-plots. All 
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statistical tests are 2-sided.No adjustments were made for multiple comparisons. Both 
PIs (Lipkin and Shen) and the Study Statistician (Zhou) were blinded to experimental 
allocations among different experimental arms for all experiments. For all parametric 
statistical analyses, data were determined to be normally distributedby the D'Agostino-
Pearson test. For all parametric and non-parametric tests, variances were similar 
between groups being compared. For comparisonbetween experimental and control 
groups at a specific time point or tissue site in Figures 1, 3 and Supplemental Figures 
1,6, 8and 10, 2-sided Student t- test or 2-sided Mann-Whitney (MW) tests were used. In 
Figure 4, linear regression analysis and ANOVA was used to estimate the tumorgrowth 
rate in different experimental groups and study sites while adjusting for differentcell lines. 
Differences in tumor growth rates between Oxaliplatin treated and the controlmice at 
each body site and the difference in the effect of Oxaliplatin treatment on tumorgrowth 
rates between different sites were further evaluated using simultaneous tests forgeneral 
linear hypotheses (Figure 4). Pvalueswere adjusted for multiple comparisons by 
controlling the experiment-wise errorrate using the conservative Bonferroni-Holm 
method (Figure 4). Statistical calculationswere performed with the Statistical Package 
for the Social Sciences version 11.5software (SPSS Inc, Chicago, IL), GraphPad, or R 
(reference: R Core Team (2013).R: A language and environment for statistical 
computing. R Foundation for StatisticalComputing, Vienna, Austria. URL http://www.R-
project.org/). The statistical test used foreach figure or table panel is indicated. All cell 
lines were purchased from ATCC in the past 2 years (or derived for PDX1-4) and were 
negative for mycoplasma. 
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Supplemental Table 2 
 
          Statistics Tests and P values in Figures 
 
In Figures 1C, 3D, 3E, Supplementary Figures 1C, 8A and Supplementary Table 2, for 
each data point, 6-8 week old male or female NOG mice were used for each 
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experimental arm (e.g. in Figure 3D 8 mice for each line’s control arm and 8 mice for the 
CCR9+ arm).MW, 2-sided Mann-Whitney test. Paired t-test, 2-sided Student paired t 
test. 
Study Approval 
All CRC tissues used were approved by the Institutional Review Board (IRB) of Weill 
Cornell Medical College and Consent obtained for each participant.All animal protocols 
in this study were approved by the IACUC committees of Weill Cornell Medical College, 
Cornell Universityor Albert Einstein College of Medicine. 
 
Accession ID 
CRC cell whole exome data are deposited in NCBI GEO as SRS542031 and RNA-seq 
data as SRR1204492. 
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Figure 1. Modeling Primary Human CRC Recurrent Mutations in Mice without 
Survival Surgery (a).Schematic of experimental approach: Lentiviral infection with virus 
containing a Tetracycline inducible CCR9 expression cassette and constitutive luciferase-RFP 
reporter genes. After puromycin selection and FACS,0.5-1 x 106 CCR9+ cells were injected into 
6-8 week old male or female (m/f) non-obese diabetic/severe combined immunodeficient (NOG) 
mice by tail vein and intestinal tumor formation monitored after 2-3 weeks by IVIS-luciferase 
imaging. Blue dots: GI tumors.(b).Representative whole body IVIS images of mice injected with 
CRC cells expressing a control luciferase reporter only (CCR9-), constitutive CCR9 expression 
and luciferase (CCR9+) or a mixture (CCR9+/-); Luciferase photon signals are 
shown.(c).Quantification of mean luciferase-detectable large intestinal tumors in 6-8 week 
miceinjected with CCR9 expressing cells (CCR9+) via tail vein. * P< 0.01 CCR9+ compared to 
the control group by 2-sided Mann-Whitney test. Error bars indicate S.E.M. (stand. error of 
mean). All cell lines combined control vs. CCR9+, P=0.001; Student paired t test. Also see 
Supplemental Table 2. 
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Figure 2. Human Primary CRC-immunoproficient Mouse Host Chimeras (a). Left: 
schematic of mouse blastocyst injection with luciferase+ RFP+ CCR9+ PDX cells (10-15 cells / 
blastocyst); Scale bars, 20μm. Middle: representative whole body IVIS images of human PDX-
mouse chimeras (8 weeks, Swiss Webster) generated by mouse blastocyst injection,(Luciferase 
- photon signal are indicated, Mock: littermate controls not injected with PDX cells.); Right: 
Three-month old human PDX-mouse chimera with abdominal tumor mass extending from 
intestine (4X). Arrow indicates tumor.(b).Representative IVIS whole-body  (left upper panel) and 
ex vivo images (right upper  and lower panels) show adult chimeras (8-weeks) with luciferase+ 
tumors detectable in the gastrointestinal tract but no other organs. (c).Anti-RFP 
immunofluorescence (Upper right) of caecal PDX tumor in chimeric mice (age 8 weeks).Left 
upper image shows Hematoxylin (nuclear: blue) and Eosin (cytoplasm: pink) (H+E) staining of 
the same intestinal tumor for comparison. Scale bars, 50μm.  Lower panel images show double-
immunofluorescence of T cells (anti-mouse CD3 antibody (green)) and human PDX cells (anti-
RFP antibody (red)). Nuclei, DAPI (blue). M, mucosa; T: regions with adenocarcinoma 
morphology. Arrows indicate CD3+ T cells. Scale bars, 50μm (left) & 5μm (right)(d).Percentages 
of chimeric mice with luciferase positive tumors in the two groups from blastocysts injected with 
CCR9+ PDX cells (CCR9+) or CCR9- PDX cells (CCR9-). ** P = 0.002 by 2-sided Mann-
Whitney test, Error bars indicate S.E.M. (E). B6-2J mouse blastocysts were microinjected 
with luciferase+ RFP+ CCR9+ PDX cells (15 cells/blastocyst) and uterine-transferred 
into day 2.5 pseudo-pregnant recipient females at the same day (12-15 blastocysts / 
female). Representative RFP florescent images (4X) of whole embryos at embryonic 
day 9.5, 10.5 and 11. Mock control: littermate controls not injected with PDX cells. White 
arrows designate hindgut location and black arrow designates vitelline duct location. 
Scale bar, 0.5 mm. Also see Supplemental Table 2. 
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Figure 3.Sequential human CRC primary GI tumor- metastasis formation (a).Schematic of 
sequential human primary CRC and liver metastasis. Using the same approach as in Figure 1, 
in 6-8 week m/f NOG mice were injected with CCR9+ human CRC cells and monitored by IVIS 
imaging for primary CRC formation. Once primary GI tumors were detected, CCR9 expression 
was silenced by withdrawing doxycycline from drinking water. Mice were monitored using IVIS-
luciferase imaging over the next 4-6 weeks and sacrificed. Blue dots: GI tumors; green dots: 
metastatic tumors. (b).Representative whole-body IVIS images(CRC line DLD1 as 
representative) show sequential lower abdominal and right upper quadrant abdominal 
detectable photons, with ex vivo confirmation of abdominal right upper quadranttumors as liver-
localized(4X) (n=8 each for CCR9+ and CCR9- arm for each cell line analyzed). (c). 
Histopathology (H+E staining) examples of different primary CRC tumors detectable as 
submucosal (2nd week), with invasion of submucosa (4thweek) and muscularis (6th week). 
Arrows indicate histopathologically confirmed tumors; M, mucosa; SM, submucosa. Scale bars, 
100μ. (d). Quantification of liver metastases in mice (n = 8 each for CCR9+ and CCR9- arm for 
each cell line analyzed) tail vein injected with control lentiviral vector infected CRC cells (control) 
or CRC cells with inducible CCR9 expression. * P< 0.05 compared to the control group by 2-
sided Mann-Whitney test. All CCR9+ vs. control cell lines, P=0.001 2-sided Student t test. (e). 
Time post-injection of cells with inducible CCR9 expression to luciferase-detectable signal in 
histopathologically confirmed primary GI or liver tumors (n = 8 mice each for CCR9+ and CCR9- 
arm for each cell line analyzed). ** P< 0.01 by 2-sided Mann-Whitney test. All cell lines liver vs. 
GI tumors, P=0.001 2-sided Student t test. Also see Supplemental Table 2. 
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Figure 4.Increased oxaliplatin chemoresistance of human CRC cells in liver vs. 
orthotopic or subcutaneous xenografts.1 x 106CCR9+ CRC cells were injected by tail-vein 
or subcutaneously inoculated into the left flank of  6-week NOG mice (n=8/each experimental 
arm) and IVIS imaging was performed to monitor tumor formation. When GI or subcutaneous 
tumors reached radiance of 5 x 106 (p/sec/cm2/sr), doxycycline was withdrawn to turn off CCR9 
expression and oxaliplatin (6mg/kg) or normal saline as control was intravenously given once 
weekly for 5 weeks (W1-W5). Tumor growth was quantified by luciferase - photon signal 
analysis with Xenogen software. Real-time whole body IVIS imaging of mice with subcutaneous 
inoculated (a, left panel) or tail-vein injected CTMM cells (a, right panel) treated with 
Oxaliplatin (CRC line DLD1 as representative) (b) and (c).Quantification of the effects of 
Oxaliplatin on growth rate of GI, liver and subcutaneous xenograftsby luciferase -photon signal 
measurement with Xenogen software. Tumor growth rate is defined as the difference between 
week 5 tumor luciferase - photon signal (i.e., cubic transformed tumor size) and the first 
measurable tumor luciferase - photon signal divided by the duration of the treatment. ANOVA 
was used to compare change in cubic root transformed DLD1and Colo205 tumor size at week5 
from week1.P-values were adjusted for multiple comparisons by controlling the experiment-wise 
error rate using the Bonferroni-Holm method** P< 0.001; * P< 0.05 compared to the control 
group. Error bars indicate S.E.M. (b: Colo205; c: DLD1).Each box-whisker plot represents 8 
mice/arm. (d) Heat map presenting the expression level of indicated transcripts in RNA-seq 
comparison of non-treated DLD1 subcutaneous vs. liver metastasis tumors. The relative 
abundance of each gene was normalized between 0 and 2. Above 1 indicates higher expression, 
below 1 indicates lower expression. Red indicates upregulation. (e).mRNA levels of DKK4, 
HES1, HES7, HAY1 and HEY2 in week 5 DLD1 liver tumors (n=6) and subcutaneous tumors 
(n=6) using quantitative PCR. ** P< 0.01; * P< 0.05compared to subcutaneous tumors by 2-
sided Mann-Whitney test. 
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Supplementary Figures 
a       b 
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Supplementary Figure 1.Engineering inducible CCR9+ CRC lines and in vitro functionally 
evaluating the efficiency of CCR9+cells. (a). Schematic of inducible CCR9 expression system 
which consists of two vectors: the regulatory vector encoding the Tet repressor (TetR) under the 
control of the human CMV promoter; and an inducible expression vector expressing human 
CCR9 or mouse Ccr9 genes under the control of CMV promoter and two tetracycline operator 2 
(TetO2) sites. This CMV promoter also drives luciferase (Luc) and Red fluorescence protein 
(RFP) expressions. After packaging the two vectors into lentivirus particles, TetR expression 
lentivirus was first used to infect common CRC or PDX lines. After puromycin selection, the 
TetR expressing lines were then infected with the CCR9 inducible expression lentivirus and 
followed with blasticidin selection and RFP FACS purification. The CCR9 expression can be 
induced by1-1.5 ug/ml (in vitro) or 1-2mg/ml (in vivo) doxycycline.(b). CCR9 protein level 
expression in parental CRC cells (Ctrl), CRC cells with (+ Doc) or without (- Doc) doxycycine 
induction were tested by using anti-human CCR9 antibody in western blots. β-actin is loading 
control.(c).In vitro migration of CRC lines toward CCL25 was significantly increased with CCR9 
expression, evaluated by Boyden chamber experiments as described in METHOD section. *P< 
0.01mean compared to parental CRC cells transfected with control vector by 2-sided MW test. 
Error bars indicate S.E.M. All cell lines control vs CCR9, P=0.001 2-sided Student t test. (n = 8 
each for CCR9+ and CCR9- arm for each cell line analyzed).Also see Supplementary Table 2. 
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Supplementary Figure 2. Histopathology of mouse subcutaneous xenografts formed by 
PDX lines. 6  week NOD/SCID mice (n=6) were subcutaneously injected with 1 x 106PDX cells / 
mouse in two flanks, and tumors began to form in 6-8 weeks. H+E staining ofsubcutaneous 
tumors formed by PDX-1 (Left) or PDX-2 (Right).Scale bars, 50μm.  
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Supplementary Figure 3.Ex vivo IVIS imaging and histopathology of orthotopic GI tumors 
formed by CCR9+ CRC lines.The specific anatomical locations of NOG mouse abdominal 
tumors identified by whole body IVIS imaging (Figure 1 b) were determined as multiple foci in 
the Duodenum, Jejunum, Ileum, Cecum and Colon, by both ex vivo IVIS imaging and 
histopathology in H+E staining (M: mucosa; T: regions with adenocarcinoma morphology).At the 
same time, no tumors were detectable by IVIS imaging in other organs, such as lung, liver, 
pancreas or kidney. Comparisons with control lines infected with non-CCR9 encoding lentivirus 
are shown. Scale bars, 50μm.(n = 6 for each cell line analyzed) 
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Supplementary Figure 4.Mouse CRC line with CCR9 expression formed GI tumors in 
immunoproficient mice with same genetic background. (a). representative whole body IVIS 
images (upper panel) of tail-vein injected mice with luciferase-RFP double labeled CT26 cells 
transfected with backbone vector (CCR9-), mixture of cells transfected with CCR9 expression 
vector and cells transfected with backbone vector (CCR9+/-), or CRC cells transfected with 
CCR9 expression vector (CCR9+); Luciferase - photon signals represent xenografts.Ex vivo 
imaging (lower panel) indicated abdominal luciferase positive tumors located in GI. 
(b).Representative H+E staining image of tumors in mouse large intestine tail vein injected with 
inducible CCR9+ CT26 cells. (M: mucosa; T: regions with adenocarcinoma morphology). Scale 
bars, 50μ(c).double- immunofluorescence in immune cells and tumor cells. T cell marker CD3 or 
B cell marker CD20 expression was detected by anti-mouse CD3 or CD20 antibody (green), 
tumor cells were detected by anti-RFP antibody (red) and nuclei were stained with DAPI (blue). 
Arrow designates T cells or B cells. Scale bars, 50μm (upper) &5μm (lower). N=6 6-8 week 
NOG mice. 
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Supplementary Figure 5. Human Primary CRC-immunoproficient Mouse Host Chimeras 
(a).Swiss Webstermouse blastocyst injection with luciferase+ RFP+ CCR9+ PDX cells (10-15 
cells / blastocyst) and representative IVIS Whole-body (left) or ex vivo images (middle and right) 
from post-natal day 10 human PDX-mouse chimeras are also shown. Mock(upper panel): no 
injection; PDX (down panel): blastocyst injected with CCR9+PDX cells. (b). PCR of human 
centromericrepeat sequences in DNA extracted from intestinal tumors excised from human 
PDX-mouse blastocyst-injected chimeras  (1-4), blastocyst injected mouse tail, in vitro culture 
PDX cells and no DNA control (negative control). Experiment was performed 3 times. 
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Supplementary Figure 6. Phenotypic and functional analysis of lymphocytes from the 
spleen and mesenteric lymph nodes (MLN) in human PDX-mouse chimeras. Spleens and 
4 MLNs / mouse were collected from 4-week old mice (n=5) developed from Swiss Webster 
mouse blastocysts injected with CCR9+ PDX-1 cells (IVIS+). The littermates (n=5) from non-
injected blastocysts were used as control for normal immune functions (IVIS-; control). (a).  
Gating strategy for phenotypic analysis is shown.  Live (DAPI)-negative cells were electronically 
gated and CD3 (T cell) or CD19 (B cell) surface staining is shown.  Electronic gating on CD3+ T 
cells was used to determine CD4 and CD8 expression as illustrated.  CD4+ T cells were 
subsequently gated to determine CD62L and CD44 expression.  (B). Relative average 
percentage of the parent population for each surface phenotype is shown.  (C). Gating strategy 
for CD4+ T cell analysis.  Live (Aqua)-negative cells were electronically gated and CD3/CD4 
surface stain was used to identify CD4+ T cells.  Intranuclear staining for Foxp3 and RORt (top 
panel) was performed on unstimulated cells.  Intracellular cytokine staining for IFN and IL-17 
was performed of PMA/ionomycin stimulated cells.  Relative percentage of mean total CD4+ T 
cells is displayed at right.  No statistically significant differences (P > 0.05) between any IVIS+ 
vs. IVIS- groups, by 2-sided Mann-Whitney test were observed.Error bars represent standard 
deviation. No adjustments for multiple comparisions were made. 
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Supplementary Figure 7. Histopathological confirmation of IVIS imaged CRC liver 
tumors.CCR9+ CRC cells were injected via tail-vein into NOG mice and serial whole body IVIS 
imaging was performed to monitor tumor growth. CCR9 expression was inhibited by 
withdrawing doxycycline after IVIS lower abdominal tumor formation was observed at 2-4 weeks. 
Subsequent tumors occur primarily in liver. In each sub-panel, Left: representative whole-body 
IVIS images of GI and metastatic tumors; Middle upper:Ex vivo IVIS imaging of liver tumors. 
Middle lower: light microscopy of the same hepatic tumors as control. (4X)Right: 
representative images of H+E staining in hepatic human CRC tumors. (T: adenocarcinoma; 
Dotted lines indicate the borders between regions with hepato-cellular or tumor morphology 
Scale bars, 100μm. N=2-4 NOG mice/cell line. 
 
 
 
 128 
 
a 
 
 
 
 
 
b 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8. Primary CRC CCR9 knockdown increases liver tumor 
multiplicity. (a). Quantification of liver IVIS + foci in NOG mice tail vein injected with inducible 
CCR9+ CRC cells. The experiment procedure is described in Figure 3. (For each cell line, 
CCR9-off (n=8 mice / cell line): no CCR9 expression s/p doxycycline withdrawal after lower 
abdominal IVIS+ signal detection; CCR9-on (n=8 mice/cell line): continuous doxycycline 
maintenance of CCR9 expression).* P<0.05 by 2-sided MW test. (b). 0.5 x 106 CCR9+ CRC 
cells were injected into 6-week NOG mouse (n=4 mice/each cell line experimental arm) by tail 
vein. After 48 hours, mice were sacrificed and livers were treated with collagenase and dispase 
to generate single-cell suspension. RFP cells were almost undetectable by FACS in mouse 
livers injected with RFP-labeled CCR9+ CRC cells. FACS Gates (dot windows) are set for RFP+ 
signal intensity; Mock: cells extracted from livers in mice injected with PBS; Positive control: 
GFP+ cells "spiked" in with mouse hepatic cells (200 RFP+ cells/million hepatic cells). 
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Supplementary Figure 9. Two-photon microscopy imaging of hepatic metastatic tumors. 
The experiment procedure to form primary CRC and sequential liver metastases was described 
in Figure 3. (a). two-photon microscopy imaging of orthotopic xenograft tumors. (representative 
images on tumors formed with CCR9+ DLD1 cells) (I. Schematic of surgical and imaging 
preparation (also referred in METHOD part); II – IV. low magnification images of intestine; V – 
VI. High magnificence imaging of intestinal tumors expressing RFP (red) surrounding 
vasculature labeled by FITC-Dextran (green).White arrows designate intravasating tumor 
cells.)(b).(Representative images on liver tumors formed with DLD1 cells)Hepatic tumor cells 
expressing RFP (red) surrounding vasculature labeled by FITC-Dextran (green).White arrows 
designate extravasating tumor cells out of blood vessel.) Scale bars, 50μm (left) & 10μm (right). 
N=6 mice were examined. 
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Supplementary Figure 10. Growth curves of human CRC cells in liver vs. orthotopic or 
subcutaneous xenografts, oxaliplatin chemoresistance and survival. (a). More detailed 
weekly growth curves of the data presented in Figure 4 are shown. 1 x 106CCR9+ CRC cells 
were tail-vein injected or subcutaneously inoculated into the left flank of 6-week NOG mice (n=8 
for each experimental arm) and IVIS imaging was performed to monitor tumor formation. When 
GI or subcutaneous tumors reached radiance of 5 x 106 (p/sec/cm2/sr), doxycycline was 
withdrawn to turn off CCR9 expression and oxaliplatin (6mg/kg) or normal saline as control was 
given IV once  weekly for 5 weeks. Tumor growth was quantified by luciferase - photon signal 
analysis with Xenogen software, with each light unit graphed representing 1 million measured 
light units. Real-time whole body IVIS imaging of mice at weeks 1-5 are shown for 
subcutaneous inoculated or tail-vein injected CTMM cells treated with Oxaliplatin. Error bars 
indicate S.E.M. *, No overlap of error bars at given time point. (b). Kaplan-Meier survival plot of 
mice analyzed in (a). 
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Supplementary Table 1.Mutation Profiles of CTMM CRC cell lines. The mutation status of 
17 CTMM cell lines for the twenty most commonly somatically altered genes in human CRC 
(COSMIC Database, http://cancer.sanger.ac.uk) is given.The presence of a somatic mutation is 
indicated by a red bar. Whole exome sequencing analysis was performed for PDX-1 through 4, 
Caco-2 and HT15. PDX-3 and PDX-4 were previously described as CCIC-1 and CCIC-2 
(reference 7). For the other cell lines, mutation status was previously described in the Cancer 
Cell Line Encyclopedia (http://www.broadinstitute.org/software/cprg/?q=node/11) or Eiden et 
al[108]. Cell lines were classified as MSI, microsatellite instability; MSS, microsatellite stable; 
Mucinous, mucinous adenocarcinoma histolopathology; CIMP,CpG Island Methylator 
Phenotype; CIN, chromosomal instability pathway, as previously described by D Ahmed, et al.  
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Supplementary Table 2. Inducible CCR9+ CRCs form orthotopicxenograft tumors in mouse 
intestine.Colorectal and small intestine tumors formed in mice injected with cells infected with 
CCR9+ vector or backbone control vector by tail vein. Asterisks denote statistically significant 
differences between CCR9+ group and control group. * P< 0.01 compared to parental control 
groups by 2-sided MW test. 
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INTRODUCTION 
    Despite devoting more than three decades of research to improve understanding of 
cancer biology and development of therapeutics, the persistence of poor outcomes 
among cancer patients highlights the need for new approaches to complement existing 
research methodology [1,21,51]. One of the major obstacles arises from intrinsic 
limitations of existing experimental systems, which poorly translate into clinical 
applications due to shortage of concordance with human studies [5,12,16,24]. For 
instance, conventional cell culture models as research platforms lack the capacity to 
maintain the interactions of tumor cells with extracellular matrix (ECM) and replicate 
tissue-specific microenvironment, which are required for tumor pathogenesis [19, 21]. 
Although animal models are valuable research tools, they are costly, time-consuming, 
and short of appropriate resolution and sensitivity to track the dynamics of cancer 
progression. Animal studies can also show considerable differences from humans with 
regard to requirements for oncogenic transformation [36]. 
     Another problem is that a tumor evolves heterogeneously and the numerous 
passenger mutations which have little function on cancer disease confound the paths of 
tumor-causing alterations (drivers) and this property makes most reverse genetics 
studies yield numerous complex genetic candidates [5,9, 10]. Therefore, testing the role 
of each gene in cancer pathogenesis is a critical albeit difficult task given the large 
number of low-frequency mutations in cancer genome. Currently large-scale high-
throughput genetic approaches have facilitated the identification of genetic alterations in 
cancers. However, distinguishing drivers from passengers is barely successful using 
genome analysis alone [5, 9]. 
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    To fundamentally bypass these limitations, we have established a new system for 
cancer research. Recent technical advance on orthotopic organ engineering and 
transplantation has paved a new avenue for isolating natural matrix with preserved ECM 
and three-dimensional tissue-specific structure, which provide more physiologically 
relevant conditions [11, 17, 37, 39, 40, 49 ]. To truly mimic human conditions and create 
a refined model qualified for studying cancer genetics, we have created an organotypic 
cancer model using human natural matrix, and to identify low-frequency driver genes, 
we applied a forward genetic screen using Sleeping Beauty (SB) transposon- based 
mutagens in this cancer model [10, 14, 15, 31, 46, 47 ]. 
    Here we have demonstrated the method by generating ex vivo human colon cancer 
tissues combined with SB mutagenesis system for studying invasion-driver genes. 
Found in ~80% of colorectal cancer (CRC), loss-of-function mutations in adenomatous 
polyposis coli (APC) gene is thought to be the initial event, which transforms normal 
colon epithelium into neoplasia. APC-dependent neoplasia requires additional mutations 
for progression from in situ mucosa to invasion through the muscularis layer into the 
submucosa where cancer cells gain access to main vascular and lymphatic systems for 
their systemic spreading. Thus invasion into submucosa is believed as a key feature for 
CRC to become malignant. As proof of principle, we first created a physiologically active 
model of human colon by reseeding primary colon epithelial cells, endothelial cells and 
fibroblasts in decellularized human colon tissues, which retain the colon’s complete 
geometry, well preserved ECM including relatively integral vascular network, and most 
importantly, maintain the intactness of muscularis layer [34]. The organotypic colon was 
sequentially transformed into APC-null in situ neoplasia and then into submucosal 
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invasive adenoma by introducing the additional genetic elements of active K-RAS and 
TGF-β [22, 45, 50]. Functional analyses and molecular characterizations indicate that 
this bioartificial CRC model has the capacity to recapitulate the major features of tumor 
malignancy, including breaking muscularis layer and invading into submucosa. This 
CRC model, derived from genetically defined epithelium, free of redundant genetic 
alterations and reproducing malignancy transformation within 4 weeks, served as a new 
platform for studying progression-driver genes. Next, we performed a forward genetic 
screen using transposon- based mutagens to induce malignancy transformation in 
the in situ APC-dependent neoplasia. Our results demonstrated that the organotypic 
cancer model combined with transposon-based mutagenesis system allow us to 
achieve rapid forward genetics study in human-originated tissues and improve 
oncogene discovery.  
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RESULTS 
Preparation of acellular human colon matrix  
    Decellularization 39,40 using sodium dodecyl sulfate (SDS) followed with Triton-X100 
washing gave better results than the PEG based or DNase/enzyme based methods for 
removal of cellular components from human colon tissues (~5 cm3) (Figure 1 A-D). DNA 
content (Supplementary Table 1) in these acellular scaffolds decreased to less than 5% 
of that in normal colon, while there was no difference in the quantities of the four main 
ECM proteins – GAG (Supplementary Table 1.), collagen (type I), laminin and 
fibronectin (Figure 1 I) [35]. Removal of most cellular components is further confirmed 
(Figure 1 I) by the observation that F-actin and nuclei are undetectable in the scaffolds 
by immunohistochemistry. The decellularized scaffolds successfully preserved the 
tissue architecture, main vasculatures and crypt niches (Figure 1 E, F and H) of the 
original colon. Most importantly, the colon matrix retained the intactness of muscularis 
layers (Figure 1 G), which form the native barrier for CRC malignancy progression and 
submucosa invasion. 
 
Recellularization of acellular human colon matrix  
     As we have proposed earlier, one key feature of the ex vivo colon model to facilitate 
identification of driver genes is having a genetically defined epithelium which is free of 
malignant origin and secondary genetic alterations. We developed primary culture of 
human colon epithelial cells (hCEC) (Supplementary Figure 1 A.) from routine 
colonoscopy patient samples [13, 28, 43]. DNA sequencing of these cells indicated no 
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mutations in hotspot regions of APC, KRAS and TP53 genes. Immortalized with protein 
expression of the human ribonucleoprotein enzyme telomerase (hTERT), hCEC formed 
organoids with microcrypt structure in 3D culture (Supplementary Figure 1 A.), and were 
capable of self-renewal and multilineage differentiation into the various major types of 
functional epithelial cells [33](Supplementary Figure 1B).  
     The small bowel mucosa with intact crypt niches and muscularis layer can be 
mechanically separated from the submucosa (Supplementary Figure 3 A and B.), thus 
allowing to populate the acellular matrix with hCEC, human colon microvascular 
endothelial cells and fibroblasts (Supplementary Figure 2.) in exact physiological 
locations (Figure 2 B and Supplementary Figure 3 C, D). The complete organotypic 
human colon model was then generated by assembling the stratified mucosa and 
submucosa layers containing native ECM proteins and secreted stromal elements 
(Figure 2 B and Supplementary Figure 3 E, F). Importantly, this ex vivo colon not only 
remained viable, but also developed physiologically active crypts including basal stem 
cells and major types of functionally differentiated cells (Supplementary Figure 4).                  
 
Establishment of colon cancer model 
It has been proposed that sequential alterations in several main genes and signaling 
pathways correlated with histological features during CRC progression. APC mutation 
constantly activating the WNT pathway is believed to be the first event transforming 
normal cells into an adenoma. In the adenoma-carcinoma sequence, common mutation 
in oncogene KRAS promotes malignant transformation of early adenoma into 
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intermediate adenoma. Abrogation of the TGF-β pathway, including mutations in 
SMAD4 and TGFBR2, is thought to occur later in CRC progression, transforming the 
adenoma to a carcinoma. To rapidly convert normal hCEC into cancerous cells, we 
introduced into the system the pathological pair of genetic elements that inhibit human 
APC by small- hairpin RNA and encode active KRAS by retroviral transfection. To test 
the tumorigenic conversion, the hCEC cells with APC null and KRAS over-expression 
were subcutaneously injected into immunodeficient mice and 4 weeks later, the TGF-β 
signaling pathway was activated by directly injecting growth factor TGF-β into the 
xenografts to induce tumor development. Within 6-8 weeks, tumors occurred in 60% of 
injection sites and presented typical epithelial CRC features with crypt-like lumen 
structure and microvasculature formation, but no tumor formed by parental hCEC 
(Supplementary Figure 5).    
Based on these findings, the same sequential genetic alterations were applied to 
transform the ex vivo colon models to the different stages of CRC models. Tumor 
initiation, progression and invasion were achieved by populating the mucosa epithelium 
with APC- hCEC, APC-KRAS+ hCEC or APC-KRAS+ hCEC treated with TGF-β, 
respectively (Figure 2 A). Similar to the native human colon tissue (Figure 2 C), the ex 
vivo colon model recellularized with normal hCEC (Figure 2 D) was found to form 
single-cellular layer in crypt niches that tightly attached to the basal membrane and 
stromal ECM. In contrast, the APC-null colon model (Figure 2 E and F) presented 
dysplasia-like structure in the mucosa epithelium including cells undergoing fast 
proliferation to form multi-cellular layers and distorted crypt structure with multi-lumenal 
fusion, a typical phenotype in early stage adenoma. The APC-null neoplasias formed in 
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only 2 weeks and were in situ restricted to mucosa layer. Next, the CRC model further 
demonstrated that constant expression of KRAS functioned synergistically with the 
activated TGF-β pathway to promote the APC-dependent neoplasia growth into large 
adenoma, breaking through the muscularis layer and invading into submucosa, a key 
feature of malignant CRC (Figure 2 G-I).This malignant transformation occurred within 4 
weeks from the onset of the in situ APC-null neoplasia.  
In summary, we have developed a colon cancer model using human natural matrix 
and genetically defined primary colon cells. This pathophysiologically active CRC model 
recapitulated the key features in tumor initiation, progression and malignant transition 
from mucosa in situ to submucosa invasion. The different stages of oncogenic 
transformation can be generated easily within weeks, correlating well with histological 
features and avoiding redundant passenger mutations. The ex vivo system also can 
provide single-cell resolution and time-lapse sensitivity for anatomically tracking and 
dissecting disease steps within CRC progression. These qualities make the ex vivo 
CRC model a potentially useful system for high-throughput genetics or therapeutics 
study.           
  
Identification of CRC driver genes   
In our previous study, SB transposon-based mutagenesis has been successfully 
used as a genetic modification tool to model many types of human cancer in mice and 
this forward genetics study facilitated the exploration of many novel genes and signaling 
pathways driving cancer in mice [7,8,10,14,15, 26, 27,31,36,46,47,48] . Here we extend 
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the SB mutagenesis system to model cancer diseases in human-origin tissues, which 
allows for identification of cancer driver genes in real human conditions. In order to 
create an active human SB transposition system covering broad target range on the 
low-frequency mutant genes of CRC, we made some improvements to the current 
T2/Onc transposition system used in mice. We added the dual selection markers of 
GFP and neomycin between the two inverted repeats/direct repeats in the transposon 
gene and this allowed the purification of the cell population with transposon insertions. 
We also replaced the SB10 transposase in the transposition system with SB100X, the 
most effective transposase currently available [20]. In the combination system of 
T2/Onc and SB100X, 500 ng transposon donor plasmids and 100 ng transposase 
helper plasmids were found to function best for hCEC cells for reaching the peak activity 
of transposase and avoiding the effect of overproduction inhibition (OPI) 
[20](Supplementary Figure 6 A). Each hCEC cell had on an average 4 ± 3 transposon 
copies inserted in its host genome after 4 weeks of antibiotics selection (Supplementary 
Figure 6 B).     
The adenoma undergoing submucosa invasion developed within 6-7 weeks in the 
colon matrix with APC-null SB-inserted hCEC seeded in the crypt niches (Figure 3 D 
and E). The average number of invasion loci in every 10 cm2 matrix was 5.5 ± 1.9 which 
is significantly higher than that of the matrix with APC-null hCEC transfected with 
transposon donor plasmid alone (Figure 3 F), and indicated that SB-based mutagenesis 
system was physiologically functional in generating genetic hits during CRC progression. 
The ex vivo system demonstrated that colon tumors in multiple disease stages can be 
sequentially reproduced and time-lapse tracked to single-cell resolution (Figure 3 G - I). 
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     In this study, 21 invasive neoplasias in total from 15 independent recellularized 
matrixes were excised by laser-capture microdissection to minimize the contaminations 
with non-invasive tumor tissues. For analysis of transposon insertion sites, ligation-
mediated PCR (LM-PCR) [4] was performed to specifically amplify the transposon 
integrated genomic fragments which were then sequenced by illumine sequencing. Low 
mapping quality reads (values less than 30) were filtered out for the following analysis. 
Among the high mapping quality reads, about half of them were mapped at the “TA” 
dinucleotide sites. Further analysis was focused on these consensus SB insertion sites. 
From the distribution of read depth at the insertion sites, it was clear that majority of the 
insertion sites resulted from background insertion events or PCR artifacts. We 
considered the top 10% of the deepest insertion sites as clonal insertion sites. We 
mapped these clonal insertion sites in each sample to the human genome annotation 
file, refGene, and picked the sites that were within 1000bp of known transcripts in 
refGene. In addition to this, big dye terminator sequence was used to confirm the 
transposon insertion sites [20].  
This forward genetics screen identified a total of 39 candidate genes which, when 
mutated, probably contributed through cooperation with APC mutations to the malignant 
transformation of the ex vivo CRC (Supplementary Table 2). All the candidate genes 
have been documented in the human colon cancer cataloged TCGA database, 
highlighting the strong concordance of the ex vivo CRC models to the real clinical 
aspect of the disease. Intriguingly, 17 of the 39 genes were found to have been 
identified earlier to contribute majorly in CRC progression and these included TCF7L2 
and WNT9B (two members in WNT pathway), DNA mismatch repair gene MSH2; 
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TWIST2 (associated with the phenomenon of epithelial to mesenchymal transition), 
JAK1and STAT3 in JAK-STAT signaling pathway; DCC (a common deletion gene in 
CRC) (Table 1). Among the remaining 22 genes which have not previously been 
implicated in CRC progression, we selected 10 genes (ASXL1, CAMTA1, CSTF3, 
DDX20, FXR1, LATS2, MITF, PAX7, PRKG1, and RPAP1) for validating the driver 
function of causing tumor malignant transformation. siRNA was used to down-regulate 
the gene expressions in APC-null hCEC or colon cancer cell line SW480. SW480 line 
was derived from early-stage adenocarcinoma and harbors APC mutation similar to that 
of hCEC in our model, thus used as a suitable cellular tool to test the candidate 
functions in real CRC cells. It was observed that 7 genes promoted cell proliferation, 4 
increased cell mobility and 7 enhanced cell invasions through matrigel matrix (Figure 4).  
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Discussion 
 
    We have described a new methodology that allows unbiased forward genetics 
studies performed in human-origin tissues under real human conditions. The 
decellularized human native matrix can provide major tissue-required elements, 
including complex tissue-specific structure, cell-matrix interaction, and physiological co-
location of multiple types of cells and these make our method advanced to conventional 
assays of cell migration or invasion though synthetic matrigel or collagen layer which 
does not exist in real tissues. Compared to the complex bioreactor and medium formula 
desired to generate native functional organs for orthotopic transplantation, we used 
simpler systems that fulfill minimal requirements for developing tissue-level tumor 
models, enabling low-cost and large-scale cancer study.  
Currently, very few animal models have been developed to study malignant events 
and test late-stage CRC, mainly because the intestinal-specific and inducible gene 
modifications in mice are available in only some of the genes relevant to human CRC 
and most global genetic manipulations barely cause colon-specific cancer phenotypes. 
Through introducing sequential pathologically-paired genetic elements, the ex vivo CRC 
model was able to recapitulate most features in different disease stages and developed 
malignant transformation within weeks, suggesting it to be a valuable complement to 
current cancer models. Genetic alteration patterns required for oncogenic 
transformation in human systems are different to animal systems. For instance, it is 
estimated that average 5-12 somatic mutations are required for a normal human cell to 
undergo malignant transformation, but only 2-4 mutations are sufficient for mouse cells. 
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The ex vivo cancer models generated from human native matrix and primary cells may 
serve as a more accurate and efficient research platform from which the results derived 
may be applied directly to the human circumstance, bridging the gaps between animal 
models and clinical diseases.  
 Transposon-based insertion mutagenesis system is believed as an unbiased and 
high-throughput genetic tool for cancer gene discovery. SB system has been used to 
model many types of mouse cancers. However our studies, to our best knowledge, at 
the first time demonstrate SB is capable to induce human cancer development under 
human native conditions. Identification of malignancy driving genes that will lead to 
developing not only drug targets but also diagnosis markers, therefore, is critically 
important for improving clinical outcomes. Currently, studying malignancy driver genes 
remains as a challenge and a tractable system that enables recapitulating the dynamic 
malignancy transition within a clear diver alteration context would largely facilitate 
oncogene discovery. The ex vivo CRC models we described here were created with 
normal primary cells free of redundant mutations and have the capacity to reproduce 
tumor initiation, promotion and progression by sequentially introducing APC, KRAS and 
TGF-β genetic alterations. Based on the tractable model system, we applied SB- 
mediated mutagenesis to simulate multiple hits during cancer evolution and the 
mutations correlated to CRC development were promptly detected by pathological 
features and efficiently identified by high-throughput LM-PCR.   
To provide the proof of principle for the forward genetic study based on the approach 
of “engineering oncology”, we identified 39 candidate driver genes involved in CRC 
submucosal invasion though cooperation with mutations in APC. All of the genes have 
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been listed in the TCGA-colon cancer database, suggesting the highly relevance of the 
ex vivo model to clinical CRC diseases and among these genes, 17 have been 
previously reported correlated to CRC progression, indicating the effectiveness and 
accuracy of the model system as a functional platform and feasibility of ex vivo SB-
based forward genetic screen for studying cancer genetics. Besides functional assays, 
the known functions of the candidate genes also provide evidence for some of them to 
be the drivers in CRC development. ASXL2 [30], for example, is a member of ASXL 
family that are epigenetic scaffolding proteins with functions of epigenetic regulations by 
recruitment of the polycomb-group repressor complex (PRC) and trithorax-group (trxG) 
activator complex and of histone modification by assembling transcription factors to 
specific genetic domains. ASXL2 as well as ASXL1, another ASXL family member, 
BRCA1 and YY1 are binding partners of BAP1 that is a nuclear de-ubiquitinating 
enzyme and strongly associated with metastasis as a tumor suppressor. Truncation 
mutations of ASXL2 have been correlated to poor prognosis in prostate cancer, 
pancreatic cancer and breast cancer. Additionally, ASXL1 has been involved in the 
malignant progression of multiple cancers including CRC with microsatellite instability 
(MSI).  
Another candidate CAMTA1 was previously identified as a putative tumor suppressor 
in neuronal cancers [23]. CAMATA1 decreases glioblastoma cell growth by stimulating 
the expression of anti-proliferative peptide NPPA and regulates neuroblastoma cell 
mobility through increasing expressions of β3 (TUBB3) tubulin, microtubule associated 
protein 2 (MAP2) and neurofilament light chain (NEFL). CAMTA1 may function through 
Ca2+ signaling pathway and mediate Ca2+ - dependent processes in cell differentiation. 
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Particularly, decreased expression of CAMTA1 was observed frequently in CRCs and 
was previously reported to be substantially associated with poor survival as an 
independent indicator [32]. Consistent to previous findings, our both in vitro and ex vivo 
functional assays that decreased CAMTA1 expression substantially promoted cell 
proliferation and invasion in hCEC and SW480 lines, further indicated that CAMTA1 
may play a tumor-suppressor role in CRC malignancy transformation. 
Because of the heterogeneity during cancer evolution and diversity in personal 
genomic background, the 39 candidates identified in this screen are sort of specificity to 
the patients that these three colon epithelial cell lines were derived from. Theoretically, 
this model system can discover broader ranges of novel oncogenes by using various 
patient cell sources or generating initial pools covering different mutation profiling 
through different rounds of SB mutagenesis. Although now mutations in tumors can be 
identified on a whole-genome scale, elucidating the roles of genetic alterations in 
tumorigenesis is still challenging. Here we demonstrated the potential value of the ex 
vivo cancer models to complement existing in vitro cell lines and in vivo animal models 
for studying the mechanistic roles of the recurrent human cancer mutations multi-
dimensionally. The new methodology of engineering ex vivo cancer models developed 
in this research also offers more opportunities to create specialized physiological 
microenvironment for mimicking real clinical diseases. For instance, further engineering 
vascular network, immune system and organ-specific microbes may be selected to 
incorporate into the miniaturized cancer tissues depending on variant research goals to 
achieve. In addition, this new engineering process also might be extent to generating 
other types of ex vivo cancer organs [38, 42], such as lung, liver, skin and kidney and 
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potentially provide new research strategy in many fields of oncology from developing 
biomarkers for diagnosis and prognosis to screening drugs, chemicals, pathogens and 
toxins for personalized medication.     
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METHODS 
Decellularization of human colon tissues. 
All primary normal colon tissues in this study were taken from the normal parts of CRC 
tissues collected by the Weill Cornell Colon Cancer Biobank, approved by the 
Institutional Review Board (IRB) of Weill Cornell Medical College. Pathological study 
has been used to check the normal origin by tissue morphology. Briefly, fresh patient 
colon tissues were collected in Medium 199 supplemented with 200 U/ml penicillin and 
200 mg/ml streptomycin, immediately after patient operative resection. Fat and blood 
clots were removed from tissues and they were rinsed 5 times in sterile PBS. Samples 
were cut into 5 cm x 2 cm pieces and incubated in sterile 1% SDS (Fisher Scientifics) in 
deionized water for 4-6 hours at room temperature and gently shaking condition. Sterile 
1% Triton –X100 (Sigma) in deionized water was applied to rinse the tissues for 1 hour 
and the acellular matrix was then washed in sterile PBS containing 
penicillin/streptomycin/amphotericin at 37°C for the first 5 hours changing the PBS 
every 30 minutes and the other 5 days changing the PBS every day. The decellularized 
matrix can be freshly used for the following recellularization or stored in – 80 °C for up 
to 6 months.  
 
Quantification of DNA and Glycosaminoglycan (GAG) 
To assess total DNA or GAG content within the native colon and decellularized colon 
matrix, 6 X 100mg (wet weight) specimens were used for the following measurements. 
For DNA measurement, specimens were minced and homogenized in 1 ml lysis buffer 
consisting of 50 mM TriseHCl (pH 8), 50 mM EDTA, 1% SDS and 10 mM NaCl, and 
then digested with Proteinase K for overnight, followed by phenol/chloroform extraction. 
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The total DNA was precipitated and washed with 70% ethanol and dissolved in RNA-
free water. Subsequently, DNA purity and concentrations were charaterized by 
nanodrop (Thermo Scientific 2000c). 
The sulfated GAG content from both native and acellular colon tissues was quantified 
using Blyscan GAG Assay Kit (Biocolor, UK). GAG concentrations were calculated by 
the absorbance at 595 nm using a microplate reader (Tecan Infinity) and compared to 
standards made from bovine tracheal chondroitin-4-sulfate.  
Culture of primary human colon cells 
With proved of IRB at Weill Cornell Medical College, Colon biopsies (0.5-1 cm3) without 
visible adenomas by pathology were obtained from patients undergoing colonoscopy 
screening. The techniques of isolation and primary culture of human colon epithelial 
cells (hCEC) were slightly modified from the previous studies. Briefly, Colonic 
specimens were immersed in cold X medium (HyClone) supplemented with 2 % 
penicillin/streptomycin, immediately after patient operative procedure and rinsed with 
sterile PBS with antibiotics/ antimycotic (invitrogen) for 5 times. The tissues were 
minced into small pieces (~1mm in size) and crypts were gently exacted by digestion in 
X medium containing collagenase type XI (150 U/ml, Sigma, St. Louis, MO), dispase 
neutral protease (40 μg/ml, Roche Applied Science), stirring at 37°C for 15-30 min. The 
crypt cells were cultured in X medium with growth supplements of 5% FBS, EGF 
(25ng/ml R&D systems), insulin (5.0 μg/ml, Sigma), hydrocortisone (1.0 μg/ml Sigma), 
transferring (2 μg/ml Sigma), BPE (50 μg/ml Sigma), B27 supplement (Invitrogen), R-
spondin 1 (200 ng/ml, R&D systems) and Noggin (50ng/ml, Peprotech) in collagen-I 
coated flasks (BD scientific) incubated at 33°C, 5% CO2. After 48 hour culture, 
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fibroblast Inhibitory reagent (Human Colon FibrOut™ from CHI Scientific) was applied to 
the culture medium for 2-3 days to reduce fibroblast growth. After cell colonization was 
observed, cells were transfected with retroviral hTERT and followed with the 
characterization by 3D matrigel culture into organoid growth and expression of stem cell 
marker Lgr5 and differentiation markers. Co-culture with human colon fibroblasts was 
required to develop tight-junction in hCEC.  
Human colon myofibroblasts and endothelial cells were primary cultured from the 
normal tissue parts of CRC patient surgical specimens and characterized by CD31 
marker for endothelial cells and α-smooth muscle actin for myofibroblasts.    
DNA sequencing of hCEC indicated no mutations in hotspot regions of APC, KRAS and 
TP53 genes and the primers are listed as following: 
Oligonucleotide sequences and PCR conditions used to amplify exons 1-14 of 
APC. Amplification was performed in the 25µl amplification mixture containing 100-
200ng DNA, 1.5mM MgCl2, 0.2mM of each dNTP, 0.5mM of each primer and 1.25U of 
Taq DNA polymerase. 
Exon Primer Sequence 5´→3´ 
 
Size (bp) 
Amplification conditions* 
1 
F AACCTTATAGGTCCAAGGGTAG 
234bp A 
R ACCTCAAGTTTACAAGAGGGAA 
2 
F AAATACAGAATCATGTCTTGAAGT 
212bp B 
R ACACCTAAAGATGACAATTTGAG 
3 
F GACCCAAGTGGACTTTTCAGG 
423bp B 
R ACAATAAACTGGAGTACACAAGG 
4 
F GAGAAGTTTGCAATAACAACTGATG 
291bp A 
R TTATCCTGAATTTTAATGGATTACCT 
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5 
F AACCTCACTCTAACTGGACCAA 
481bp A 
R AACAGAGCTGTAATTCATTTTATTCC 
6 
F GGTAGCCATAGTATGATTATTTCT 
204bp B 
R CTACCTATTTTTATACCCACAAAC 
7 
F AAGAAAGCCTACACCATTTTTGC 
238bp B 
R GATCATTCTTAGAACCATCTTGC 
8 
F GACACTTCATTTGGAGTACCTTAACA 
222bp A 
R GGCATTAGTGACCAGGGTTT 
9 
F AGTCGTAATTTTGTTTCTAAACTC 
394bp B 
R TTTGAAACATGCACTACGAT 
10 
F TTGCTCTTCAAATAACAAAGCAT 
192bp A 
R TCCACCAGTAATTGTCTATGTCA 
11 
F GATGATTGTCTTTTTCCTCTTGC 
215bp B 
R CTGAGCTATCTTAAGAAATACATG 
12 
F TGACAAAGGAAGAACAGATAGCA 
390bp B 
R GCAGTGAGCTGAGATTGCAC 
13 
F TTTCTATTCTTACTGCTAGCATT 
306bp B 
R ATACACAGGTAAGAAATTAGGA 
14 
F AGGGACGGGCAATAGGATAG 
390bp A 
R GGTCTTTTTGAGAGTATGAATTCTG 
*A: an initial denaturation at 94ºC for 2min, followed by 40 cycles at 94ºC for 30", (50ºC, for exon 10, and 55ºC) 
for 45” and 72ºC for 1min, and a final extension step at 72ºC for 7min.  
B: The touchdown PCR protocol consists on: an initial denaturation at 94ºC for 2 min, followed by 3 cycles (94ºC 
for 30s, 60ºC for 40s and 72ºC for 30s), 3 cycles (94ºC for 30s, 58ºC for 40s and 72ºC for 30s), 25 cycles (94ºC for 
30s, 55ºC for 40s and 72ºC for 30s) and a final extension step at 72ºC for 7 min. 
15-1 5’GTTACTGCATACACATTGTGAC3’ 
5’TGTGGTTGGAACTTGAGGTG3’ 
1375bp 15 IVS15-54 -3275 
 
15-2 5’CAGATGAGCAGTTGAACTC 3’ 
5’GATTTGGTTCTAGGGTGC 3’ 
907bp  15 3095-4001 
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15-3 5’ACAGGAAGCAGATTCTGC 3’ 
5’GAGCCTCATCTGTACTTCTGC3’ 
1223bp 15 3879-5101 
 
15-4 5’AGTGATCTAACAATCGAATCC3’ 
5’CACCCTTGAGTCTTGAAGGG3’ 
1204bp 15 4972-6175 
 
* KRAS mutational analysis by PCR & sequencing  
The genomic region harboring mutational sites was amplified using three different 
primer data set to obtain respectively 198 bp, 181 bp and 162 bp amplicons:  
* KRAS 198 bp forward: 5´ GGTACTGGTGGAGTATTTGATAGTG 3´ and reverse: 5´ 
GTTGGATCATATTCGTCCACAA 3´  
* KRAS 181 bp forward: 5´ GGTACTGGTGGAGTATTTGATAGTG 3´ and reverse: 5´ 
CCACAAAATGATTCTGAATTAGC 3´  
* KRAS 162 bp forward: 5´ TGTAAAACGACGGCCAGTGGCCTGCTGAAAATGACTGAA 3´and 
reverse: 5´ CAGGAAACAGCTATGACCGGTCCTGCACCAGTAATATGC 3´  
PCR was performed in 50-µl reaction volumes containing 1X AmpliTaq ® Gold DNA 
Polymerase Buffer (Applied Biosystems, CA, USA); 2 mM of MgCl 2 ; 0.02 mM of each 
deoxynucleotide; 0.2 µM of each primer; 5 units AmpliTaq Gold ® DNA Polymerase 
(Applied Biosystems) and 80 ng of DNA template. PCR reactions to amplify KRAS 198-
bp amplicons were performed by incubating the samples at 95°C for 10 min, followed by 
40 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 1 min. The final extension step 
was performed for 10 min at 72°C and the samples were then chilled to 4°C. The 
amplification of KRAS 181-bp and 162-bp PCR fragments was obtained with the same 
conditions, but using 2.5 mM MgCl2 . PCR reactions were run in a Veriti PCR apparatus 
(Applied Biosystems). 
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The sequence data were analyzed using the Sequencer software Version 4.8 (Gene 
Codes Corporation, MI, USA) to identify mutations and to assign genotypes to individual 
DNA samples. The identified DNA changes were compared with a reference sequence 
of KRAS (Gene Bank accession NM_004449.3). Sequence results were scored by 
visual inspection of the chromatograms, performed by three independent analysts 
(Nicola Normanno, Pietro Carotenuto, Cristin Roma or Anna Maria Rachiglio). A 
mutation was called when three independent observers agreed. 
* TP53 mutational analysis by PCR & sequencing  
DNA fragments were amplified by PCR using primer pairs previously described 
(http://www-p53.iarc.fr), with the exception of the primers used to sequence exons 2 and 
3 (Table S1).  
Lentivirus transduction of primary hCEC. 
The lentiviral vector pEco-CMV-H1-shRNA-GFP encoding a shRNA hairpin sequence 
( 5"-gatccccGCTCTGCTGCCCATACACAttcaagagaTGTGTATGGGCAGCAGAGCtttttggaaa-3" 
and 5"-agcttttccaaaaaGCTCTGCTGCCCATACACAtctcttgaaTGTGTATGGGCAGCAGAGCggg-
3".) was used for knockdown of APC expression. The psi-LVRH1GP (CMV-H1-APC 
shRNA-SV40-KRASG12D - neomycin) encoding both APC- shRNA hairpin sequence and 
human KRASG12D sequence was used for knockdown of APC expression and over-
expression of KRAS G12D in hCEC. To generate the lentiviral vectors, the above 
plasmids were transfected into HEK293T cells with the Gentarget lentivirus packaging 
mix (GenTargetInc, San Diego, CA) according to the manufacturer’s protocol. High titer 
virus particles were used to transduce hCEC in serum free conditions and the efficiency 
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of APC knockdown and KRAS expression was verified by Western Blotting after 
antibiotic selection.  
Recellularization of acellular colon matrix 
The mucosa layer of decellularized colon matrix was physically separated from 
submucosa by forceps and seeded human endothelial cells by microinjection of 1000 
cells/side into four sides of 1 cm3 mucosa layer. After 5 days culture in endothelial cell 
medium, 0.2 million hCEC were planted to the 1 cm3 mucosa evenly with cells seated in 
crypt niches and cultured for 10 days in epithelial cell medium with 1:1 matrix of 
endothelial cell basal medium. The myofibroblasts were seeded in the opposite surface 
of mucosa and continue culturing for another 10-15 days. Last, the mucosa layers were 
assembled with submucosa part and returned back to culture in epithelial cell medium 
with 1:1 matrix of endothelial cell basal medium for certain time until developing CRC in 
different stages.          
Establishment of SB – TIM system in hCEC 
Insertion of CMV-GFP-Puromycin into T2/Onc vector 
• Use BglII and BsaBI to cut T2/Onc vector.  
Double Digest Recommendation(s) for BglII + BsaBI:  
• Digest in NEBuffer 3 at 37°C with BglII, then add BsaBI and raise temperature to 
60°C.  
At least one enzyme has < 100% activity in this buffer, so additional units of 
enzyme and/or longer incubation time may be necessary. 
• Design PCR primers with BgLII and BsaBI ends for the CMV-GFP-Puro: add 
BglII in CMV end and BsaBI in Puromycin end.  
LEFT PRIMER        TGACCTTACGGGACTTTCCTAC  
RIGHT PRIMER      CAGCGTATCCACATAGCGTAAA  
PRODUCT SIZE: 2754, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 2.00  
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So the end with BglII is: 5’- agatctTGACCTTACGGGACTTTCCTAC– 3’  
GC% = 46%, Tm = 60C  
The end with BsaBI is: 5’- gatnnnnatcCAGCGTATCCACATAGCGTAAA – 3’  
(in T2/Onc VECTOR the BsaBI site is 5’… gattatgatc … 3’)  
= 5’- GATTATGATCCAGCGTATCCACATAGCGTAAA – 3’  
GC% = 41%, Tm = 61C  
TOTAL LENGTH IS 2754bp 
Perform PCR amplification of the DNA piece of CMV-GFP-Puro with BglII and 
BsaBI ends  
PCR conditions:  
Initial denaturation: 95 C for 2 min  
30 cycles: 95C for 30S  
           55 C for 30S  
           68 C for 4 min  
Final extension: 72C for 7 min  
Hold: 4 C   
 Ligation of the two DNA fragments by T4 ligase 
The Schema map of T2/Onc – CMV-GFP-Puro  
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Transfection of hCEC 
50,000 hCEC cells with APC shRNA were seeded into 24 well plates one day prior to 
transfection.  500 ng transposon T2/Onc – GFP-Puro and 100 ng transposase SB 100X 
were used to transfect hCEC in each well with presence of Lipofectamine 3000 
(invitrogen) and after 3 days incubation, cells were transferred into collagen-I coated 
flasks for continuing culture starting with puromycin selection. After 3 weeks antibiotic 
selection, the hCEC cells were used immediately for populating the 3D colon matrix.  
Laser-capture microdissection  
The cells undergoing submucosal invasion were harvested by laser-capture 
microdissection according to the company instruction (Carl Zeiss MicroImaging, 
Germany) and DNA was exacted from the samples using QIAamp DNA MicroKit 
(#56304, Qiagen).  
LM-PCR amplification and preparation for illumina sequencing 
Restriction digest 
1. Digest 1μg of tumor DNA with NlaIII (IRR) or AluI (IRL). Do not use more than 2 μg of 
genomic DNA as this 
will lead to concatomerization of genomic fragments during the ligation step. Less than 1 μg of 
genomic 
DNA can be used, but the final volume should be scaled to maintain a similar DNA 
concentration in the 
reaction. 
1 μL enzyme 
4 μL buffer 
4 μL 10X BSA (if needed) 
X μL H2O 
Y μL DNA        
20 μL Total 
 
2. Incubate at least 3 hours at 37°C. 
 
3. Heat inactivate enzyme. 
The restriction digest can be incubated overnight. In this case, heat inactivation of the enzyme is 
not required. 
However, overnight incubation should be performed in a 37°C incubator (not a water bath) to 
prevent 
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evaporation of the sample. 
 
Ligation 
1. Prepare the adaptor by mixing the linker+ and linker- primers (each at 100μM) at a 1:1 ratio 
(see below for 
primer details). Linkers should be re-suspended at 100μM when stored. Heat the primer solution 
at 95°C 
for 5 minutes. Turn off the heat and allow the primers to slowly cool to room temperature. This 
allows the 
single-stranded oligos to anneal and form the double-stranded adaptor. 
2. Set up ligations: 
10.0 μL digested genomic DNA 
2.0 μL 10X NEB buffer 4 
2.0 μL 10 mM ATP 
1.5 μL adaptor 
1.0 μL T4 ligase (2,000U) 
3.5 μL dH2O 
20.0 μL Total 
ligate 2-3 hours at room temperature or overnight at 16°C 
3. Heat inactivate the T4 ligase (65°C for 10 minutes). 
4. Digest ligation with BamHI. This prevents the fragment from transposons within the 
concatomer from being 
amplified. BamHI solution is made in a 10μL volume per tube. To each tube add: 
1.0 μL BamHI 
1.0 μL NEB Buffer 4 
3.0 μL 10X BSA 
5.0 μL dH2O 
10.0 μL Total 
If the digest ligation is performed overnight at 37°C then column purification is not required as 
the BamHI has degraded. Otherwise, a column purification is needed to remove the BamHI 
enzyme. 
 
PCR 
 
2.00 μL ligation reaction Step 1 98°C 30 seconds 
10.00 μL 5X buffer 
1.00 μL 10 mM dNTPs Step 2 98°C 10 seconds 
1.50 μL primer 1 (10 μM) 63°C 20 seconds 
1.50 μL primer 2 (10 μM) 72°C 30 seconds 
0.25 μL Phusion polymerase (NEB) repeat Step 2 for 25 cycles 
33.75 μL H2O 
50.00 μL Total Step 3 72°C 2 minutes 
Hold at 4°C 
- dilute 3 μL of PCR reaction in 147 μL H2O (1:50 dilution) 
- store remaining primary PCR reaction at 4°C 
Set up secondary PCR 
4.00 μL diluted primary PCR (diluted 1:50 in H2O) 
20.00 μL 5X buffer 
2.00 μL 10 mM dNTPs 
3.00 μL nested primer 1 (10 μM) 
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3.00 μL nested primer 2 (10 μM) 
1.00 μL Phusion polymerase (NEB) 
67.00 μL H2O 
100.00 μL Total 
- perform PCR using the same cycle conditions as primary PCR (25 cycles) 
 Analyze 25 μL of PCR product on 1.5% agarose gel. 
 Purify remaining PCR product to remove excess primers/dNTPs. 
 Determine concentration of purified PCR products (Nanodrop or UV spec is sufficient) 
 Pipet 25 ng of each PCR product pool into a single tube to be run on a single lane on the 
Illumina 
 platform 
 Adjust the final concentration of the mixed sample to be ~20-25 ng/μL. 
 Incubate the diluted products at 37-42°C for 30 minutes 
 Submit sample for sequencing 
 
Primers to generate adaptors: 
IRDRR adaptor 
NlaIII linker+ 5’-GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG-3’ 
NlaIII linker- 5’-Phos-GTCCCTTAAGCGGAG-C3spacer-3’ 
IRDRL adaptor 
AluI linker+ 5’-GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC-3’ 
AluI linker- 5’-Phos-GTCCCTTAAGCGGAG-C3spacer-3’ 
All adaptor primers are resuspended in STE* buffer at 100μM. All PCR primers were used at 10 
μM 
concentration. C3spacer modification is available from Integrated DNA Technologies. 
 
Primers for IRR amplification (NlaIII-digested DNA): 
Primary PCR 
IRR 5’GGATTAAATGTCAGGAATTGTGAAAA 3’ 
linker primer 5’GTAATACGACTCACTATAGGGC 3’ 
 
Primers for IRL amplification (BfaI and AluI-digested): 
Primary PCR 
IRL 5’AAATTTGTGGAGTAGTTGAAAAACGA 3’ 
linker primer 5’GTAATACGACTCACTATAGGGC 3’ 
 
Secondary PCR (for IRR and IRL) 
IR-A1 
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
(barcode)TGTATGTAAACTTCCGACTTCAACTG 
Linker-A2 
5’CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTAGGGCTCCGCTTAAGGGAC 3’ 
 
Then the DNA samples are ready for direct illuma sequencing 
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CIS analysis 
For analysis of transposon insertion sites, ligation-mediated PCR (LM-PCR) was 
performed to specifically amply the transposon integrated genomic fragments which 
were then sequenced by illumine sequencing. Low mapping quality reads (values less 
than 30) were filtered out for the following analysis. Among the high mapping quality 
reads, about half of them were mapped at the “TA” dinucleotide sites. Further analysis 
was focused on these consensus SB insertion sites. From the distribution of read depth 
at the insertion sites, it was clear that majority of the insertion sites resulted from 
background insertion events or PCR artifacts. We considered the top 10% of the 
deepest insertion sites as clonal insertion sites. We mapped these clonal insertion sites 
in each sample to the human genome annotation file, refGene, and picked the sites that 
were within 1000bp of known transcripts in refGene. In addition to this, big dye 
terminator sequence was used to confirm the transposon insertion sites.  
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Knockdown candidate genes through siRNA 
siRNA was used to knockdown expressions of candidate genes in hCEC or SW480 
cells with Lipofectamine RNAiMAX (invitrogen) and Q-PCR was used to test the 
knockdown efficiency. 
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FIGURES 
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Figure 1. Preparation and characterization of acellular human colon matrix. (B) and (D) 
representative images of decellularized human colon; comparison with (A) and (C) native 
human colon tissues. H+E staining of decellularized colon matrix (F) and native colon tissue (E), 
Acellular colon matrix well preserved vasculature (Asterisks), &crypt niches (Triangles). (G) 
Electron microscope image of acellular mucosa preserved integral muscularis layer (ML); M: 
mucosa area; SM: submucosa area. (H) Quantification of crypt numbers and diameters, blood 
vessel number and ML integrity in native tissue and acellular matrix. (I) Representative 
immunostaining images of left to right: F-actin for cell skeleton, DAPI for cell nuclei, collagen-I, 
laminin and fibronectin in acellular matrix (down) and native tissues (up).   
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Figure 2. Creation of organotypic human colon model and transformation into CRC 
cancer models. (A) Schematic of creating ex vivo colon model through recellularization and 
transforming normal colon models into CRC models; (B) representative images of H+E staining 
(up) and dual immunostaining (down) of cytokeratin & fibronectin in recelluarized colon or native 
colon tissues. ML: Muscularis layer; Representative images of native colon (C), recellularized 
colon with hCEC (D), APC-null hCEC (E) & (F), APC-null-KRAS-overexpression hCEC which is 
also treated with TGF-β (G) & (H). (I) Quantification of in situ neoplasia and invasive neoplasia.         
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Figure 3. Invasive adenoma induced by SB transposon-based mutagenesis. (A) Schematic of 
different stage CRC models induced by SB transposon-based mutagenesis; Representative 
images (H+E in B & D; immunostaining of keratin & fibronectin in C & E) of CRC models 
recellularized with APC-null hCEC transfected with SB transposition system (down) or only SB 
transposon donor plasmids (up, as negative control). (F) Quantification of invasive neoplasia 
formation in the samples with SB mutagenesis system or in the negative control. (G-I) 
representative images (dual immunostaining in keratin & fibronectin) of neoplasia progression 
from in situ to submucosal invasion.   
 172 
 
 
 
 
Table 1. Candidates have been previously identified as malignancy driving genes in CRC. * 
copy number of transposons inserted in each gene; ** number of invasive neoplasia with the 
same insertion. *** Genetic functions affected by transposon insertions.  
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A  
 
 +: two folds;  ++: three folds 
B 
 
+: two folds;  ++: three folds 
 
Figure 4. In vitro and ex vivo functional validation of candidate genes. Evaluated the effects of 
10 genes on APC-null hCEC (A) or colon cancer cell line SW480 (B) in cell proliferation, migration 
and invasion through matrigel in Boyden chamber, when gene expressions were down 
regulated by siRNA. 
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Supplementary Figures 
 
     * Value Not Available 
   ** Value Not Distinguishable from Zero. 
Supplementary Table 1. Molecular characterization of acellular human colon matrix.  
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Supplementary Fig 1. Characterization of primary human colon epithelial cells (hCEC). (A) 
representative images of hCEC cells in 2D flask culture or 3D matrigel culture. In matrigel 
culture, (left to right) individual hCEC progressively form organiod-type structure. (B)  
Expressions of stem cell marker Lgr5, epithelial markers cytokeratin 18 & 20, zonula occludens-
1 (ZO-1), A33, and differentiation markers villin, mucin 2 and chromogranin; (C) Quantification 
of stem cells and differentiated functional cells.  
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Supplementary Fig 2. Characterization of primary human colon microvascular endothelial 
cells and fibroblasts. (A) Primary cultured colon fibroblasts in light microscope (left) or stained 
with anti-α smooth muscle actin (right). (B) Primary cultured colon microvascular endothelial 
cells in light microscope (left) or stained with anti-CD31 (right).   
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Supplementary Fig 3. Engineering organotypic human colon model through microinjection 
The acellular colon matrix was physically separated into mucosa layer (A) with 20x in big 
window and 40 x in small window, and submucosa layer (B); white arrow designated the intact 
epithelial crypt niches. (C) And (D) representative images of the microinjection procedure that 
the endothelial cells was microinjected into mucosa layer. (F) Colon matrix was populated with 
hCEC, endothelial cells and fibroblasts after 4 week in vitro culture, compared to the acellular 
matrix (E). 
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Supplementary Fig 4. Molecular characterization of physiological active crypts recellularized 
with hCEC. Immunostaining of intestinal stem cell marker Lgr5, and other differentiation 
biomarkers (MUC1 for non-terminally differentiated colonic epithelial cells MUC2 for goblet 
cells; Lysozyme for paneth cells; chromogranin for enteroendocrine) in the colon models 
recellularized with immortalized hCEC.    
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Supplementary Fig 6. Creation of transposition system by T2/Onc and SB100X in hCEC. (A) 
quantification of transposition activity in fixed dose of tranposon-donor plasmids (500 ng of 
T2/Onc) under variant doses of transposase-plasmids (SB 100X); (B) average transposon copy 
numbers in hCEC individual colonies.  
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Supplementary Table 2. Candidate genes identified by SB – based forward 
genetics screen. * listed in TCGA – colon cancer database; ** identified as driver 
genes in Dvoli et, al list 
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CHAPTER 4 
Future Recommendation  
Project 1 (in chapter 1) 
    Common cancer cell lines that are adapted for long-term in vitro culture and have 
accumulated numerous passenger mutations barely retain the native properties of 
primary cancer cells. One of the advantages in our study is that we established working 
protocols for deriving primary culture colon cancer cells directly from clinical patient 
samples at different disease stages and keeping these primary cells in low-passage and 
native conditions for most of our experiments. The benefits of using primary cells were 
demonstrated in the findings that CCR9 expression, as an adaptive phenotype in native 
colon cancers, was retained at high levels only in early-stage non-invasive primary CRC 
cells, which enabled a functional response to its ligand CCL25, while CCR9 expression 
could not be detected in most common cell lines. The relationship of chemokine CCL25 
– CCR9 signaling regulating CRC progression, otherwise, could not been studied 
effectively using common CRC lines.   
    In this project, we revealed the crosstalk between NOTCH-JAG1 signaling and 
CCL25-CCR9 signaling that activated NOTCH by JAG1 directly down-regulated CCR9 
levels in CRC cells through CCR9 proteosomal degradation. What we found was 
NOTCH activation decreased CCR9 expression in protein level, but not in RNA level, 
and the CCR9 protein decrease can be blocked by proteosome inhibitor PS-341. Based 
on the current data, it is difficult to draw the conclusion that CCR9 protein is one of the 
direct downstream targets of NOTCH pathway and further investigation is necessary to 
understand whether the CCR9 protein restored by blocking proteosome function is 
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exactly the one regulated by NOTCH signaling, or due to the different CCR9 protein, 
because of blocking the proteosomal degradation of other signaling pathways which 
otherwise would have decreased CCR9 expression. 
Project 2 (in chapter 2) 
    Through engineering inducible CCR9+ expression in CRC cells, orthotopic mouse 
intestinal tumors could be formed with many common CRC lines or primary cultured 
CRC cells through tail vein injection. CTMM models are relatively fast, low-cost and 
robust in developing GI tumors and metastases within several weeks, and this property 
makes CTMM a valuable model for tracking and studying multiple steps in CRC 
progression from cancer cell invasion, migration, blood vessel intravasation, traveling in 
circulation system, extravasation to colonization in distant organs. Furthermore, similar 
to the engineering approach of CTMM, other types of chemokine and cell trafficking 
markers could be used to generate orthotopic cancer models in various types of organs. 
For instance, CXCR4 could be utilized to target the growth of leukemia cells specifically 
in bone marrow which express ligand SDF-1, or CCR6 could be applied to guide human 
hepatocellular carcinoma cells to specifically grow in mouse liver, which is one of the 
major organs secreting CCR6 ligand CCL20.  
     Another interesting finding is that we demonstrated liver metastases are more 
chemoresistant than orthotopic GI tumors or subcutaneous xenografts, and explored the 
potential molecular mechanisms of increased DKK4 level and NOTCH signaling 
involved in the chemoresistance to Oxaliplatin, as consistent to the study using clinical 
patient samples. Our RNA-Sequencing and quantitative RCP double confirmed that 
DDK4 level was 80 times up-regulated in metastasis than that in primary GI tumors, 
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indicating there could be a sort of “on” and “off” switch of genetic regulation involved in 
DKK4 signaling. Further studied will be required to reveal the broader signaling network 
involved in CRC chemoresistance, such as the regulation of DKK4 mediated TFAP2E-
dependent resistance, or the DKK4 activation of WNT pathways with crosstalk of 
NOTCH pathway. These results also highlight the concordance of our CTMM to the 
clinical CRC diseases, and further studies might be performed to interdict the detailed 
molecules and signaling network undergoing in CRC chemoresistance. In addition, 
CTMM could be applied as an advanced pre-clinical model for middle-throughput 
screening of potential drugs, chemicals, toxin and other therapeutics, or studying 
biomarkers for prevention and diagnosis.  
      The technology of engineering humanized orthotopic cancer in immunoproficient 
mice through blastocyst injection shed more light on creating humanized chimera 
models. CCR9+ CRC cells could be substantially incorporated into and grow along with 
mouse embryos at a successful rate, having RFP+ human cells detected in the hindgut 
and co-localized with regions expressing ccl25. Comparing to embryos, it is much more 
difficult to detect the RFP+ human cells in adult mouse intestines and this could be due 
to the immune rejection by mature adult immune system or the dormancy of human 
cells losing the capability of proliferation. Nevertheless, our methodology demonstrated 
the proof of principle that CCR9 expression promoted human CRC cells survive in mice 
with normal immune system. Our research provide the potential approaches of 
engineering humanized organs or tissues through chemokine targeting, and similar to 
the CCR9 procedure, other chemokines such as CXCR4 or CCR6 could be applied to 
engineer humanized mouse bone marrow or liver tissues.  
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     Another interesting question is how the CCR9+ human cells evade xeno-immune 
rejection from mouse hosts. Immunologically, the chimeric mice represent a 
complicated situation. T cells are educated in the thymus on mouse Major 
Histocompatibility Complex (MHC) and this would make human antigens only cross-
presented by mouse antigen presenting cells. However these T cells would be unable to 
recognize the human cells with human MHC. One possibility to test the mechanism of 
central immune tolerance is to identify whether colonized human CRC cells exist in the 
thymus in the chimeric mice. If true, there could be neonatal central tolerance to the 
human cells. If not, peripheral tolerance mechanisms might be operative, especially 
when mouse T cell, not negatively selected for xenogenic (human) MHC, encounter 
human MHC in the periphery under non-acute inflammatory conditions. To test this, the 
same CRC cells coud be grafted subcutaneously in the chimeras at 6 weeks of age 
when the mouse immune system becomes mature. If the xenografts occur, this would 
prove the immune-proficiency versus systemic tolerance.    
Project 3 (in chapter 3) 
Decellularization removed cellular components from the human colon tissue while 
retaining intact tissue architecture, blood vessel network and ECM. The integral 
vasculature provided a possibility for modeling angiogenesis in cancer tissues. 
Moreover, future technical improvements are necessary to complement the current 
decellularization method for preserving native soluble molecules, growth factors and 
other biomaterials along with the acellular matrix.  
    In addition to three types of colon cells: epitheial cell, endothelial cells and fibroblasts, 
other types of cells such as lymphocytes, adipocytes, or microbes could be potentially 
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incorporated into the ex vivo colon model system for achieving various research goals. 
The ex vivo CRC models can also be personalized and retain the pathological and 
genetic features in individual patients by having the normal colon epithelial cells 
replaced with patient-derived primary CRC cells. Furthermore, because of its properties 
of single-cell resolution, time-lapse sensitivity and easy genetic manipulation, the ex 
vivo CRC model could be applied for exploring sophisticated questions in genetics, and 
proteomics, such as fate determination of stem cells, cellular behaviors in complete 
tissue context as well as the reciprocal effects between cells and ECM.   
    It was quite amazing to perform forward genetics study in real human conditions and 
we demonstrated that many novel genes and signaling steps were successfully 
identified through transposon-based forward screens in the ex vivo human CRC models. 
However, carefully designed functional validations are critical to analyze the candidate 
genes identified from ex vivo models. Here for testing driver genes in malignant 
transformation, the ideal model will be APC min mouse models and further studies could 
be developed to investigate the tumor progression through knockdown or over-
expressing the candidate genes in intestine-specific conditions.   
    Through this forward screen, we identified a total of 22 novel candidate genes. In 
addition to functional assays, the known functions of the candidate genes provided 
evidence for some of these to be the drivers in CRC development. At least 5 of them 
are promising since they have already been implicated in other types of cancers or 
independently correlated to clinical patient outcome. Further studies are recommended 
for exploring the molecular mechanisms of each candidate in CRC progression. Another 
interesting finding is that besides insertions in genetic coding regions, SB also inserted 
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in non-coding regions and some of them target gene promoters or the genomic “dark” 
area such as the domains related to transcriptions of microRNA or long non-coding 
RNA. It will be good to know the exact functions of these mciroRNA and long non-
coding RNA in CRC progression through further mechanistic studies.  
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APPENDIX 
Engineering Colorectal Cancer and Metastasis Models for Mechanism 
And Therapeutic Studies 
 
Thesis Dissertation Proposal presented to Professors Xiling Shen, Micheal Shuler, 
Steven Lipkin and Robert Weiss in May. 2013 in partial fulfillment of the requirements 
for the admission to Ph. D. Candidacy exam (A exam) 
Abstract 
Whereas Primary colorectal cancers (CRC) can be cured by surgery, metastasis is the 
major cause of CRC mortality. To effectively treat CRC diseases largely depends on 
precisely interdicting the mechanisms of metastasis and developing drugs targeting the 
mechanisms. However, we currently lack advance in vivo and in vitro research systems 
to accurately model metastatic CRC diseases and test therapies.  
Here, we engineered orthotopic and metastatic CRC mouse models utilizing chemokine 
switch. Based on our former study that early stage CRC cells are CCR9 positive and 
they spontaneous form GI tumors by tail vein injection, we created primary and 
commercial CRC lines with inducible CCR9 expressions and show these cells were able 
to form tumors in mouse intestine simple through tail vein injection. After forming 
orthotopic tumors, CRC cells are free to metastasize from the primary tumor after CCR9 
turns off, if they possess the intrinsic ability to metastasis. This model recapitulates the 
most features of CRC metastasis progression directly from primary GI locations to 
distant organs. In addition, we broadly engineered CCR9 expressing cell lines 
representing all major CRC molecular subtypes in TCGA list, to form orthotopic CRC 
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accounting for clinical patient genetic diversity. At last we indicated that the new CRC 
mouse models facilitate mechanism study by combining with whole body IVIS imaging 
as well as multi-photon microscopy and also provide effective and efficient platform for 
pharmaceutics study.  (This project is close to end and we currently prepare paper 
submission.)  
In the other hand, we created an in vitro organotypic human colon by reseeding primary 
colon epithelial, endothelial cells and fibroblasts in decellularized human colon tissues, 
which retain colon’s complete geometry, preserves the extracellular matrix including 
relative intact vascular network, and most importantly, maintains the integrity of 
muscularis layer. The organotypic colon can then be transformed into APC-null invasive 
neoplasia in CRC-associated genetic pathways. Functional analyses and molecular 
characterizations indicate the bioartificial organ has the ability to recapitulate the major 
features of CRC malignant progression.  
Our future research plan is to use the pathophysiologically relevant bioartificial human 
CRC as a culture platform to identify invasion driving genes. We will apply SB 
transposon systems as mutagens to induce submucosa invasion of APC in situ 
neoplasia in the bioartificial colon. Then we will perform in vitro and in vivo functionally 
validations to corfirm the invasion driver genes we captured. (For this part, we 
collaborate with Copeland & Jenkins lab, and Zalton Ivics group and we suppose to 
finish in ~ 1.5 years.) Overall, my PhD research goal is to engineer in vivo and in vitro 
CRC models which can fill the gaps between conventional 2D cell culture and animal 
models, serving as better research platforms for mechanism and therapeutics studies.   
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Part A: Inducible Colorectal Cancer Metastasis Mouse Model via a Chemokine 
Switch  
Background 
Colorectal cancer (CRC) is a major public health source of morbidity and mortality, with 
proximately 150,000 new diagnoses each year in the United States[109].  25% CRC 
patients eventually die from metastatic diseases. CRC progresses through multiple 
distinct stages. Firstly, inappropriate proliferation cause colon stem or progenitor cells to 
transform into colon cancer stem cells, which start with adenoma formation and evolve 
into carcinoma in situ[110]. Then, pre-invasive CRCs by accumulating more genetic 
mutations, acquire the ability to invade through the submucosa and muscularis, 
metastasize, and survive outside the colon microenvironment niche and in the distant 
organs[111, 112]. Precisely understanding mechanisms of CRC formation, transition 
from localized to metastatic stages and developing drugs to block the mechanisms are 
criticalpre-requirements to improve patient outcomes. While current CRC animal models, 
as basal research tools, have their weaknesses whichretardus from fully understanding 
metastasis mechanisms and developing effective drugs.  
Genetically engineered mouse model (GEMM, transgenetic mice) is a very powerful tool 
for cancer study. However, it is relatively expensive and time consuming to create. Also, 
due to its over-simple genetic background, GEMM hardly captures all the features of the 
genetic mutations and epigenetic regulations in human CRC diseases. For example, 
mouse screens for cooperating mutations are not always concordant with TCGA (The 
Cancer Genome Atlas) results to identify the most common mutations, genomic 
rearrangements and epigenetic in the corresponding human cancers. Subcutaneous 
 195 
 
xenograft models, the currently workhorse for drug screening, lack the native gut 
microenvironment [113, 114]and the property of distant metastasis, thus lead to many 
false positive cures.Surgical implantation of CRC cells under the kidney capsule, or 
orthotopic implantation through intra-cecum or rectal injection overcomes this limitation. 
However, injection needle tracts create potential artifacts for cell egress, disturb the 
extracellular matrix and artificially generate a local inflammatory microenvironment, 
which confound the research results. Additionally, we currently do not have robust, 
consistent models of CRC liver metastasis from primary intestinal sites[115, 116]. 
Therefore, advance methods are required to model more accurately CRC metastasis 
and therapeutics[117].  
Approaches 
Here, we create an inducible colorectal cancer metastasis mouse model via a 
Chemokine Switch. Chemokines are a family of secreted ligands that play important 
roles for trafficking lymphocytes in the body to different organs, including bone marrow, 
skin, thymus, intestine,liver and other sites.The G protein–coupled chemokine receptor 
9 (CCR9) and its ligand chemokine 25 (CCL25) comprise a signaling axis that is 
particularly important for the small intestine and colon[15]. Intestinal epithelial cells 
produce CCL25, which attracts circulating CCR9+ T cells to intravasateinto the gut 
toward the CCL25 source.Normal colon epithelial cells also are CCR9+. Recently our 
study[73]showed that early but not late stage CRCs are CCR9+ and when injected by 
tail vein can spontaneously form gut tumors.Thus, our working hypothesis is by making 
inducible CCR9 expression in human CRC cells, we can have the CRC cells forming 
tumors in the native mouse gut microenvironment simply through tail vein injection and 
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then metastasizing to the most common anatomical sites when CCR9 expression turns 
off. We used this as a platform to develop a more general metastasis system.Solid 
tumors are heterogeneous and this is a problem for metastasis study becauseof over-
extrapolating results from a limit diversity of genetic backgrounds. To address this issue, 
we made a series of CCR9+ lines that cover the major CRC molecular subtypes as 
defined in TCGA. This should be a useful research resources or tools for mechanistic 
studies and drug screening.These inducible CCR9+ lines also have luciferase and 
fluorescence double labeling for real time in vivo tracking by IVIS system for middle-
throughput drug screening and time lapse imaging to study deep metastatic 
mechanisms like tumor cell intra-/extravasations, epithelial mesenchymal transition. 
Finally, we evaluateoxaliplatin effects, one of the first line drugs in clinical CRC therapy, 
using the inducible CRC metastasis model as well as current standard subcutaneous 
xenograft model.     
Experimental Designs and Results 
1. Engineering inducible CCR9+ primary or commercial CRC lines and In vitro 
evaluating the efficiency of inducible CCR9 expression, migration to CCL25, cell 
growth and death with CCR9 expression.  
We first constructed an inducible CCR9 expression lentivirus vector, in which the open 
reading frame (ORF) of human or mouse CCR9 and a Red fluorescence protein (RFP) 
marker are sub-cloned under a CMV promoter(Figure 1 A). The CMV promoter is 
tetracycline inducible promoter (conditional knock-in) which means the CCR9 gene is 
silent until certain amounts of tetracycline derive doxycycline is given in vivo or in vitro. 
Then we infected a panel of human or mouse CRC lines with the lentivirus particles and 
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test the CCR9 expression is inducible with doxicyclineby western blots(Figure 1 B).The 
boyden chamber experiment was then performed to functionally evaluate the in vitro 
migration of CCR9+ cellstoward CCL25(Figure 1 D). Additionally, we tested that CCR9 
expression has no significanteffects on CRC cell proliferation[14] and apoptosis by the 
cellular ATP (adenosine triphosphate) levels(Figure 1 C). 
2. Qualify and quantify GI (gastrointestinal) vs extra-GI tumor formationby 
engineered CRC lines. 
We performed whole body IVIS imaging on mice iv injected with CCR9- (parental) only, 
CCR9+/- (mixture) and CCR9+ only CRC cells(Figure 2 B and Figure 1 A is the 
experiment schema). Most CCR9- cells developed tumors in lung locations, and the 
CCR9+/- mixture cells formed tumors in both lung and abdominal sites, while the pure 
CCR9+ cells only formed tumors in abdominal sites. The abdominal tumors were further 
confirmed(Figure 3)by ex vivo IVIS imaging and histopathology asmultiple foci along 
intestinal system from Duodenum, Jejunum, Ileum, cecum to colon.We totally 
engineered 13 CCR9+ commercial human CRC lines and 2 CCR9+ primary CRC lines 
derived from clinical patient samples(Figure 2 C), among which 12 commercial lines 
and 2 primary lines formed tumors in GI. We then quantified(Table 1) extra-GI, small 
intestinal and large intestinal tumors formed by different CRC lines, in multiplicity, sizes, 
and rates, compared to their parental lines. 
3. Broadly engineering human CCR9+ cell lines representing all major CRC 
molecular subtypes in TCGA list and a mouse CRC lines to develop murine 
orthotopic CRC model in immunoproficient environment. 
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We expanded the CCR9+ engineering in 13 human commercial CRC lines and 2 
primary CRC lines which harbor most top 20 genetic mutations in TCGA list(Table 2). 
The orthotopic CRC mouse models developed by these lines may serve as practical 
research resources or platforms for genetic subtype CRC study and drug development 
targeting specific molecular signaling. They also enable studying CRC tumor in its 
orthotopic organ site, with higher resolution and allows tracking of dynamics. As a 
demonstration, we performed in vivo multi-photon imaging of the gut tumor(Figure 5). 
We also created a CCR9+ murine CRC line CT26(Figure 4), which formed intestinal 
tumors and liver metastasis in the same BALB/C genetic background through CCR9+ 
controlling. This orthotopic mouse CRC model in immunoproficient conditions could be 
a useful tool to study the effects of immune system on CRC progression. 
4. Create the inducible metastasis models that orthotopic CRC tumors 
metastasize after CCR9 expression turns off and use the models to demonstrate 
the dynamics of CRC metastasis progression. 
We performed real time whole body IVIS imaging on mice iv injected with CCR9+ CRC 
cells(Figure 6). The CCR9 expression was turned off after lower abdominal tumor 
formation and subsequently metastasis occurred mainly in liver which is the most 
common organ the human CRC diseases metastasize. The CCR9 expression shutting 
down returns the engineered CRC lines back into their parental stages and the 
metastasis was caused by cell native properties. EX VIVO imaging combining 
histopathology(Figure 7 A) were used to further quantify the locations and numbers of 
primary and metastasis tumors, comparing to the control. The histological analyses of 
H+E staining (Figure 7 B) indicate the primary tumor undergoing progression from in 
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situ carcinoma (Stage I), submucosa invasion (stage II), to muscularis invasion (stage 
III). We also compare(Figure 8)the occurring time and numbers of liver metastasis foci 
between doxycline-keep group (CCR9-on) and withdrew group (CCR9-off). The data 
showing the doxycline withdrew group develop more liver metastatic foci in shorter 
period of time indicate metastasis correlates with doxycycline induction. In total, (Figure 
8 B)three commercial CRC lines and one primary CRC line were able to develop the 
inducible metastasis mouse models. Furthermore, most liver tumors by CCR9 
engineered lines occur later than their primary GI tumors and also later than those liver 
tumors developed by wild-type lines, indicating it is possible that most liver tumors are 
the metastases from GI tumors (Figure 8 C).In addition, we show the dynamic tumor 
growths in primary and metastatic locations can be time-lapse monitored by luciferase - 
IVIS imaging, indicate this model can be used more practically for drug screening       
5. The chemokine inducible CRC metastasis models (CIMM) serve as a powerful 
platform for imaging the dynamics of the metastasis progress. 
Combining multi-photon microscopy, we apply real-time imaging on primary GI as well 
as liver metastasis tumors. Since vasculature was labeled by green fluorescent dyes 
and engineered CRC cells have RFP marker, it is possible to track the tumor cell 
intravasation and extravasation, as important steps in metastasis generation(Figure 5 
and Figure 9). Similarly, the interaction between tumor cells and microenvironment, 
dynamic alternation of molecular markers and signaling pathway associated with 
metastasis progress could be more directly and practically studied in this system.    
6. CIMM models have the similar drug responses to that of clinical CRC diseases.  
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Oxaliplatin is an alkylating agent breaking DNA strand and causing cell apoptosis, which 
combined with 5-fluorouracil is the first line drug in clinical CRC therapy regimen. We 
applied the CRC mouse models in therapeutic study(Figure 10 and Figure 11). We 
tested oxaliplatin treatment on subcutaneous, orthotopic and liver metastatic xenograft 
tumors by Colo205 (CIN type) and DLD1 (MIS type) and evaluate therapy efficiency by 
tumor growth inhibition and mouse survival rates. The study show metastatic tumors are 
more chemoresistantthan primary GI tumors and subcutaneous xenografts. Interestingly, 
we also found oxaliplatin treatment is intended to induce further metastases probably by 
having more effects on primary tumors than metastatic tumors or promoting 
chemoresistant subpopulation amplification by eradicating the chemosensitive group.  
To evaluate whether CIMM model produce similar drug responses to those of CRC 
patients, we studied 14 patients with primary colorectal cancer and 11 patients with liver 
metastases (Figure 12 and Figure 13). Chi-Square tests in tumor volume or growth 
dynamics indicate there is significant difference in drug responses between primary 
CRC tumors and metastatic tumors, proving the similar conclusion that metastatic 
tumors are more chemoresistant than primary CRC tumors. 
Conclusion 
We develop a novel CRC metastatic model. The CIMM system, in which human CRC 
cells form primary tumors in native gut microenvironment and metastasize to the most 
common anatomical sites, recapitulates most features of CRC metastasis progression. 
This model is easy to handle (tail-vein injection), is repeatable, and generates 
metastasis robustly, which has not been achieved by other CRC models.In CIMM 
system, chemokine engineering does not affect cellular native capability to metastasize 
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because chemokine expression in CIMM is inducible and controllable, meaning the 
engineered cell lines could be changed back to parental stage right after seeding in the 
primary gut sites and metastasis is generated by cellular native properties.  
We generated a broad panel of CIMM systems with all the major molecular CRC 
subtypes in TCGA, as research platforms for specific mechanism study on different 
genetic background and evaluating drugs that target specific molecular signaling.  
Furthermore, we demonstrate that CIMM combined with multiple-photon microscopy 
can be applied to study the dynamic interaction between CRC cells and vasculatures, 
and the CRC metastatic progress under native microenvironment. 
Low-cost, surgery-free, repeatable and capturing the most features of primary CRC 
formation and metastasis progression, CIMM can be anovel and practical tool for 
pharmaceutical screening, by filling the gaps between subcutaneous xenograft and 
clinical trials.  
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Part B: In Vivo Imaging of Epithelial Mesenchymal Transition (EMT) in CIMM 
models 
Background 
An epithelial mesenchymal transition (EMT) is a biological process that allows the 
polarized epithelial cells to functionally undergo multiple biochemical changes into 
migratory mesenchymal cells secreting ECM components[118]. EMT is required for 
embryonic development, tissue remodeling, and wound repair. Recently, accumulating 
evidence indicates that tumor progression, invasion, and metastasis involve 
theinduction of EMT. During EMT, the loss of E-cadherin facilitates tumor cells 
dissociated from cell-cell or cell-extracellular matrix adhesions, and the induction of 
mesenchymal markers such as N-cadherin or vimentin leads to the reorganization of 
cellular skeleton and acquisition of a motile and invasive capacity.   
 
EMT research raises the hypothesis that the tumor cells undergoing EMT are supposed 
to have higher invasive and metastatic capability than those cells that do not, thus 
closely associated with metastasis formation. While, up to date, this hypothesis [119]is 
still short of direct evidence to prove and this difficulty partly comes from the lack of a 
reliable metastatic model that recapitulates the most properties of metastasis (CRC 
invasion and intravasation from the primary tumor) and that allows real-time monitoring 
of this dynamic process in single cell resolution. 
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Approaches 
Here, we utilize the combination of CIMM model and multiphoton microscopy to explore 
the above questions.  We first develop CIMM models with E-/N-cadherin dual reporter 
cell lines, which could designate EMT by fluorescence colors. By the promoter reporters, 
we could further determine whether the invasive cells intravasing into vasculature are 
undergoing functional EMT, how the occurrence of EMT coincides with distant 
metastasis.  
 
Experimental Designs and Results 
1. In vivo imaging of CRC cells undergoing EMT in CIMM mice. 
First, we engineered two EMT reporter CRC lines (CCR9-SW480 and CCR9-SW620) 
which are transfected with DNA plasmids of E-cadherin promoter driving GFP and N-
cadherin promoter driving mCherry(Figure 14). Then multi-phone microscopy will be 
performed in CIMM mice to visualize the CRC cells in primary GI and liver locations. 
The cells undergoing EMT can be captured by GFP and mCherry dual markers.  
2. Quantity of the EMT cells correlated with invasion, intravasation and 
metastasis 
Furthermore, we will study the relationships between EMT cells and CRC progression. 
We will quantify the EMT cells in different GI positions: mucosa in situ, submucosa 
invasion and muscular invasion. The intravasating EMT CRC cells also will be identified 
and the percentage of EMT cells will be quantified in the total amount of CTC cells 
which is in RFP marker.  
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Conclusion 
We apply CIMM model to explore some critical questions in CRC fields, which are hard 
to study using conventional animal models. EMT correlated with CRC cancer 
metastasis is hypothesized, based on the research well studied in vitro cell culture 
models, while it has not been completely proved in vivo[120]. These hypotheses have 
significant implications for anti-metastasis therapies. The difficulty largely lies in the lack 
of a reliable metastatic model that recapitulates the onset of metastasis (CRC invasion 
and vascularintravasation from the primary tumor) and that allows real-time monitoring 
of thisdynamic process.Here, we try to fill the gap by directly visualizing the EMT 
phenomena in orthotopic CRC and study the correlation between EMT and tumor 
progression by using CIMM models.   
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Part C:Identification of Invasion Driver Genes Utilizing a Bioartificial Colorectal 
Cancer Model with Transposon Mutagenesis 
Background 
Human colorectal cancers (CRC) generally can be divided into two classes based on 
the genetic background displaying chromosomal instability (CIN) or microsatellite 
instability (MSI), in which CIN phenotype occurs in 80-90% CRC cases. CRC displaying 
CIN frequently harbor loss-of-function mutations in adenomatous polyposis coli (APC) 
which transforms normal colon epithelium into neoplasia. APC neoplasia requires 
gaining additional mutationsin order to progress from in situ mucosa and invade through 
the basement membrane (muscularis layer) into the submucosa where cancer cells get 
access to the vascular and lymphatic systems for their systemic spreading[121]. 
Invasion into submucosa is therefore considered the first checkpoint in CRC becoming 
malignancy, and identification of invasion driving mutations is critical to illuminate CRC 
mechanisms and to develop potential therapeutic targets, which could eventually 
improve patient outcomes. 
However, limited progress has been made to date due to three difficulties: 
1.Conventional cell or animal-based research platforms have intrinsic limitations[122]. 
The former could not recapitulate intercellular interactions and tissue microenvironment, 
which are required for tumor malignancy. While animal models are not only costly and 
time-consuming, they also lack the appropriate resolution and sensitivity to track or 
monitor the dynamic and transientmalignant transition. 2. The difference between 
human and animal makes the results from animal studies usually inconsistent to clinical 
patient data. 3. Although second generation sequencing facilitates reverse gene studies, 
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tumor heterogeneous evolutions and numerous passenger mutations confound the 
curves of driver alterations.Therefore, animal or patient based reverse genetic studies 
generally yield numerous and complex genetic candidates, including both driver and 
passenger mutations that makes hard for functional validation.  
 
Approaches 
To overcome the first two difficulties, we will utilize a pathophysiologically relevant 
model[123] of bioartificial human colon as the research platform, which provides 
sufficient resolution, time-lapse monitoring for rapid gene screening, and also because 
of human tissue, produces responses that are more predictive of humans than animal 
models. First, we create an organotypic human colonby reseeding primary colon 
epithelial, endothelial cells and fibroblasts in decellularized human colon tissues[124, 
125], which retain colon’s complete geometry, preserves the extracellular matrix 
including relative intact vascular network, and most importantly, maintains the integrity 
of muscularis layer. Then we transform the organotypic colon into APC-null invasive 
neoplasias by deregulating APC expression, upregulatingK-RAS expression and TGF-β 
treatment[126, 127]. Functional analyses and molecular characterizations indicate the 
bioartificial organ has the ability to recapitulate the major features of CRC malignant 
progression. 
To overcome the third difficulty, we will perform forward, instead of reverse, gene 
screen using transposon-based insertional mutagenesis (TIM).Transposons are discrete 
DNA elements including transposon and transposase, which have the unique ability to 
change their genomic position through “cut and paste” mechanism and leave 5 bp 
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common insertion sites (CIS) in the hostgenome after transposition.To our knowledge, 
the TIM system has been considered non-biased, efficient, and thus the best mutagen 
system to date to simulate somatic mutations in cancer models.We plan to use the 
Sleeping Beauty (SB) DNA transposon systemdeveloped by the Copeland & Jenkins 
lab[128] at Methodist Research Institute, as mutagen to simulate the additional insertion 
hits on the APC-null in situneoplasia.During the same time, we will perform time-lapse 
microscopy monitor on the neoplasia and capture the cells undergoing invasion into 
submucosa. By analyses of SB CIS in the invasive subgroup cells, we can identify the 
invasion driving genes. Finally, we will cross outside human databases such as TCGA 
(The Cancer Genome Atlas) of APC subtype CRC or murine datasets of APC 
dependent intestinal tumorigenesis[129], to verify and narrow down our driver 
candidates for further functional validation. 
 
Experimental Designs and Results 
1. Create acellular human colon bioscaffolds by decellularization.  
We performed detergent-based decellularization slightly modified from D.A.Taylor. Nat. 
Med. 2008[130], whichaccording to our pilot experiment results[131], works best to 
remove cellular components in human colon tissues than othermethods(Figure 
15).DNA content (Figure 17)in decellular scaffolds decreased to less than 5% of that in 
normal colon, while there was no difference in GAG, Collagen (collagen I)[132], 
laminin[133] and fibronectin[134] contents. Removal of most cellular components is 
further conformed (Figure 18) that F-actin and nuclei are undetectable in the scaffolds 
by immunohistochemistry. As expected, the decellular scaffolds (Figure 16)leaved main 
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vasculatures and crypt niches intact and retained the integrity of basal membranes 
(muscularis layers).  
2. Primary cultures of human colon epithelial cells, myofibroblasts and 
microvascular endothelial cells and identification.  
Subsequently, we did primary cultures of human colon epithelial cells (hCEC)[135, 136], 
myofibroblasts and endothelial cells, the main cast needed for scaffold 
recellularization(Figure 19). In order to maintain long-term in vitro culture, hCEC have 
to be immortalized by overexpression of the non-oncogenic gene of telomerase reverse 
transcriptase (TERT) by retrovirus infection. We succeeded to grow out and maintain 
three hCEC primary lines in vitro which form microcrypt/villi in matrigel 3D 
culture(Figure 20) andexpress markers of colonic epithelial cells such as pan 
cytokeratins, zonula occludens-1, mucins-2, antigen A33, chromogranin A and stem cell 
marker Lgr5(Figure 21). Interestingly, about 20 % hCECs form crypt-like structure when 
keep cultured in 3-D mitrigel without high Wnt/ Notch signaling stimulation[137] for 5-6 
days, indicating harboring stem cell like cells. Myofibroblasts are identified as more than 
90% cells expressingα- smooth muscle actin and similarly vascular endothelial cells are 
positive in CD31 expression.  
3. Bioscaffoldrecellularization and characterization.  
Before recellularization, the mucosa layers with complete muscularis layers were 
physically separated from submucosa(Figure 15).For the mucosa fabrication, we then 
seededhCECs in the crypt niches and the mixture of endothelial cells andmyofibroblasts 
(1:1) in the extracellular matrix outside crypt niches by capillary injection of hand-pulled 
glass needles or microinjection needles(Figure 22). After the cells attached to the 
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extracellular matrix and start proliferation, the myofibroblasts were planted on the 
muscularis layer opposed to the mucosa(Figure 22). In addition, we seed endothelial 
cells in the submucosa scaffolds. The two scaffolds of mucosa and submucosa were 
physiologically placed together and mounted in proper culture medium. After 20-30 day 
culture, both morphology(Figure 23) (H+E staining) and molecular markers(Figure 
24)(immunohistochemistry) were applied to test the physiological properties and 
differentiation of the recellularizedorganotypic colon. 
4. The organotypic colon recapitulates the feathers of APC-dependent malignant 
transition from mucosa in situ to submucosa invasion.  
We then performed functional analysis whether the organotypic colon can be 
transformed into APC -dependent invasive neoplasias. We generatedthree groups of 
organotypic colons fabricated with APC knockdown hCEC, APC knockdown + K-Ras 
overexpression hCEC or APC knockdown + K-Ras overexpressionhCEC + TGF-β 
treatment, and firstly APC knockdown + K-Ras overexpression hCECs were 
subcutaneously implanted in immunodeficient (NSG) mice to test the tumorigenesis 
capability by xenograft formation(Figure 25). Subsequently, in order to test whether the 
organotypic colon has the ability to transform normal epithelial cells into APC-null 
invasive neoplasia in CRC-associated genetic pathways, the three subgroups of hCECs 
were seeded in the crypt niches of decellular scaffolds along with endothelial cells and 
fibroblasts. After 20-30 day culture, we observed neoplasiain situ formation in APC 
knockdown group (Figure 26) and with additional K-Ras overexpression, the neoplasia 
became larger, making crypt shape deformed and mucosa disorganized (Figure 
26).Furthermore, in the third group of APC knockdown + K-Ras overexpressionhCEC + 
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TGF-βtreatment developedsubmucosainvasive neoplasias in the organotypiccolon 
system (Figure 26).Functional analyses and molecular characterizations will be 
performed to prove the bioartificial organ has the ability to recapitulate the major 
features of CRC malignant progression. 
Future plan: 
Apply sleeping beauty (SB) insertion mutations in the APC-dependent neoplasias 
and capture the invasion driving genetic signatures.  
Currently I and Zhubo Wei, the postdoc in Copeland & Jenkins labs have been working 
together to transfect SB transposon vectors (the transposon plasmid T2/Onc2 and 
transposase plasmid SB100x) in hCECs with enough gene copies inserted in host 
genome, which ensure SB can be mobilized at frequencies high enough to induce 
submucosa invasion(Figure 27).APC-null hCECs transfected with SB, along with 
endothelial cells and fibroblasts will be seeded in the acellular colon matrix to form colon 
neoplasia. During the same time, time-lapse monitoring will be performed to track and 
capture the cells undergoing invasion into submucosa. A modified splinkerette PCR 
method by barcoded primers will be used to amplify the SB CIS from the invasive 
hCECs, and the mutation sites, types, and copy number variations can be identified by 
sequencing PCR products. We currently collaborate with the SB transposon 
discoverer[138] and geneticist, Dr. ZoltánIvics, who provides technical support 
withhuman cellular SB CIS mapping to identify the candidate mutations[139, 140]. Then 
we will cross outside human databases such as TCGA (The Cancer Genome Atlas) of 
APC subtype CRC or murine datasets of APC dependent intestinal tumorigenesis, to 
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verify and narrow down our driver candidates for further functional validation in the next 
step(Figure 28).  
6. Functional validation of the gene signatures.  
For functional validation of the driver genes, we will use siRNA to silence the candidate 
oncogenes and use DNA vectors to knockin the candidate suppressor genes in APC – 
null hCECs or common CRC cell lines. Subsequently, in vitro cell proliferation, migration 
and invasion assays will be performed to test the driver genes. If time and funds allow, 
an APCmin knockout mouse model will be used to verify the drivers of invasive 
progression by monitoring histological changes in the CRC tissues (Figure 28). 
Conclusion 
To our knowledge, this is the firstorganotypic human colon created to be a natural 
platform by de-/re-cellularization[141], as a third research model to fill the gap between 
2D cell culture and animal models. This will be also the first tumor model[142]developed 
on a bioartificial colon and induced from genetically defined primary colon epithelial cells. 
The APC-dependent neoplasias created from the organotypic colon will recapitulate the 
features of invasive malignancy and serve as an ex vivo platform to screen genetic 
signaling driving tumor progression. 
Moreover, this study will be the first application of SB transposon-mediated forward 
gene screen in human organotypic system for cancer research. It was reported by 
Copeland & Jenkins group and othersthat SB transposon germlineinsertions, as 
mutagens to mimic somatic mutations, enable to inducevariant types of tumors in mice. 
This forward gene screen that tumors result from SB insertion mutagenesis, facilitates 
the identification of the gene and signaling pathways that drive tumor formation[143, 
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144]. However, the forward gene screens based on transposon systems can beonly 
applied[145] in non-human systems, which have quite different genetic background and 
mechanisms of tumorigenesis than human body. Here, we try to explore the forward 
genetic study of the SB transposon mutagenesis in human systems, the 
physipathological relevant bioartificial colon, to identify CRC invasion driving genes, 
providing a potential way to bridge the gaps between animal and human study.  
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